Page last updated: 2024-11-04

rabeprazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Rabeprazole is a proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD) and other conditions associated with excess stomach acid. It works by blocking the enzyme (H+/K+-ATPase) that pumps hydrogen ions into the stomach, thereby reducing acid production. Rabeprazole is available in oral form, typically taken once daily. It is generally well-tolerated, but common side effects include headache, diarrhea, and abdominal pain. Rabeprazole has been shown to be effective in treating GERD, heartburn, and other acid-related conditions. It is also used to prevent ulcers in patients who are taking nonsteroidal anti-inflammatory drugs (NSAIDs). The synthesis of rabeprazole involves multiple steps and includes the use of various reagents and catalysts. Research on rabeprazole continues to explore its potential for treating other conditions, such as Helicobacter pylori infection and Zollinger-Ellison syndrome. '

Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5029
CHEMBL ID1219
CHEBI ID8768
SCHEMBL ID23336
MeSH IDM0583264

Synonyms (87)

Synonym
BIDD:GT0019
HMS3394P03
ly307640
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1h-benzimidazole
MLS001401446
smr000469174
117976-89-3
C07864
rabeprazole
DB01129
rabeprazole [inn:ban]
hsdb 7321
1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-
2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1h-benzimidazole
CHEBI:8768 ,
HMS2052P03
e-3810 (ppi)
eraloc
CHEMBL1219
pariprazole
D08463
eraloc (tn)
rabeprazole (inn)
2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole
2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]-1h-benzimidazole;rabeprazole
A803856
habeprazole
pariets
rabeloc
32828355ll ,
ly 307640
unii-32828355ll
2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole
CCG-101158
2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1h-1,3-benzodiazole
FT-0602569
PB21725
AKOS015895259
S4845
gtpl7290
rabeprazole [mi]
rabeprazole [vandf]
rabeprazole [who-dd]
rabeprazole [hsdb]
rabeprazole [inn]
HY-B0656
AB00698237-06
NC00408
SCHEMBL23336
2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1h-benzimidazole
2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1h-benzimidazole
2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1h-benzimidazole
YREYEVIYCVEVJK-UHFFFAOYSA-N
rabeprazol
2-{4-(3-methoxypropoxy)-3-methylpyridine-2-yl}methylsulfinyl-1h-benzimidazole
2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl}-1h-benzimidazole
DTXSID3044122 ,
2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methane}sulfinyl)-1h-1,3-benzodiazole
bdbm50070209
J-003691
SR-01000763041-3
sr-01000763041
mfcd00868879
1h-benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-
SBI-0206867.P001
NCGC00388029-07
BCP06638
FT-0674301
FT-0674302
AS-34993
2--1h-benzimidazole
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1h-benzo[d]imidazole
Q3515
AMY10338
BRD-A39390670-236-04-0
STL186112
NCGC00388029-09
2[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
(r)-2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole
(s)-2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole
EN300-7404394
2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1h- benzimidazole(national library of medicine, sis; chemidplus record for rabeprazole (117976-89-3) available from, as of august 11, 2005: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.j
rabeprazolum
dtxcid1024122
a02bc04
2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1h-benzimidazole

Research Excerpts

Overview

Rabeprazole sodium is a proton pump inhibitor used for the treatment of gastroesophageal reflux disease (GERD) Rabeprazoles presents a very advantageous pharmacodynamic and pharmacokinetic profile over older PPIs. It is a useful, well tolerated and cost-effective option.

ExcerptReferenceRelevance
"Rabeprazole is a representative of proton pump inhibitors and widely used in anti-ulcer treatment. "( Rabeprazole destroyed gastric epithelial barrier function through FOXF1/STAT3-mediated ZO-1 expression.
Cheng, Y; Geng, L; Gong, S; Huang, J; Huang, L; Li, L; Liang, X; Pan, W; Xu, W; Yang, F; Zhou, Y, 2023
)
3.8
"Rabeprazole is a representative of proton pump inhibitors and widely used in anti-ulcer treatment."( Rabeprazole suppresses cell proliferation in gastric epithelial cells by targeting STAT3-mediated glycolysis.
Chen, H; Chen, J; Chen, P; Chen, S; Geng, L; Gong, S; Huang, L; Li, H; Liang, D; Ren, L; Wu, P; Xiong, L; Xu, W; Yang, F; Zhang, Y; Zhao, J; Zhou, Y, 2021
)
2.79
"Rabeprazole is an effective proton pump inhibitor to treat acid-related diseases. "( Stereoselective pharmacokinetics of (R)-(+)- and (S)-(-)-rabeprazole in human using chiral LC-MS/MS after administration of rabeprazole sodium enteric-coated tablet.
Ding, L; Li, D; Li, TF; Shen, YW; Sun, LN; Wang, YQ; Ying, YW; Zhang, XH; Zhao, P, 2018
)
2.17
"As rabeprazole is a less potent CYP2C19 inhibitor than other PPIs, we studied the interaction between rabeprazole and the antiplatelet actions and pharmacokinetics of clopidogrel."( Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Azizi, M; Ducint, D; Funck-Brentano, C; Gaussem, P; Molimard, M; Remones, V; Steichen, O; Szymezak, J, 2013
)
1.29
"Rabeprazole sodium is a proton pump inhibitor used for the treatment of gastroesophageal reflux disease (GERD). "( Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
Green, B; Kimko, H; Mannaert, E; McLeay, SC; Thyssen, A; Treem, W, 2014
)
2.13
"Rabeprazole is a proton pump inhibitor (PPI) presenting a very advantageous pharmacodynamic and pharmacokinetic profile over older PPIs. "( Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
Marelli, S; Pace, F; Pallotta, S, 2008
)
3.23
"Rabeprazole is a proton pump inhibitor that can be used in the treatment of acid-peptic-related disorders (gastroesophageal reflux disease [GERD], duodenal ulcer, gastric ulcer, gastric acid hypersecretory syndromes) and Helicobacter pylori. "( Rabeprazole: a pharmacologic and clinical review for acid-related disorders.
Dadabhai, A; Friedenberg, FK, 2009
)
3.24
"Rabeprazole is a useful, well tolerated and cost-effective option for the treatment of GORD, NERD, peptic ulcer and other gastric acid-related diseases (including ZES), and provides an appropriate alternative to other currently available PPIs, with the added benefits of having a consistent efficacy profile and low drug interaction potential due to its predominantly nonenzymatic metabolism."( Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Baldwin, CM; Keam, SJ, 2009
)
2.52
"Rabeprazole sodium [1] is a proton pump inhibitor, used as an antiulcerative. "( Identification, isolation and characterization of new impurity in rabeprazole sodium.
Gupta, PB; Islam, A; Mukkanti, K; Rajput, P; Rao, DV; Rao, PS; Ray, UK, 2010
)
2.04
"Rabeprazole is a potent and irreversible inhibitor of H(+)/K(+)-ATPase gastric pump, and it is indicated for the treatment of gastroesophageal reflux disease, Zollinger Ellison syndrome, duodenal and gastric ulcers and for the eradication of Helicobacter pylori in combination with antibiotics."( Rabeprazole for the treatment of acid-related disorders.
Marelli, S; Pace, F, 2012
)
2.54
"Rabeprazole is a potent proton pump inhibitor that may not be affected as greatly by H."( Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Chilton, A; Nwokolo, CU; Pounder, RE; Sercombe, J; Usselmann, B; Williams, MP, 2003
)
1.26
"Rabeprazole sodium is a potent proton pump inhibitor. "( [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer].
Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY, 2003
)
2.07
"Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category. "( Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P, 2003
)
1.99
"Rabeprazole is a new proton pump inhibitor producing rapid inhibition of gastric acid secretion. "( Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC, 2003
)
2.12
"Rabeprazole sodium is a proton pump inhibitor that covalently binds and inactivates the gastric parietal cell proton pump (H+/K+ ATPase). "( New liquid chromatographic method for determination of rabeprazole sodium in coated tablets.
Garcia, CV; Paim, CS; Steppe, M,
)
1.82
"Rabeprazole is a second generation PPI with rapid onset of action that quickly relieves symptoms of GERD."( Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
Goh, KL; Lim, PW, 2004
)
1.31
"Rabeprazole is a newer generation proton pump inhibitor that suppresses the gastric proton pump and acid secretion more rapidly than does omeprazole, lansoprazole or pantoprazole."( Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Miner, P, 2004
)
1.26
"Rabeprazole sodium is an antisecretory agent that inhibits the enzyme H+/K+ ATPase present in the stomach parietal cells. "( Validation of a capillary electrophoresis method for analysis of rabeprazole sodium in a pharmaceutical dosage form.
Garcia, CV; Garcia, SS; Jablonski, A; Schapoval, EE; Sfair, LL; Sippel, J; Steppe, M,
)
1.81
"Rabeprazole (Pariet) is a substituted benzimidazole proton pump inhibitor with potent gastric acid suppression properties."( Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
Sharara, AI, 2005
)
2.49
"Rabeprazole is an effective and well-tolerated drug for GERD treatment."( [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
Baek, JT; Chung, IK; Jeong, HY; Kim, AN; Kim, SH; Kim, SJ; Lee, BS; Lee, DS; Lee, GS; Lee, JM; Lee, SH; Lee, TY; Nam, SW; Oh, JI; Shin, JE; Sung, JK; Yoon, SJ, 2006
)
1.3
"Rabeprazole is known to be a substrate of CYP2C19. "( Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2006
)
2.05
"Rabeprazole is a proton pump inhibitor which is particularly suitable for use in short-term Helicobacter pylori eradication treatment. "( Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
Bilardi, C; Dulbecco, P; Giannini, EG; Mamone, M; Mansi, C; Santi, ML; Savarino, V; Testa, R, 2006
)
1.97
"Rabeprazole is a PPI whose metabolism shows fewer interactions compared to other PPIs."( Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.
Giannini, EG; Savarino, V; Testa, R, 2006
)
1.32
"Rabeprazole sodium is a proton pump inhibitor, used in acid-related disorders, like peptic ulcers and gastroesophageal reflux. "( Structural elucidation of rabeprazole sodium photodegradation products.
Garcia, CV; Nudelman, NS; Schapoval, EE; Steppe, M, 2008
)
2.09
"Rabeprazole is a proton pump inhibitor with antisecretory properties. "( Rabeprazole.
Faulds, D; Prakash, A, 1998
)
3.19
"Rabeprazole (E3810) is a new substituted benzimidazole H+,K+ ATPase inhibitor."( An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
Barbuti, RC; Humphries, TJ; Kovacs, TO; Lew, EA; Sytnic, B; Walsh, JH, 1998
)
1.25
"Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis. "( Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998
)
2.05
"Rabeprazole sodium is a new substituted benzimidazole proton pump inhibitor with several differences compared with existing proton pump inhibitors. "( Review article: the pharmacology of rabeprazole.
Pounder, RE; Williams, MP, 1999
)
2.02
"Rabeprazole is an inhibitor of the gastric proton pump. "( Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry, HD; Markham, A, 1999
)
3.19
"Rabeprazole is a new, highly potent proton pump inhibitor (PPI) being introduced for the treatment of disorders of gastric acid hypersecretion. "( Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy.
Lew, EA, 1999
)
1.75
"Rabeprazole is a new member of a class of substituted benzimidazole drugs known as proton pump inhibitors. "( Review article: rabeprazole's tolerability profile in clinical trials.
Cockburn, I; Thjodleifsson, B, 1999
)
2.09
"Rabeprazole is likely to be a valuable new addition to its class in treating patients with acid-related gastrointestinal diseases given its efficacy in acid suppression, high healing rates, rapid symptom relief, and convenient dosing."( Review article: rabeprazole's profile in patients with gastrointestinal diseases.
Barth, J; Humphries, TJ, 1999
)
1.37
"Rabeprazole is an effective and well-tolerated alternative treatment for patients with active duodenal ulcer disease."( Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study.
Breiter, JR; Humphries, TJ; Riff, D, 2000
)
2.47
"Rabeprazole is a new PPI with demonstrated efficacy in both the acute and maintenance treatment of erosive GERD."( Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Beker, JA; Bjaaland, T; Dekkers, C; Finnegan, V; Humphries, TJ; Thjodleifsson, B, 2000
)
2.47
"Rabeprazole sodium is a proton pump inhibitor."( Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection.
Fukazawa, K; Ishino, Y; Kawakami, S; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Sugano, K, 2000
)
3.19
"Rabeprazole is a potent proton pump inhibitor and is mainly reduced to thioether rabeprazole by a non-enzymatic pathway and partially metabolized to demethylated rabeprazole by CYP2C19 in the liver. "( Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Furuta, T; Hanai, H; Ishizaki, T; Nakagawa, K; Ohashi, K; Shirai, N; Sugimura, H; Takashima, M; Xiao, F, 2001
)
1.96
"Rabeprazole is a new, potent, proton pump inhibitor. "( Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Asaka, M; Hige, S; Hokari, K; Ishizuka, J; Kagaya, H; Kato, M; Komatsu, Y; Kudo, M; Miyagishima, T; Mizushima, T; Nishikawa, K; Saito, M; Sugiyama, T; Takeda, H, 2001
)
2.04
"Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects."( Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2001
)
3.2
"Rabeprazole is an inhibitor of the gastric proton pump. "( Rabeprazole: an update of its use in acid-related disorders.
Carswell, CI; Goa, KL, 2001
)
3.2
"Rabeprazole is a well tolerated proton pump inhibitor. "( Rabeprazole: an update of its use in acid-related disorders.
Carswell, CI; Goa, KL, 2001
)
3.2
"Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD)."( Integrated acidity and rabeprazole pharmacology.
Barth, JA; Gardner, JD; Hahne, WF; Perdomo, C; Robinson, M; Rodriguez-Stanley, S; Sloan, S, 2002
)
1.35

Effects

Rabeprazole 10 mg has a similar efficacy and safety profile in Asians with NERD as esomeprazole 20 mg. It does interfere with the absorption of digoxin and ketoconazole because of its antisecretory effects.

Rabeprazole (10 mg/day) has excellent therapeutic effect on the symptoms of duodenal ulcer patients. The drug has a comparable efficacy compared to ranitidine when given on-demand for the treatment of NERD.

ExcerptReferenceRelevance
"Rabeprazole has a well established efficacy and safety profile in the treatment of gastric acid-related diseases."( Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Baldwin, CM; Keam, SJ, 2009
)
2.52
"Rabeprazole has a comparable efficacy compared to ranitidine when given on-demand for the treatment of NERD. "( A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
Aswad, R; El-Samad, S; Haddad, R; Hashash, JG; Jamali, FR; Kobeissy, AA; Ladki, R; Skoury, AM; Soweid, AM, 2012
)
2.08
"Rabeprazole has a faster onset of antisecretory activity than omeprazole and lansoprazole. "( Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S, 2003
)
1.98
"Rabeprazole 10 mg has a similar efficacy and safety profile in Asians with NERD as esomeprazole 20 mg. "( Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.
Ang, TL; Chua, TS; Fock, KM; Ng, TM; Tan, YL; Teo, EK, 2005
)
3.21
"Rabeprazole, which has a similar mechanism of action, has not previously been studied in these diseases."( An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
Bjaaland, T; Humphries, T; Merrouche, M; Mignon, M; Morocutti, A, 2006
)
1.37
"Rabeprazole, which has a low potential for interacting with drugs metabolized by cytochrome P450, does interfere with the absorption of digoxin and ketoconazole because of its antisecretory effects."( Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy.
Lew, EA, 1999
)
1.02
"Rabeprazole has a faster onset of antisecretory action than omeprazole, and it is of interest to determine whether this translates into faster symptom relief in patients with gastro-oesophageal reflux disease."( A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002
)
2
"Rabeprazole has a favourable profile with rapid action and good safety."( [Pharma-clinics medication of the month. Rabeprazole (Pariet)].
Louis, E, 2002
)
1.3
"Rabeprazole (20 mg) has proved similar Helicobacter pylori eradication rates compared with omeprazole (40 mg) when co-administered with of antibiotics (amoxicillin and clarithromycin) for two weeks."( Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection.
Amatya, GL; Gurung, SB; Gyawali, P; Kc, SR, 2020
)
2.29
"Rabeprazole has a well established efficacy and safety profile in the treatment of gastric acid-related diseases."( Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Baldwin, CM; Keam, SJ, 2009
)
2.52
"Rabeprazole has a comparable efficacy compared to ranitidine when given on-demand for the treatment of NERD. "( A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
Aswad, R; El-Samad, S; Haddad, R; Hashash, JG; Jamali, FR; Kobeissy, AA; Ladki, R; Skoury, AM; Soweid, AM, 2012
)
2.08
"Rabeprazole (10 mg/day) has excellent therapeutic effect on the symptoms of duodenal ulcer patients. "( [The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer].
Lin, S, 2002
)
1.76
"Rabeprazole has been demonstrated to be a potent antisecretory agent and has been shown to be clinically effective in the treatment of acid-related diseases."( Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer.
Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C, 2002
)
2.06
"Rabeprazole has a faster onset of antisecretory activity than omeprazole and lansoprazole. "( Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S, 2003
)
1.98
"Rabeprazole 10 mg has a similar efficacy and safety profile in Asians with NERD as esomeprazole 20 mg. "( Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.
Ang, TL; Chua, TS; Fock, KM; Ng, TM; Tan, YL; Teo, EK, 2005
)
3.21
"Rabeprazole has dual effects on solid emptying: an initial acceleration with a subsequent deceleration, resulting in an overall delay."( Dual effects of rabeprazole on solid-phase gastric emptying assessed by the 13C-octanoate breath test.
Anjiki, H; Kuyama, Y; Sanaka, M, 2005
)
2.12
"Rabeprazole has been known to inhibit H(+)/K(+)-ATPase more rapidly than omeprazole, the prototype proton pump inhibitor (PPI). "( Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
Baik, SK; Jee, MK; Ji, S; Kim, HS; Kim, JW; Kwon, SO; Lee, DK; Park, KW; Song, JS; Uh, Y, 2006
)
2.07
"Rabeprazole, which has a similar mechanism of action, has not previously been studied in these diseases."( An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
Bjaaland, T; Humphries, T; Merrouche, M; Mignon, M; Morocutti, A, 2006
)
1.37
"Rabeprazole has 2- to 10-fold greater antisecretory activity than omeprazole in vitro."( Rabeprazole.
Faulds, D; Prakash, A, 1998
)
2.46
"Rabeprazole, which has a low potential for interacting with drugs metabolized by cytochrome P450, does interfere with the absorption of digoxin and ketoconazole because of its antisecretory effects."( Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy.
Lew, EA, 1999
)
1.02
"Rabeprazole has been shown to be more potent and faster than other proton pump inhibitors in in vitro studies and highly effective in decreasing oesophageal acid exposure in patients with gastro-oesophageal reflux disease (GERD)."( Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
Avasthy, N; Ducrottè, P; Fournet, J; Galmiche, JP; Humphries, TJ; Rampal, P; Zerbib, F, 2001
)
1.98
"Rabeprazole has also been shown to have a more consistent suppression of acid, including at night."( Optimizing acid-suppression therapy.
Barnett, JL; Robinson, M, 2001
)
1.03
"Rabeprazole has a faster onset of antisecretory action than omeprazole, and it is of interest to determine whether this translates into faster symptom relief in patients with gastro-oesophageal reflux disease."( A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002
)
2
"Rabeprazole has a favourable profile with rapid action and good safety."( [Pharma-clinics medication of the month. Rabeprazole (Pariet)].
Louis, E, 2002
)
1.3

Actions

Rabeprazole clearance was lower in CYP2C19 PMs than in EMs. Subjects had lower GERD-related costs, less escalation, and lower DACON (measured as number of tablets consumed per day)

ExcerptReferenceRelevance
"Rabeprazole clearance was lower in CYP2C19 PMs than in EMs (with average values of 10.7 vs. "( Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
Lin, CJ; Uang, YS; Wang, TH; Yang, JC; Yang, YF, 2009
)
2.02
"Rabeprazole subjects had lower GERD-related costs, less escalation, and lower DACON (measured as number of tablets consumed per day), compared to lansoprazole and omeprazole subjects. "( Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Dodd, S; Durkin, M; Hall, J; Sloan, S, 2002
)
1.76

Treatment

Rabeprazole treatment does not drive enterochromaffin-like cells and parietal cells as strongly as omepazole treatment. Treatment with rabeprazoles resulted in a decrease from 18.6 at baseline to 6.7 at week 8 in underweight reflux esophagitis.

ExcerptReferenceRelevance
"Rabeprazole treatment significantly decreased both the FSSG and the PSQI score."( Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole.
Arakawa, T; Fujiwara, Y; Hayakawa, T; Kaji, M; Kohata, Y; Machida, H; Nebiki, H; Sasaki, E; Tanigawa, T; Tominaga, K; Watanabe, K; Watanabe, T; Yamasaki, T, 2010
)
1.29
"Rabeprazole treatment significantly improved subjective indices of sleep quality."( The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux.
Goodrich, S; Orr, WC; Robert, J, 2005
)
1.05
"With rabeprazole treatment this ratio decreased to 27.6% (p<0.05)."( The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
Bektaş, M; Cetinkaya, H; Ozden, A; Soykan, I; Törüner, M, 2004
)
1.14
"Rabeprazole treatment reduced aggregate postprandial symptoms, particularly fullness, 30 min after the meal (P = 0.01)."( Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study.
Burton, DD; Camilleri, M; Grudell, AB; Stephens, DA, 2006
)
1.06
"Rabeprazole-treated patients had numerically greater symptom relief at all 12 points of comparison."( Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group.
Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1998
)
1.38
"Rabeprazole-treated patients had similar relief of the frequency and intensity of heartburn to those treated with omeprazole."( Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999
)
1.25
"Rabeprazole-treated patients had significantly greater improvement in daytime pain symptom relief than those treated with omeprazole at the conclusion of the study (P = 0.038)."( Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.
Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999
)
1.39
"Rabeprazole treatment does not drive enterochromaffin-like cells and parietal cells as strongly as omeprazole treatment despite its potent acid suppressive effect, suggesting that it represents a new generation of proton pump inhibitors."( The effects of rabeprazole on parietal cells and enterochromaffin-like cells in rats: a comparison with omeprazole.
Haruma, K; Kajiyama, G; Kawano, M; Kodama, K; Okahara, S; Sumii, K; Tari, A; Yonei, Y, 2002
)
2.11
"Pretreatment with rabeprazole resulted in significant reductions in atazanavir C"( Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.
Benet, LZ; Faber, KP; Frassetto, LA; Kadiyala, P; Wu, HF; Xu, X; Yago, MR, 2017
)
1.05
"Treatment with Rabeprazole helps efficiently jugulate reflux disease symptoms and accurately improve quality of life index."( [The quality of life dynamics in patients with gastroesophageal reflux disease during rabeprazol therapy].
Golubev, NN; Iablunovskaia, GI; Maev, IV; Odintsova, AN; Samsonov, AA, 2009
)
0.69
"Treatment with rabeprazole resulted in a decrease from 18.6 at baseline to 6.7 at week 8 in underweight reflux esophagitis subjects, and from 15.0 to 6.3 in underweight NERD patients."( Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Hongo, M; Kusano, M; Miwa, H, 2012
)
0.72
"Treatment with rabeprazole is expected to ameliorate asthma in non-steroid-dependent patients who have symptomatic GER defined by the QUEST score."( A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux.
Ashida, S; Fujiki, S; Hosaki, Y; Mitsunobu, F; Mizuno, M; Okada, H; Okamoto, M; Shiratori, Y; Tanizaki, Y; Tsugeno, H, 2003
)
0.98
"The treatment with Rabeprazole supplied authentic data concerning faster pain reduction in the heart area and heartburn starting from the first day of treatment."( [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
Danilin, MS; Kucheriavyĭ, IuA; Maev, IV, 2003
)
0.64

Toxicity

Rabeprazole was effective and safe in 1- to 11-year-old children with GERD. Triple therapy with two antibiotics for 1 wk is safe and effective in eradicating H.

ExcerptReferenceRelevance
" There were no clinically significant effects on patient laboratory tests or serious adverse events."( An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
Barbuti, RC; Humphries, TJ; Kovacs, TO; Lew, EA; Sytnic, B; Walsh, JH, 1998
)
0.53
" The most common side effects were loose stools, headache, and taste disturbance, but there were no serious adverse events related to the study medication."( Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998
)
0.61
" The adverse effects were minimal and transitory."( [Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases ].
Chinzon, D; de Freitas, JA; Fragoso, HJ; Lima, LM; Olivieri, JC; Ranieri, JL,
)
0.39
" All three were safe and well tolerated during 5 years of treatment."( A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003
)
0.55
" No significant adverse effects were reported."( Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.
Abdul-Baki, H; Aoun, E; Araj, GF; Chaar, HF; Kanj, SS; Sharara, AI, 2006
)
0.64
" In the present article, the adverse effects of PPIs are reviewed, with special emphasis on those related to their continued administration and on the special circumstances of patients, as in the case of the elderly, those with liver failure, pregnant and breastfeeding mothers and children."( [Safety of proton pump inhibitors].
Esplugues, JV; Martí-Cabrera, M; Ponce, J, 2006
)
0.33
" A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events."( Long-term proton pump inhibitor use in children: a retrospective review of safety.
Boyer, K; Tolia, V, 2008
)
0.35
") occurring after the start of rabeprazole treatment were handled as adverse events."( Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan.
Mizokami, Y, 2009
)
0.95
" In 199 patients treated with DAT alone (control group) and 103 patients treated with rabeprazole plus DAT (rabeprazole group), we examined the incidences of GI bleeding and major adverse cardiac events (MACE) including stent thrombosis."( [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
Chubachi, H; Ikee, R; Miyasaka, Y; Saito, S; Yasu, T, 2010
)
0.85
" We performed serial endoscopy, checked gastroesophageal reflux disease (GERD) symptoms, adverse events, laboratory values and serum gastrin."( Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.
Fujimoto, K; Hongo, M, 2011
)
0.6
" Although effects on the gastric mucosa were not ruled out, long-term use of RPZ was confirmed to be safe overall."( Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.
Fujimoto, K; Hongo, M, 2011
)
0.6
" The most common (>10%) treatment-emergent adverse events included cough and vomiting (14% each), abdominal pain (12%), and diarrhea (11%)."( Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013
)
0.7
"Rabeprazole was effective and safe in 1- to 11-year-old children with GERD."( Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013
)
2.14
" Equal percentages (47%) reported adverse events in placebo and combined rabeprazole groups, with no new safety signals emerging."( Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD.
Hoffman, D; Hu, P; Hussain, S; Kierkus, J; Lekich, R; Sloan, S; Treem, W, 2014
)
0.9
" Overall incidence of treatment-emergent adverse events was 63%; upper respiratory tract infections (13%) and vomiting (11%) were the most commonly reported (>10%)."( Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD.
Haddad, I; Hu, P; Kierkus, J; Leitz, GJ; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2014
)
0.67
" There were no significant differences between the groups in regard to the eradication rates and adverse events."( Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
Hong, SN; Kim, JJ; Lee, H; Lee, JH; Lee, YC; Min, BH; Rhee, PL, 2015
)
0.42
" The safety and tolerability of the study drug was assessed by monitoring adverse events, vital signs and physical examination."( An Open Label, Prospective, Single Centre Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Rabeprazole (Enteric-Coated, EC) 20 mg + Domperidone (Sustained Release, SR) 30 mg Capsule in Treatment of Patients with Laryngopharyngeal Ref
Mukaddam, QI; Naik, M; Semmanaselvan, K, 2015
)
0.63
" No adverse event was reported by any patient during the study period."( An Open Label, Prospective, Single Centre Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Rabeprazole (Enteric-Coated, EC) 20 mg + Domperidone (Sustained Release, SR) 30 mg Capsule in Treatment of Patients with Laryngopharyngeal Ref
Mukaddam, QI; Naik, M; Semmanaselvan, K, 2015
)
0.63
" The combination was found to be safe and well tolerated."( An Open Label, Prospective, Single Centre Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Rabeprazole (Enteric-Coated, EC) 20 mg + Domperidone (Sustained Release, SR) 30 mg Capsule in Treatment of Patients with Laryngopharyngeal Ref
Mukaddam, QI; Naik, M; Semmanaselvan, K, 2015
)
0.63
"Proton-pump inhibitors (PPIs) have been proved as safe and effective ways to treat patients with non-erosive reflux disease (NERD)."( The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis.
Chen, L; Chen, Y; Li, B, 2016
)
0.43
"61) without an increase in the occurrence of adverse events (RR = 0."( Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis.
Gao, F; Lin, M; Luo, R; Shi, J; Sun, J; You, J; Zhang, C; Zhang, J; Zhang, M; Zhang, S, 2020
)
0.8
"Our study suggests that KFX combined with rabeprazole showed positive therapeutic effects and is safe for treating PU, which may provide more reliable evidence for the clinical use of KFX in the treatment of PU."( Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis.
Gao, F; Lin, M; Luo, R; Shi, J; Sun, J; You, J; Zhang, C; Zhang, J; Zhang, M; Zhang, S, 2020
)
1.06
" For the rate of adverse events, there was no significant difference among all the PPIs, vonoprazan, and placebo."( Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Chen, J; Deng, W; Xie, Z; Yang, S, 2022
)
0.72
" Adverse events were monitored for safety."( Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study.
Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H, 2022
)
0.95
" The incidence of treatment-emergent adverse events was similar for anaprazole (72/220, 32."( Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study.
Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H, 2022
)
0.95
" Both drugs were well tolerated, and the adverse event incidence profile was low."( Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease.
Abdo-Francis, JM; Cabrera-Álvarez, G; Martínez-Torres, H; Remes-Troche, JM, 2022
)
0.98
" The secondary outcomes were symptom improvement rate, patient compliance, and incidence of adverse events."( Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y, 2023
)
0.91
" In addition, the symptom improvement rate, overall adverse reaction rate, and patient compliance were similar among the three groups (P >0."( Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y, 2023
)
0.91

Pharmacokinetics

The study was conducted to characterize the pharmacokinetic and safety profile of rabeprazole sodium tablets in children and adolescents with gastroesophageal reflux disease. An HPLC-tandem mass spectrometry (HPLC-MS/MS) method for analysis was used.

ExcerptReferenceRelevance
" Three separate studies were conducted to evaluate the safety and to establish the pharmacokinetic profile of E3810 after oral administration to healthy male subjects."( Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers.
Hasegawa, J; Morishita, N; Nakai, H; Ogawa, T; Ohnishi, A; Shimamura, Y; Tomono, Y; Yasuda, S, 1994
)
0.29
" The pharmacokinetic parameters, Cmax, t(max), AUC and t1/2, showed no statistically significant differences when rabeprazole was administered alone, concomitantly with antacid or one hour after antacid administration."( Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers.
Higashi, S; Kawaguchi, M; Murakami, M; Tomono, Y; Yasuda, S, 1999
)
0.76
"This single-center, open-label study was undertaken to compare the tolerability and pharmacokinetic profiles of rabeprazole, a new proton-pump inhibitor (PPI), in healthy volunteers and in subjects with chronic cirrhosis."( Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis.
Grimes, I; Hoyumpa, AM; Humphries, TJ; Trevino-Alanis, H, 1999
)
1.96
"The authors compare the pharmacokinetic profiles, safety, and tolerability of rabeprazole, a new proton pump inhibitor (PPI), in healthy volunteers and in subjects with stable, end-stage renal failure."( Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure.
Grimes, I; Humphries, TJ; Keane, WF; Swan, SK, 1999
)
1.97
" The maximum plasma concentration (Cmax) and the area under the plasma concentration time curve (AUC) are linearly related to dose, while the time to maximum plasma concentration (tmax) and elimination half-life (t1/2) are dose-independent."( Review article: the pharmacokinetics of rabeprazole in health and disease.
Hoyumpa, AM; Merritt, GJ; Swan, SK, 1999
)
0.57
" As a result of structural and functional similarities, the PPIs share many pharmacokinetic features."( Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy.
Lew, EA, 1999
)
0.3
" Based on the metabolic and pharmacokinetic differences among other proton pump inhibitors such as omeprazole, lansoprazole and pantoprazole, rabeprazole appears to be the least affected proton pump inhibitor by the CYP2C19-related genetic polymorphism."( Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Furuie, H; Horai, Y; Irie, S; Ishizaki, T; Kimura, M; Koga, Y; Matsuguma, K; Matsui, T; Murakami, M; Nagahama, T; Urae, A; Yao, T, 2001
)
0.76
"To determine whether the pharmacodynamic effects of rabeprazole on intragastric pH and serum gastrin levels, and its pharmacokinetics depend on the CYP2C19 genotype status."( Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Furuie, H; Horai, Y; Irie, S; Ishizaki, T; Kimura, M; Koga, Y; Matsuguma, K; Matsui, T; Murakami, M; Nagahama, T; Urae, A; Yao, T, 2001
)
0.81
"The pharmacodynamic effects of rabeprazole and its pharmacokinetics depend on the CYP2C19 genotype status."( Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Furuie, H; Horai, Y; Irie, S; Ishizaki, T; Kimura, M; Koga, Y; Matsuguma, K; Matsui, T; Murakami, M; Nagahama, T; Urae, A; Yao, T, 2001
)
0.85
"A comparative pharmacokinetic study with each PPI was designed as an open, randomized, and crossover study of 18 Japanese healthy volunteers who were classified into the homozygous, heterozygous extensive metabolizer and the poor metabolizer based on the CYP2C19 genotype determined by PCR-RFLP method."( CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Aoyama, N; Hohda, T; Kasuga, M; Kita, T; Nishiguchi, K; Nishitora, Y; Okumura, K; Sakaeda, T; Sakai, T; Sirasaka, D; Tamura, T; Tanigawara, Y, 2001
)
0.31
" As for rabeprazole, the pharmacokinetic profile was independent of the CYP2C19 genotype."( CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Aoyama, N; Hohda, T; Kasuga, M; Kita, T; Nishiguchi, K; Nishitora, Y; Okumura, K; Sakaeda, T; Sakai, T; Sirasaka, D; Tamura, T; Tanigawara, Y, 2001
)
0.74
"To determine the pharmacokinetic and pharmacodynamic rationale for the optimum regimen of rabeprazole in the treatment of Helicobacter pylori infection in patients who are cytochrome P450 (CYP) 2C19 poor metabolizers or extensive metabolizers."( Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Chern, HD; Lin, CJ; Uang, YS; Wang, TH; Yang, JC, 2003
)
0.77
"Prospective, multiple-dose pharmacokinetic and pharmacodynamic study."( Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Chern, HD; Lin, CJ; Uang, YS; Wang, TH; Yang, JC, 2003
)
0.55
"Pharmacokinetic and pharmacodynamic parameters were compared between CYP2C19 poor and extensive metabolizers on day 1 and day 4 of dosing."( Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Chern, HD; Lin, CJ; Uang, YS; Wang, TH; Yang, JC, 2003
)
0.55
" The elimination half-life of rabeprazole sodium (1."( Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects.
Hasegawa, J; Humphries, T; Laurent, A; Setoyama, T, 2005
)
0.94
" The method was suitable for therapeutic drug monitoring and was applied to pharmacokinetic study in human volunteers."( Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2005
)
0.67
"There were some differences for the area under the plasma concentration-time curve (AUC), the elimination half-life (t(1/2 ke)) and the maximum plasma concentration (c(max)) in the three groups."( Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Gao, N; Guo, YZ; Hu, YR; Jia, LJ; Qiao, HL; Tian, X; Zhang, LR, 2006
)
0.33
"The pharmacokinetic characteristics of the three PPIs are significantly dependent on the CYP2C19 genotype status."( Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Gao, N; Guo, YZ; Hu, YR; Jia, LJ; Qiao, HL; Tian, X; Zhang, LR, 2006
)
0.33
"01) in heterozygous EMs, and significantly prolonged the elimination half-life of rabeprazole and rabeprazole thioether in homozygous EMs and in heterozygous EMs, whereas no difference in any pharmacokinetic parameters was found in PMs."( Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2006
)
0.83
"The pharmacokinetic parameters of rabeprazole were not altered by clarithromycin or verapamil irrespective of the CYP2C19 genotypes."( Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2006
)
0.88
"In order to evaluate the pharmacokinetic (PK) profile of rabeprazole (RA) sterile powder for injection, a rapid, sensitive and specific assay for quantitative determination of RA in dog plasma was developed and validated."( Liquid chromatographic/mass spectrometric assay of rabeprazole in dog plasma for a pharmacokinetic study.
Feng, S; Guangji, W; Haitang, X; Hao, L; Jianguo, S; Jingwei, Z; Tian, L; Xiaoyan, Z, 2006
)
0.83
" Speed and duration of acid suppression and intensity of effect after a single dose may be important pharmacodynamic properties in clinical use."( Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn.
Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007
)
0.6
" administration of RSPI was at least four times larger than that following oral administration of Pariet tablet at an equivalent dose but the elimination half-life of these two formulation was similar (p>0."( Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats.
Shao, F; Sun, J; Wang, G; Xie, H; Zhang, J; Zhu, X, 2007
)
0.56
"This study was conducted to characterize the pharmacokinetic and safety profile of rabeprazole sodium tablets in children and adolescents with gastroesophageal reflux disease (GERD)."( Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study.
James, L; Kao, R; Lomax, K; Reyes, J; Varughese, S; Walson, P, 2007
)
0.84
" The pharmacokinetic parameters calculated included C(max), T(max), AUC, t(1/2), and apparent oral clearance (day 5/7 only)."( Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study.
James, L; Kao, R; Lomax, K; Reyes, J; Varughese, S; Walson, P, 2007
)
0.61
" The results of the pharmacokinetic analyses of single and multiple oral doses indicated no apparent accumulation of rabeprazole or its thioether metabolite with the 10-mg dose."( Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study.
James, L; Kao, R; Lomax, K; Reyes, J; Varughese, S; Walson, P, 2007
)
0.82
" The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11."( Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
Habuchi, T; Inoue, K; Kagaya, H; Miura, M; Saito, M; Satoh, S; Suzuki, T, 2008
)
0.63
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" As a result of that, there was no significant difference between pharmacokinetic parameters."( High performance liquid chromatographic analysis of rabeprazole in human plasma and its pharmacokinetic application.
Go, BW; Kam, SH; Lee, HS; Lee, KH; Park, CW; Park, ES; Rhee, YS, 2008
)
0.6
"Two-way crossover pharmacokinetic studies were conducted in 9 healthy subjects."( Prokinetics influence the pharmacokinetics of rabeprazole.
Arai, K; Imawari, M; Takeuchi, Y; Tsukurimichi, A; Uchida, N; Watanabe, H, 2008
)
0.6
" The developed assay method was applied to a pharmacokinetic study in human volunteers."( Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study.
Bharathi, DV; Chatki, PK; Hotha, KK; Jagadeesh, B; Mullangi, R; Naidu, A; Thriveni, K, 2009
)
0.57
" The formulations were compared using the pharmacokinetic parameters area under the plasma concentration-time curve (AUC(0-t)), area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) and peak plasma concentration (Cmax)."( Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers.
Agarwal, S; Bhaumik, U; Bose, A; Das, A; Ghosh, D; Pal, TK; Roy, B; Sahoo, BK, 2009
)
0.58
" This method was successfully applied for the evaluation of pharmacokinetic profiles of rabeprazole tablet in 18 healthy volunteers."( Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study.
Deng, H; Xiang, B; Yu, L, 2010
)
0.81
"The CYP2C19 genotype played a considerable role in the pharmacokinetic characteristics of rabeprazole, and this might need to be taken into account for clinical use."( Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.
He, YC; Sheng, YC; Wang, K; Yang, J; Zheng, QS, 2010
)
0.81
" The increase in acid suppression was predominantly due to prolonged acid suppression during the night-time; this was supported by the extended-release pharmacokinetic characteristics."( An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
Chen, H; Lu, Y; Morelli, G; Rege, B; Rossiter, G, 2011
)
0.58
" Twenty-four-hour esophageal pH monitoring was performed before and on treatment (at week 4) to assess the pharmacodynamic effect of these doses of rabeprazole."( Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.
Ashida, K; Hongo, M; Kinoshita, Y, 2011
)
0.87
" Pharmacokinetic parameters of rabeprazole and the thioether metabolite were calculated using noncompartmental methods."( Pharmacokinetics and tolerability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux disease.
Doose, DR; Gonzalez, MD; Haddad, I; Leitz, GJ; Mulberg, AE; Rusch, S; Solanki, B; Zannikos, PN, 2011
)
0.93
" Full plasma pharmacokinetic (PK) profiles of rabeprazole and its thioether metabolite were collected; concentrations were estimated via LC-MS/MS."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012
)
0.84
" An HPLC-tandem mass spectrometry (HPLC-MS/MS) method for analysis of (R)-(+)-rabeprazole was developed and validated, and used to acquire the pharmacokinetic parameters in beagle dogs."( The chiral bioconversion and preclinical pharmacokinetic analysis of (R)-(+)-rabeprazole in beagle dogs by HPLC and HPLC-MS/MS.
Gao, YH; Lou, HX; Song, L; Su, ZX; Xu, JX, 2013
)
0.85
" The pharmacodynamic effects of both proton pump inhibitors were not significantly different between BMI groups, and no evidence was found for an interaction between BMI and treatment."( On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?
Bruley des Varannes, S; Coudsy, B; Delemos, B; Ducrotté, P; Lococo, J; Waechter, S; Xiang, J, 2013
)
0.39
" The AUC0-24 and Cmax of active clopidogrel metabolite decreased with both omeprazole and rabeprazole, and conditions of bioequivalence were not met, except for AUC0-24 with rabeprazole."( Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Azizi, M; Ducint, D; Funck-Brentano, C; Gaussem, P; Molimard, M; Remones, V; Steichen, O; Szymezak, J, 2013
)
1
" However, under our experimental conditions and proton-pump inhibitor doses, there was no significant pharmacodynamic interaction between rabeprazole or omeprazole and clopidogrel, despite a significant decrease in the formation of clopidogrel active metabolite."( Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Azizi, M; Ducint, D; Funck-Brentano, C; Gaussem, P; Molimard, M; Remones, V; Steichen, O; Szymezak, J, 2013
)
0.98
" The objective of this study was to develop a population pharmacokinetic model for rabeprazole that describes concentration-time data arising from phase I and phase III studies in adult and pediatric subjects, including neonates and preterm infants, and propose dosing recommendations for pediatric subjects aged 1-11 years."( Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
Green, B; Kimko, H; Mannaert, E; McLeay, SC; Thyssen, A; Treem, W, 2014
)
0.91
"A total of 4,417 pharmacokinetic observations from 597 subjects aged 6 days to 55."( Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
Green, B; Kimko, H; Mannaert, E; McLeay, SC; Thyssen, A; Treem, W, 2014
)
0.69
" The aim of this study was to evaluate the pharmacokinetic properties and bioavailability of RSPI in healthy Chinese volunteers."( Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection.
Ge, J; Li, F; Li, J; Li, X; Lu, C; Ma, Z; Song, Y; Wen, A, 2016
)
0.66
" The plasma elimination half-life was short and independent of formulation."( Pharmacokinetics of rabeprazole granules versus tablets, and the effect of food on the pharmacokinetics of rabeprazole granules in healthy adults-cross-study comparison.
Gonzalez, M; Leitz, G; Mannaert, E; Solanki, B; Thyssen, A; Treem, W, 2014
)
0.73
"The results of this study suggest that vismodegib can be administered with acid-reducing agents and P-gp and CYP inhibitors without the risk of a clinically meaningful pharmacokinetic drug-drug interaction."( A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Chandra, P; Colburn, D; Dresser, MJ; Graham, RA; Hop, CE; Malhi, V; Williams, SJ, 2016
)
0.43
" One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmacokinetic disposition."( Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.
Dash, RP; Rais, R; Srinivas, NR, 2018
)
0.99
"Although acid suppressants are needed to attenuate gastrointestinal bleeding (GIB) after percutaneous coronary intervention (PCI), pharmacodynamic interaction between clopidogrel and proton pump inhibitor (PPI) can increase the risk of high platelet reactivity (HPR)."( Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: The randomized, prospective, PROTECT trial.
Ahn, JH; Bae, JS; Hwang, JY; Hwang, SJ; Jang, JY; Jeong, YH; Kang, MG; Kim, KH; Koh, JS; Kwak, CH; Park, JR; Park, Y, 2020
)
0.93

Compound-Compound Interactions

Study suggests that KFX combined with rabeprazole showed positive therapeutic effects and is safe for treating PU.

ExcerptReferenceRelevance
" The aim of this study was to evaluate rabeprazole in combination with antibiotics for the eradication of Helicobacter pylori (H."( Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998
)
0.88
" Thus, it is important to understand the potential for clinically significant drug-drug interactions in this setting."( Review article: drug interactions with agents used to treat acid-related diseases.
Humphries, TJ; Merritt, GJ, 1999
)
0.3
" Time-kill curve assays of RPZ, when combined with amoxicillin, clarithromycin, or metronidazole, disclosed that synergistic effects were demonstrated in combination with each antibiotic examined."( In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.
Akahane, T; Gotoh, A; Katsuyama, T; Kawakami, Y; Oana, K; Okabe, T; Okimura, Y; Takahashi, Y; Yamaguchi, M, 2000
)
0.62
" PPIs may interact with other drugs through numerous mechanisms."( Proton pump inhibitors and their drug interactions: an evidence-based approach.
Gerson, LB; Triadafilopoulos, G, 2001
)
0.31
" We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole, amoxicillin and clarithromycin for Helicobacter pylori infection."( Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Ohnita, K; Wen, CY, 2005
)
0.76
"The addition of sofalcone, but not polaprezinc, significantly increased the cure rate of H pylori infection when combined with the rabeprazole-amoxicillin-clarithromycin regimen."( Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Ohnita, K; Wen, CY, 2005
)
0.74
"To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents."( [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients].
Lin, SR, 2005
)
0.89
"Whether labeprazole was used alone or combined with anti-Hp agents, it is an effective and safe therapy for the treatment of peptic ulcer."( [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients].
Lin, SR, 2005
)
0.62
" The aim of our study was to evaluate the effects of proton pump inhibitors alone or in combination with H2 receptor blockers on gastric acidity with 24-hour gastric pH monitoring."( The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
Bektaş, M; Cetinkaya, H; Ozden, A; Soykan, I; Törüner, M, 2004
)
0.68
"Postcholecystectomy patients with bile reflux gastritis confirmed by endoscopy and 24 h gastric bilirubin monitoring were randomly assigned to one of four eight-week treatments: observation (group A), rabeprazole alone (group B), hydrotalcite alone (group C) and rabeprazole in combination with hydrotalcite (group D)."( Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy.
Chen, H; Chen, X; Cui, Y; Gao, Y; Ge, Z; Li, X, 2010
)
1.99
"Rabeprazole combined with hydrotalcite is an effective therapeutic option in the treatment of patients with bile reflux gastritis after cholecystectomy."( Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy.
Chen, H; Chen, X; Cui, Y; Gao, Y; Ge, Z; Li, X, 2010
)
3.25
" We here investigated the activity of E-3810 combined with different cytotoxic agents in a MDA-MB-231 triple-negative breast cancer xenograft model."( The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Forestieri, D; Giavazzi, R; Licandro, SA; Richter, P; Taraboletti, G; Zucchetti, M, 2013
)
0.39
" Very few cases of adverse side-effects related to these drugs, when given individually, have been reported; serious side-effects of clarithromycin in combination with rabeprazole have never been reported."( Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis.
Feng, Z; Hu, S; Huang, J; Xu, Y; Zhang, M, 2013
)
0.83
"To quantify the drug-drug interactions between dabigatran etexilate (DE) and proton pump inhibitors (PPI) and in particular the role of P-gp activity modulation."( In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors.
Accassat, S; Basset, T; Bertoletti, L; Delavenne, X; Hodin, S; Mismetti, P; Ollier, E, 2015
)
0.42
"The results of this study suggest that vismodegib can be administered with acid-reducing agents and P-gp and CYP inhibitors without the risk of a clinically meaningful pharmacokinetic drug-drug interaction."( A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Chandra, P; Colburn, D; Dresser, MJ; Graham, RA; Hop, CE; Malhi, V; Williams, SJ, 2016
)
0.43
" When pantoprazole is used in combination with clobazam, dose reduction of clobazam should be considered, or significance of PPIs is seen to avoid adverse effects."( Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study.
Baddam, R; Gone, V; Pasupuleti, B; Prasad, OP; Venisetty, RK, 2020
)
0.56
"Our study suggests that KFX combined with rabeprazole showed positive therapeutic effects and is safe for treating PU, which may provide more reliable evidence for the clinical use of KFX in the treatment of PU."( Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis.
Gao, F; Lin, M; Luo, R; Shi, J; Sun, J; You, J; Zhang, C; Zhang, J; Zhang, M; Zhang, S, 2020
)
1.06
" To investigate the drug-drug interaction mechanism between CDK inhibitors and proton pump inhibitors, the in-silico docking approach was designed by applying computer simulation modules to predict the binding and inhibitory potential."( Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy.
Birangal, S; Farooqui, J; Fatima, F; Jagadish, PC; Patil, PH; Pinjari, J; Rao, M; Rastogi, H; Sharma, T; Shenoy, GG, 2022
)
0.72
"Proton pump inhibitors alter the conformation of the CYP3A4 and CYP2C19 enzymes and interact with the heme prosthetic group, as determined by docking studies."( Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy.
Birangal, S; Farooqui, J; Fatima, F; Jagadish, PC; Patil, PH; Pinjari, J; Rao, M; Rastogi, H; Sharma, T; Shenoy, GG, 2022
)
0.72
"Using dynamic models, we determined that proton pump inhibitors such as rabeprazole and omeprazole indeed have the potential to cause clinically significant drug-drug interactions with CDK inhibitors in the treatment of estrogen receptor (ER) positive and HER2-positive breast cancer."( Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy.
Birangal, S; Farooqui, J; Fatima, F; Jagadish, PC; Patil, PH; Pinjari, J; Rao, M; Rastogi, H; Sharma, T; Shenoy, GG, 2022
)
0.95
" As such, this 2-part clinical drug-drug interaction study was conducted to assess the effect of itraconazole (a strong CYP3A4 inhibitor), rifampicin (a strong CYP3A4 inducer), rabeprazole, and omeprazole (both proton pump inhibitors) on the pharmacokinetics of belumosudil."( A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors.
Alabanza, A; Lohmer, L; Patel, J; Schueller, O; Singh, N; Willson, A, 2022
)
0.91
"This study aimed to investigate the application and effectiveness of Morodan combined with rabeprazole in patients with chronic gastritis, focusing on its impact on gastric mucosa repair."( The Efficacy of Morodan in Combination with Rabeprazole for the Treatment of Chronic Gastritis and its Impact on Gastric Mucosal Repair.
Guo, R; Li, Y; Ma, Q; Ma, S, 2023
)
1.39

Bioavailability

The pharmacokinetic parameters (C(max), AUC(o-t), t(max) of this drug have been evaluated to compare the single dose (20 mg) bioavailability of rabeprazole sodium with the standard reference. The study was designed to determine th

ExcerptReferenceRelevance
" Its bioavailability is not influenced by the coingestion of either food or antacids."( Review article: the pharmacokinetics of rabeprazole in health and disease.
Hoyumpa, AM; Merritt, GJ; Swan, SK, 1999
)
0.57
" They have comparable rates of absorption, maximum plasma concentrations, and total drug absorptions resulting in similar bioavailability after single-dose administration."( Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy.
Lew, EA, 1999
)
0.3
" The substance has an absolute bioavailability upon oral administration of approximately 52% which is robust against food intake or administration of antacids."( Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.
Fuhr, U; Jetter, A, 2002
)
1.76
" The pharmacokinetic parameters (C(max), AUC(o-t), t(max)) of this drug have been evaluated to compare the single dose (20 mg) bioavailability of rabeprazole sodium with the standard reference."( Bioequivalence study of rabeprazole sodium on healthy human volunteers.
Banerjee, SN; Chattaraj, TK; Ganesan, M; Jayakumar, M; Mondal, U; Pal, TK; Roy, K, 2004
)
0.83
"The study was designed to determine the absolute bioavailability of 20 mg rabeprazole tablets in normal, healthy subjects in comparison with intravenous administration of 20 mg rabeprazole."( Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects.
Hasegawa, J; Humphries, T; Laurent, A; Setoyama, T, 2005
)
0.88
"The absorption and bioavailability of proton pump inhibitors is influenced by food intake."( A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study.
Adachi, K; Azumi, T; Furuta, K; Kinoshita, Y; Koshino, K; Miki, M, 2006
)
0.33
" A greater understanding of metabolic stability and its modulation by pharmaceutical excipients would be useful for optimizing the bioavailability of rabeprazole at the early formulation stages."( In vitro metabolic stability of moisture-sensitive rabeprazole in human liver microsomes and its modulation by pharmaceutical excipients.
Kim, A; Lee, BJ; Park, MJ; Ren, S, 2008
)
0.8
"25 and the relative bioavailability of rabeprazole and itopride test and reference formulations was 98."( Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers.
Agarwal, S; Bhaumik, U; Bose, A; Das, A; Ghosh, D; Pal, TK; Roy, B; Sahoo, BK, 2009
)
0.85
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"A rapid, simple and sensitive reversed-phase high-performance liquid chromatographic-tandem mass/mass spectrometry (HPLC/MS/MS) method has been developed for the measurement of rabeprazole (CAS 117976-89-3) concentrations in human plasma and its use in bioavailability studies has been evaluated."( Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study.
Deng, H; Xiang, B; Yu, L, 2010
)
0.78
" However, no published data is available regarding the combined pharmacokinetics and bioavailability of this particular fixed dose combination."( Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects.
Chakrabarty, US; Chatterjee, B; Das, A; Mukherjee, J; Pal, TK; Roy, B; Sahoo, B; Sengupta, P, 2010
)
0.6
"To evaluate the relative bioavailability of a new formulation containing 5 mg mosapride and 10 mg rabeprazole (T) and compare it with the branded formulations of both drugs co-administered in separate tablets (R) to meet the regulatory requirements of bioequivalence in Argentina."( Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study.
Assefi, AR; Bertuola, R; Czerniuk, P; de Mena, F; Di Girolamo, G; Keller, GA; Simoni, MV, 2011
)
0.84
" Herein, we identified AL3810 as a novel and orally bioavailable small molecular inhibitor with potent inhibitory activity against multiple tyrosine kinases involved in the process of angiogenesis."( AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.
Chen, Y; Ding, J; Geng, M; Jiang, H; Lin, L; Luo, C; Shen, Y; Tong, L; Wang, Y; Wen, W; Xi, Y; Xie, H; Zhang, J; Zhou, Y, 2012
)
0.38
"The primary objective of this study-conducted on the sponsor's initiative-was to compare the bioavailability of rabeprazole granules when mixed with various dosing vehicles (small amount of soft food or infant formula) with that of a rabeprazole suspension with inactive vehicle granules (reference), to determine which dosing vehicle can be used to deliver rabeprazole in children."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012
)
0.79
"In these healthy adult subjects, the bioavailability of rabeprazole granules was comparable between all of the dosing vehicles tested, and rabeprazole was well tolerated."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012
)
0.83
" Since cobimetinib exhibited absorption variability in cancer patients, a series of single-dose studies in healthy subjects were conducted to determine absolute bioavailability and elucidate potential effects of formulation, food, and elevated gastric pH on cobimetinib bioavailability."( Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects.
Chan, IT; Choo, E; Deng, Y; Dresser, MJ; Eppler, S; Musib, L; Rooney, I, 2013
)
0.61
"This phase 1, open-label crossover study evaluated the relative bioavailability of dacomitinib in healthy volunteers under fed and fasted conditions and following coadministration with rabeprazole, a potent acid-reducing proton pump inhibitor (PPI)."( Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
Bello, CL; Boutros, T; Ellery, CA; Goldberg, Z; LaBadie, RR; Liang, Y; Masters, JC; Mendes da Costa, L; Ni, G; Ruiz-Garcia, A, 2016
)
0.63
" The aim of this study was to evaluate the pharmacokinetic properties and bioavailability of RSPI in healthy Chinese volunteers."( Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection.
Ge, J; Li, F; Li, J; Li, X; Lu, C; Ma, Z; Song, Y; Wen, A, 2016
)
0.66
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The objectives of this phase 1, open-label crossover study (NCT02569554) in healthy adult participants were to determine (1) the effects of the proton pump inhibitor (PPI) rabeprazole on lorlatinib pharmacokinetics (PK), (2) the effects of a high-fat meal on lorlatinib PK, and (3) the relative bioavailability of an oral solution to tablet formulation of lorlatinib under fasted conditions."( Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
Ginman, K; James, LP; Nepal, S; O'Gorman, MT; Pithavala, YK; Xu, H, 2021
)
1.05

Dosage Studied

Rabeprazole is administered at reduced as well as high dosages in eradication therapy for Helicobacter pylori. There was, however, a suggestion of accumulation with multiple dosing of rabeprazoles 20 mg.

ExcerptRelevanceReference
" No appreciable change in drug pharmacokinetics was observed during repeated oral dosing of E3810."( Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers.
Hasegawa, J; Morishita, N; Nakai, H; Ogawa, T; Ohnishi, A; Shimamura, Y; Tomono, Y; Yasuda, S, 1994
)
0.29
"This study examined the dose-response effects of the new proton-pump inhibitor rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease."( Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
Greenwood, B; Humphries, TJ; Maton, PN; Robinson, M; Rodriguez, S, 1997
)
0.87
" A dosage was considered effective if reflux time was reduced to < 6%, a number which has been our internal laboratory reference."( Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
Greenwood, B; Humphries, TJ; Maton, PN; Robinson, M; Rodriguez, S, 1997
)
0.64
" pylori infection by serology and 13C-urea breath test, were studied on the 1st and 8th day of dosing with either placebo, rabeprazole 20 mg or omeprazole 20 mg, once each morning, in a crossover fashion."( A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
Hamilton, MI; Pounder, RE; Sercombe, J; Williams, MP, 1998
)
0.74
" These results indicate that no dosage adjustment of rabeprazole is required in patients with renal dysfunction."( Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure.
Grimes, I; Humphries, TJ; Keane, WF; Swan, SK, 1999
)
2
" A once-daily dose of 20 mg has consistently achieved profound decreases in 24-h intragastric acidity in single and repeat dosing studies, in healthy volunteers and patients with either peptic ulcer disease or gastro-oesophageal reflux disease."( Review article: the pharmacology of rabeprazole.
Pounder, RE; Williams, MP, 1999
)
0.58
" These findings suggest that dosage adjustment is not required in these special patient populations."( Review article: the pharmacokinetics of rabeprazole in health and disease.
Hoyumpa, AM; Merritt, GJ; Swan, SK, 1999
)
0.57
" However, the pharmacokinetic findings suggest that no dosage adjustment is required in these special populations."( Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy.
Lew, EA, 1999
)
0.3
"The selection of agents to treat patients with acid-related gastrointestinal diseases requires knowledge of their efficacy, tolerability, and ease of dosing among individuals with differing disease severities and other baseline characteristics."( Review article: rabeprazole's profile in patients with gastrointestinal diseases.
Barth, J; Humphries, TJ, 1999
)
0.65
" In this study, we focused on whether 20 mg of rabeprazole is effective in our patient population by comparing that dosage with 40 mg of rabeprazole and 60 mg of lansoprazole."( Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Miwa, H; Murai, T; Nagahara, A; Ogihara, T; Ohkura, R; Ohta, K; Sato, K; Sato, N; Takei, Y; Yamada, T, 2000
)
0.85
"Twenty-four healthy male volunteers were studied on the 7th day of morning dosing with either placebo or rabeprazole 10, 20 or 40 mg in a crossover fashion."( A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects.
Blanshard, C; Millson, C; Pounder, RE; Sercombe, J; Williams, MP, 2000
)
0.74
" pylori infection appears to be closely related to the occurrence of nocturnal gastric acid breakthrough during dosing with a proton pump inhibitor."( Helicobacter pylori infection influences nocturnal gastric acid breakthrough.
Adachi, K; Amano, K; Katsube, T; Kawamura, A; Kinoshita, Y; Uchida, Y; Watanabe, M, 2000
)
0.31
"To determine the effect of CYP2C19 genotype status on intragastric pH during dosing with lansoprazole or rabeprazole."( CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi, K; Amano, K; Fukuda, R; Ishihara, S; Katsube, T; Kawamura, A; Kinoshita, Y; Takashima, T; Watanabe, M; Yuki, M, 2000
)
0.75
" On the other hand, the median pH in PMs during lansoprazole dosing was higher than in homo-EMs and hetero-EMs."( CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi, K; Amano, K; Fukuda, R; Ishihara, S; Katsube, T; Kawamura, A; Kinoshita, Y; Takashima, T; Watanabe, M; Yuki, M, 2000
)
0.53
"Rabeprazole 20 mg in two different dosing schedules is as effective as omeprazole 20 mg QD with regard to efficacy and tolerability in patients with erosive GERD."( Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
Cohen, G; Delchier, JC; Humphries, TJ, 2000
)
3.19
"Little is known about differences in the disposition kinetics and pharmacological effects on gastrin levels between lansoprazole and rabeprazole given in a repeated dosing scheme with respect to the polymorphic CYP2C19."( Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Fukushima, Y; Hasegawa, J; Ieiri, I; Ishizaki, T; Kishimoto, Y; Kitano, M; Momiyama, K; Morisawa, T; Morita, T; Nakagawa, K; Okochi, H; Otsubo, K, 2001
)
0.74
"The acid inhibitory effects of omeprazole and rabeprazole are significantly dependent on the CYP2C19 genotype status, as well as on their intrinsic pharmacokinetic and pharmacodynamic characteristics and dosing schemes."( Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
Chiba, K; Furuta, T; Hanai, H; Ishizaki, T; Kobayashi, K; Kosuge, K; Moriyama, Y; Nakagawa, K; Ohashi, K; Okochi, H; Shirai, N; Takashima, M; Xiao, F, 2001
)
0.8
" No dosage adjustment is necessary in renal and mild to moderate hepatic impairment."( Rabeprazole: an update of its use in acid-related disorders.
Carswell, CI; Goa, KL, 2001
)
1.75
" Mean pH AUC in the first 5 h after dosing on day 5 was higher after esomeprazole than rabeprazole (P=0."( Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.
Baisley, K; Boyce, M; Miller, N; Morocutti, A; Tejura, B; Warrington, S, 2002
)
0.93
" Compliance (as measured by a medication-possession ratio), dosage escalation (> 25 percent of initial dose), and daily average consumption (DACON) were measured."( Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Dodd, S; Durkin, M; Hall, J; Sloan, S, 2002
)
0.31
" pylori eradication on intragastric acidity and plasma gastrin during dosing with lansoprazole, omeprazole, rabeprazole and placebo."( Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Chilton, A; Nwokolo, CU; Pounder, RE; Sercombe, J; Usselmann, B; Williams, MP, 2003
)
0.75
" pylori eradication during dosing with proton pump inhibitors is a drug-class effect, particularly affecting nocturnal acid control."( Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Chilton, A; Nwokolo, CU; Pounder, RE; Sercombe, J; Usselmann, B; Williams, MP, 2003
)
0.54
" However, no significant difference was noted between day 1 and day 4 of dosing within the same genotype groups."( Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Chern, HD; Lin, CJ; Uang, YS; Wang, TH; Yang, JC, 2003
)
0.55
"Rapid and consistent acid suppression on the first day of dosing may be important in treating acid-related disorders."( Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
Blum, AL; Dorta, G; Jornod, P; Pantoflickova, D; Ravic, M, 2003
)
0.32
" Split dosing of rabeprazole was more effective than the single morning dose for inhibiting nocturnal gastric acid secretion."( Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens.
Adachi, K; Amano, Y; Fujishiro, H; Karim Rumi, MA; Kawamura, A; Kinoshita, Y; Komazawa, Y; Mihara, T; Ono, M; Yuki, M, 2003
)
0.9
" These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms."( Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.
McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003
)
0.57
"To achieve more potent and long-lasting acid suppression, different dosage regimens of rabeprazole were compared in relation to the CYP2C19 genotype status."( Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.
Horikawa, Y; Inoue, M; Kuroiwa, T; Shimatani, T, 2004
)
1.99
"To compare the effects of standard-dose esomeprazole with those of standard doses of lansoprazole and rabeprazole on intragastric pH during repeated daily oral dosing in healthy volunteers."( Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
Junghard, O; Nilsson-Pieschl, C; Nyman, L; Röhss, K; Wilder-Smith, CH, 2003
)
0.75
" The proposed method was applied to the determination of rabeprazole in the tablet dosage form."( Voltammetric behaviour of rabeprazole at a glassy carbon electrode and its determination in tablet dosage form.
Abd El-Ghany, N; Radi, A; Wahdan, T, 2004
)
0.87
"To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD)."( Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Lind, T; Röhss, K; Wilder-Smith, C, 2004
)
0.74
" We aimed to develop optimal dosage regimens for rabeprazole to control nocturnal acidity in relation to cytochrome P450 (CYP) 2C19 genotypes."( Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Furuta, T; Hishida, A; Ishizaki, T; Kajimura, M; Ohashi, K; Sakurai, M; Shirai, N; Sugimoto, M, 2004
)
0.87
"We propose that rabeprazole dosage regimens for sufficient acid inhibition are 20 mg once daily for PMs, 20 mg twice daily for heterozygous EMs, and 10 mg 4 times daily for homozygous EMs or heterozygous EMs."( Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Furuta, T; Hishida, A; Ishizaki, T; Kajimura, M; Ohashi, K; Sakurai, M; Shirai, N; Sugimoto, M, 2004
)
0.96
"A concomitant dosage regimen of a histamine 2 receptor antagonist with a proton pump inhibitor (PPI) effectively decreases the incidence of nocturnal acid breakthrough, which is one of the problems encountered when acid-related diseases are treated with a PPI alone."( Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Furuta, T; Hishida, A; Ishizaki, T; Kajimura, M; Nakamura, A; Ohashi, K; Shirai, N; Sugimoto, M, 2005
)
0.59
"The combination regimen of famotidine plus rabeprazole is more effective for nocturnal acid inhibition in homozygous and heterozygous EMs than the increased dosage regimen of rabeprazole."( Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Furuta, T; Hishida, A; Ishizaki, T; Kajimura, M; Nakamura, A; Ohashi, K; Shirai, N; Sugimoto, M, 2005
)
0.85
"Ten normal subjects underwent two 8-day oral dosing regimens with placebo or rabeprazole 20 mg each morning in a randomized, double-blind protocol."( The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study.
Doma, S; Fisher, RS; Parkman, HP; Simonian, HP; Vo, L, 2005
)
0.92
" For the better PPI-based treatment, doses and dosing schemes of PPIs should be optimized based on CYP2C19 genotype status."( Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M, 2005
)
0.33
" Therefore it is administered at reduced as well as high dosages in eradication therapy for Helicobacter pylori; however, there is incomplete assessment of the efficacy of a reduced dosage of rabeprazole as might be employed in therapy."( Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
Horikawa, Y; Inoue, M; Kuroiwa, T; Nakamura, M; Shimatani, T; Tazuma, S; Xu, J, 2005
)
0.77
" dosing of rabeprazole."( Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Hall, M; Higbee, A; Mathur, S; Sampliner, RE; Sharma, P; Wani, S; Weston, AP, 2005
)
0.72
" Long-term dosing schedule (high dose or step-down dose) was based on current market data."( Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Brown, RE; Remák, E; Robinson, A; Yuen, C, 2005
)
0.33
" In humans, once-daily dosing of 5-40 mg of rabeprazole inhibits gastric acid secretion in a dose-dependent manner."( Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
Sharara, AI, 2005
)
2.03
" Pre-meal dosing maximizes efficacy while sub-optimal dose timing may limit efficacy."( Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006
)
0.33
"To determine the prevalence of sub-optimal proton pump inhibitor dosing in a community-based gastro-oesophageal reflux disease population."( Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006
)
0.33
"One hundred patients on proton pump inhibitors referred for persistent gastro-oesophageal reflux disease symptoms were questioned about their proton pump inhibitor dosing habits and classified as optimal or sub-optimal dosers."( Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006
)
0.33
"Forty-six percent dosed optimally."( Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006
)
0.33
"In this study, 54% of patients dosed proton pump inhibitors sub-optimally and only 12% dosed in a manner that maximized acid suppression."( Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006
)
0.33
"Mean intragastric pH was higher after esomeprazole than rabeprazole during 0-5 h after dosing (P=0."( Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects.
Baisley, K; Boyce, M; Dunn, K; Morocutti, A; Warrington, S, 2006
)
0.88
"Oral dosage of the H2 receptor antagonists, ranitidine and famotidine, has no significant effect on gastric emptying."( Influence of acid suppressants on gastric emptying: cross-over analysis in healthy volunteers.
Amano, Y; Ishihara, S; Kinoshita, Y; Kushiyama, Y; Miyake, T; Ose, T; Sato, S; Takahashi, Y; Yuki, T, 2006
)
0.33
"To compare antisecretory effects of rabeprazole and esomeprazole after single and repeat dosing in Helicobacter pylori-negative healthy volunteers."( Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers.
Baisley, K; Dunn, K; Morocutti, A; Norris, V; Warrington, S, 2007
)
0.84
" The studies compared: (a) 5 days' dosing of 20 mg rabeprazole and esomeprazole (n = 24); (b) single doses of rabeprazole 20 mg and esomeprazole 40 mg (n = 27) and (c) 5 days' dosing of rabeprazole 10 mg and esomeprazole 20 mg (n = 29)."( Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers.
Baisley, K; Dunn, K; Morocutti, A; Norris, V; Warrington, S, 2007
)
0.82
" In general, intragastric pH AUC during 0-5 h after dosing was higher after esomeprazole than rabeprazole, whereas the reverse was true during the night."( Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers.
Baisley, K; Dunn, K; Morocutti, A; Norris, V; Warrington, S, 2007
)
0.79
"To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P450 (CYP) 2C19 polymorphism in a population with a high prevalence of people who metabolize PPI poorly."( Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Chiu, HM; Lee, YC; Lin, JT; Wang, HP; Wu, MS, 2007
)
0.85
" Subjects were given either esomeprazole 40 mg (n = 18) or rabeprazole 10 mg (n = 18) orally once daily for 5 days during the first dosing period, then the other medicine at the set dosage for the second dosing period."( Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Cheng, NN; Li, ZS; Liao, Z; Xu, GM; Zhan, XB, 2007
)
0.88
"A new simple, economical, rapid, precise and accurate method for simultaneous determination of rabeprazole sodium and itopride hydrochloride in capsule dosage form has been developed."( Spectrophotometric simultaneous determination of rabeprazole sodium and itopride hydrochloride in capsule dosage form.
Dhavale, ND; Gandhi, SV; Jadhav, VY; Sabnis, SS, 2008
)
0.82
" Elevated serum gastrin levels occurred in 73% of children with no statistically significant differences in gastrin level by PPI type, dose, and dosing frequency or treatment duration."( Long-term proton pump inhibitor use in children: a retrospective review of safety.
Boyer, K; Tolia, V, 2008
)
0.35
"The aims of this study were to fast screen the compatibility of rabeprazole and excipients using a spectrocolorimeter and to examine the relationship between the color change value and drug contents/drug degradation products in solid dosage forms."( Application of instrumental evaluation of color for the pre-formulation and formulation of rabeprazole.
Kam, SH; Lee, KH; Park, CW; Park, ES; Rhee, YS; Shin, YS, 2008
)
0.81
" There was, however, a suggestion of accumulation with multiple dosing of rabeprazole 20 mg, which requires confirmation in larger studies."( Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study.
James, L; Kao, R; Lomax, K; Reyes, J; Varughese, S; Walson, P, 2007
)
0.84
"To determine, whether oral rabeprazole, administered 5 h before the initiation of therapeutic dosing of aspirin protects the gastroduodenal mucosa."( Rapid protection of the gastroduodenal mucosa against aspirin-induced damage by rabeprazole.
Desipio, J; Fisher, RS; Irani, S; Kim-Jaffe, J; Krevsky, B; Maqbool, S, 2008
)
0.87
"Simple, sensitive high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC) methods are developed for the quantitative estimation of rabeprazole and mosapride in their combined pharmaceutical dosage forms."( High-performance liquid chromatography and thin-layer chromatography for the simultaneous quantitation of rabeprazole and mosapride in pharmaceutical products.
Patel, BH; Patel, JR; Patel, MM; Suhagia, BN, 2008
)
0.76
"A new, simple column reversed-phase high-performance liquid chromatographic (HPLC) method for simultaneous determination of rabeprazole sodium (RAB) and domperidone (DOM) in a combined tablet dosage form has been developed and validated."( Column reversed-phase high-performance liquid chromatographic method for simultaneous determination of rabeprazole sodium and domperidone in combined tablet dosage form.
Dnvandev, DN; Gandhi, SV; Jadhav, VY; Sabnis, SS,
)
0.55
"The main aim of this work is to develop and validate two spectrophotometric methods for the quantitative analysis of rabeprazole sodium in commercial dosage forms."( Quantitative analysis of rabeprazole sodium in commercial dosage forms by spectrophotometry.
Azmi, SN; Bano, Z; Rahman, N, 2008
)
0.86
" All the studied methods have been validated and successfully applied to the determination of rabeprazole sodium in tablet dosage form."( Chemometric determination of rabeprazole sodium in presence of its acid induced degradation products using spectrophotometry, polarography and anodic voltammetry at a glassy carbon electrode.
Moneeb, MS, 2008
)
0.86
" Subsequent studies should be performed to evaluate antibiotic resistance, doses, dosing intervals, duration of treatment, and safety of these two regimes."( Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.
Coelho, L; Moretzsohn, L; Sanches, B; Vieira, G, 2008
)
0.35
"A new, simple, high-performance thin-layer chromatographic method for determination of rabeprazole sodium (RAB) and domperidone (DOM) in combined tablet dosage form has been developed and validated."( High-performance thin-layer chromatographic determination of rabeprazole sodium and domperidone in combined dosage form.
Gandhi, SV; Jadhav, GA; Jadhav, RT; Jadhav, SS; Khan, SI,
)
0.6
" These findings suggest a safer dosing and monitoring of tacrolimus coadministered with rabeprazole early on after liver transplantation regardless of the CYP2C19 and CYP3A5 genotypes of transplant patients and their donors."( Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study.
Hosohata, K; Inui, K; Kaido, T; Masuda, S; Ogura, Y; Oike, F; Sugimoto, M; Takada, Y; Uemoto, S; Yonezawa, A, 2009
)
0.82
" Fifteen healthy Japanese volunteers are dosed for 7 days in a 5-way randomly crossover trial: placebo, aspirin 100 mg, rabeprazole 10 mg, and aspirin 100 mg plus rabeprazole 10 mg either once daily or 4 times per day."( Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Sugimura, H; Tanaka, T; Yamade, M, 2010
)
0.8
" The optimum assay conditions were investigated and the recovery of the drugs from their dosage forms ranged from 99."( Spectrophotometric determination of peptic ulcer sulfur-containing drugs in bulk form and in tablets.
El-Tantawy, AS; Khalil, SM; Mohamed, GG; Nour El-Dien, FA, 2010
)
0.36
"A stability-indicating thin layer chromatographic (TLC) method for determination of dexrabeprazole (DEX) and domperidone (DOM) in combined dosage form has been developed and validated."( Stability-indicating TLC-densitometric method for estimation of dexrabeprazole and domperidone in pharmaceutical dosage form.
Chitlange, SS; Mulla, AI; Pawbake, GR; Wankhede, SB, 2010
)
0.82
" The RPZ dosage was increased to 10 mg twice daily for an additional 2 weeks and again to 20 mg twice daily for another 2 weeks if heartburn was not relieved."( Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research G
Chiba, T; Fujiwara, Y; Furuta, T; Hongo, M; Ishihara, S; Kinoshita, Y; Koike, T; Kusano, M; Shimatani, T; Sugimoto, M, 2011
)
0.37
" Twenty-four individuals received a once-daily dose, with dosing interval 24 h of 5, 10, 20, or 40 mg rabeprazole for 5 days in a 4-period crossover fashion."( Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
Abe, H; Hasegawa, S; Hayato, S; Hojo, S; Horai, Y; Munesue, M; Ohnishi, A; Okawa, H; Sugisaki, N, 2012
)
0.88
"15 healthy Japanese volunteers were dosed for 7 days in a four-way random crossover trial with 100 mg entero-coated type aspirin only once daily, 100 mg aspirin + 20 mg famotidine twice daily, 15 mg lansoprazole once daily, or 10 mg rabeprazole once daily."( Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012
)
0.56
" The incidence of esophageal mucosal injury was reduced however with concomitant dosing of aspirin and famotidine (26."( Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012
)
0.38
" Daily dosing of AL3810 has shown broad-spectrum anti-tumour activity in human kidney, pancreas, liver cancer xenograft models."( AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.
Chen, Y; Ding, J; Geng, M; Jiang, H; Lin, L; Luo, C; Shen, Y; Tong, L; Wang, Y; Wen, W; Xi, Y; Xie, H; Zhang, J; Zhou, Y, 2012
)
0.38
"Once-daily dosing with esomeprazole 40 mg provides a more effective and faster acid-inhibitory effect than rabeprazole 20 mg."( A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld, NG; Kuipers, EJ; Mathot, RA; Touw, DJ; van Schaik, RH, 2012
)
0.83
"The primary objective of this study-conducted on the sponsor's initiative-was to compare the bioavailability of rabeprazole granules when mixed with various dosing vehicles (small amount of soft food or infant formula) with that of a rabeprazole suspension with inactive vehicle granules (reference), to determine which dosing vehicle can be used to deliver rabeprazole in children."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012
)
0.79
" In a randomized sequence, fasting subjects received a single dose of 10-mg rabeprazole granules per treatment period, mixed with small amounts of 1 of 5 dosing vehicles (a strawberry-flavored suspension of rabeprazole granules with inactive vehicle granules reconstituted with water, yogurt [1 tablespoon], applesauce [1 tablespoon], or infant formula [5 mL], or a suspension of rabeprazole granules with inactive vehicle tablet reconstituted with water)."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012
)
0.81
" Rabeprazole and rabeprazole thioether plasma PK properties were comparable between all of the dosing vehicles tested."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012
)
1.49
"In these healthy adult subjects, the bioavailability of rabeprazole granules was comparable between all of the dosing vehicles tested, and rabeprazole was well tolerated."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012
)
0.83
"Standard dosing (i."( Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.
Furuta, T; Ichikawa, H; Kodaira, C; Miyajima, H; Nishino, M; Sahara, S; Shirai, N; Sugimoto, K; Sugimoto, M; Uotani, T; Yamade, M, 2012
)
1.82
"To evaluate acid inhibitory effects by different dosing times of a PPI at the same daily dosage, in a study involving 70 rounds of pH monitoring."( Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.
Furuta, T; Ichikawa, H; Kodaira, C; Miyajima, H; Nishino, M; Sahara, S; Shirai, N; Sugimoto, K; Sugimoto, M; Uotani, T; Yamade, M, 2012
)
1.82
"Four times daily dosing with rabeprazole 10 mg achieved potent acid inhibition, including during the night-time, suggesting its potential usefulness as a regimen for patients who are refractory to standard once daily PPI treatment."( Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.
Furuta, T; Ichikawa, H; Kodaira, C; Miyajima, H; Nishino, M; Sahara, S; Shirai, N; Sugimoto, K; Sugimoto, M; Uotani, T; Yamade, M, 2012
)
2.11
"Although endoscopic submucosal dissection (ESD)-induced ulcers heal faster and recur less often than non-iatrogenic gastric ulcers, the optimal dosage and duration of proton pump inhibitor treatment for ESD-induced ulcers remain unclear."( Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer.
Hong, JH; Jo, KW; Kim, BR; Kim, HS; Kim, JW; Park, HJ; Park, SY, 2013
)
0.79
" These data do not support adapting the dosage of rabeprazole and pantoprazole according to BMI in GORD patients when administered as an on-demand therapy schedule."( On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?
Bruley des Varannes, S; Coudsy, B; Delemos, B; Ducrotté, P; Lococo, J; Waechter, S; Xiang, J, 2013
)
0.64
"This study, named the SAMURAI study, aimed to assess the efficacy and dose-response relationship of rabeprazole in Japanese patients with FD in a multicentre, double-blinded, randomised, placebo-controlled trial."( Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan.
Arakawa, T; Fujimoto, K; Furuta, K; Furuta, T; Haruma, K; Higuchi, K; Hiraishi, H; Hongo, M; Inamori, M; Iwakiri, K; Iwakiri, R; Kanke, K; Kato, M; Kinoshita, Y; Kusano, M; Masuyama, H; Miwa, H; Nagahara, A; Naito, Y; Takahashi, S; Tominaga, K; Watanabe, S, 2013
)
0.9
" This pilot study evaluated the extent and time course of gastric reacidification after a solid oral dosage form of anhydrous betaine HCl in healthy volunteers with pharmacologically induced hypochlorhydria."( Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria.
Benet, LZ; Budha, NR; Dresser, MJ; Frassetto, LA; Frymoyer, AR; Smelick, GS; Ware, JA; Yago, MR, 2013
)
0.63
" Given these findings, dosing of GDC-0941 in clinical trials was not constrained relative to fasted/fed states, but the concomitant use of ARAs was restricted."( Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
Dalziel, G; Ding, X; Dresser, MJ; Fridyland, J; Holden, SN; Jin, JY; Morrisson, G; Pellett, JD; Salphati, L; Smelick, GS; Sutton, R; Ware, JA; West, DA, 2013
)
0.65
"Twice-daily dosing of proton pump inhibitors (PPIs) is used to treat Helicobacter pylori or acid-related diseases, such as gastro-oesophageal reflux disease (GERD) refractory to standard dose of a PPI."( Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Yamada, T; Yamade, M, 2013
)
0.59
"To compare acid-inhibitory effects of the four PPIs dosed twice daily in relation to CYP2C19 genotype."( Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Yamada, T; Yamade, M, 2013
)
0.59
"In intermediate and rapid metabolisers of CYP2C19, PPIs dosed twice daily could attain sufficient acid suppression, while in CYP2C19 RMs, esomeprazole 20 mg twice daily caused the strongest inhibition of the four PPIs."( Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Yamada, T; Yamade, M, 2013
)
0.59
" Four times daily dosing (q."( Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
Furuta, T; Ichikawa, H; Sahara, S; Sugimoto, K; Sugimoto, M; Uotani, T; Yamade, M, 2014
)
0.4
" This unique case with serial endoscopy and histology at baseline and monthly suggests the current recommendation of at least two months therapy with PPIs dosed twice daily is appropriate."( Case report of proton pump inhibitor responsive esophageal eosinophilia: why 2 months of proton pump inhibitors is required.
Champeaux, A; Lipka, S; Muhammad, A; Richter, JE, 2016
)
0.43
"Using pH monitoring, we compared acid inhibition at standard dosage of omeprazole (20 mg, 50 times), lansoprazole (30 mg, 68 times), and rabeprazole (10 mg, 65 times) in Helicobacter pylori-negative healthy young Japanese volunteers."( Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.
Furuta, T; Ichikawa, H; Kagami, T; Kodaira, C; Nishino, M; Sahara, S; Shirai, N; Sugimoto, K; Sugimoto, M; Uotani, T, 2014
)
0.61
" Specificity was investigated by analysis of laboratory prepared mixtures containing the cited drugs and their combined tablet dosage form."( Spectrophotometric methods manipulating ratio spectra for simultaneous determination of binary mixtures with sever overlapping spectra: a comparative study.
Fayez, Y; Moustafa, H, 2014
)
0.4
"To conduct a randomised, double-blind, triple-dummy, active-controlled, multicentre trial, named the PLANETARIUM study, to assess the efficacy, dose-response relationship and safety of rabeprazole for peptic ulcer recurrence in Japanese patients on long-term LDA therapy."( Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.
Arakawa, T; Fujimoto, K; Fujishiro, M; Higuchi, K; Iwakiri, R; Kato, M; Kinoshita, Y; Nakagawa, H; Ogawa, H; Okada, Y; Sanomura, M; Sugisaki, N; Takeuchi, T; Watanabe, T; Yamauchi, M, 2014
)
0.83
"Rabeprazole prevents the recurrence of peptic ulcers with no evidence of a major dose-response effect in subjects on low-dose aspirin therapy."( Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.
Arakawa, T; Fujimoto, K; Fujishiro, M; Higuchi, K; Iwakiri, R; Kato, M; Kinoshita, Y; Nakagawa, H; Ogawa, H; Okada, Y; Sanomura, M; Sugisaki, N; Takeuchi, T; Watanabe, T; Yamauchi, M, 2014
)
2.08
" The objective of this study was to develop a population pharmacokinetic model for rabeprazole that describes concentration-time data arising from phase I and phase III studies in adult and pediatric subjects, including neonates and preterm infants, and propose dosing recommendations for pediatric subjects aged 1-11 years."( Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
Green, B; Kimko, H; Mannaert, E; McLeay, SC; Thyssen, A; Treem, W, 2014
)
0.91
" A dosage regimen of 5 mg once daily for children <15 kg, and 10 mg for children ≥15 kg is recommended for 1- to 11-year-old pediatric patients with GERD."( Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
Green, B; Kimko, H; Mannaert, E; McLeay, SC; Thyssen, A; Treem, W, 2014
)
0.69
" Examination of eradication rates according to CAM dosage revealed an eradication rate of 65."( Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A, 2014
)
0.4
" Analysis with PPI categorized according to defined daily dose (DDD), showed some evidence for a dose-response effect (osteoporosis medication: <400 DDD: SHR=1."( The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
de Vries, OJ; Dobson, AJ; Peeters, GMEEG; Tett, SE; van der Hoorn, MMC, 2015
)
0.42
"Four times daily dosing (qid) with a proton pump inhibitor can cause rapid increase in intragastric pH."( One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.
Furuta, T; Hamaya, Y; Ichikawa, H; Iwaizumi, M; Kagami, T; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Uotani, T; Yamade, M, 2015
)
0.68
" Main criteria are indication, dosage frequency, treatment duration, best published evidence, available formulations, drug interactions, and pharmacokinetic and pharmacodynamic properties."( Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar.
Al-Badriyeh, D; Al-Khal, A; Alabbadi, I; Fahey, M; Zaidan, M, 2016
)
0.43
" Here, we present an eradication regimen consisting of four-times-daily dosing (q."( Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
Andoh, A; Ban, H; Furuta, T; Ichikawa, H; Kagami, T; Otsuka, T; Sahara, S; Sugimoto, M, 2017
)
0.75
" This study also showed that the histamine-2 receptor antagonist famotidine and local antacid with staggered dosing had no impact on palbociclib exposure under fed conditions."( Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.
Kirkovsky, L; Klamerus, KJ; Kosa, M; O'Gorman, M; Pawlak, S; Plotka, A; Sun, W; Wang, D; Yuhas, LM, 2017
)
0.46
"Introduction: On the pharmaceutical market of Ukraine, there are six international non-proprietary names of proton pump inhibitors (PPIs) - Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole, Esomeprazole, Dexlansoprazole, which differ in a number of pharmacokinetic and pharmacodynamic parameters, safety profile, range of dosage forms and their cost."( Qualimetric analysis of proton pump inhibitors in Ukraine.
Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM, 2019
)
0.71
"We developed and validated a simple, convenient and reproducible method for simultaneous estimation of six proton-pump inhibitors (PPIs), omeprazole (OPZ), esomeprazole (EOPZ), lansoprazole (LPZ), pantoprazole (PPZ), rabeprazole (RPZ) and ilaprazole (IPZ) in pharmaceutical dosage forms by a single marker."( Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Chen, F; Fang, B; He, X; Wang, S, 2020
)
0.74
"The proposed method, which is selective, economical and accurate, was applied successfully for determination of the cited PPIs in their respective pharmaceutical dosage forms."( Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Chen, F; Fang, B; He, X; Wang, S, 2020
)
0.56
" When a 200-mg single oral dose of belumosudil was coadministered with both rabeprazole and omeprazole, parent and metabolite exposures were largely reduced, suggesting that belumosudil dosage should be increased when given with PPIs."( A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors.
Alabanza, A; Lohmer, L; Patel, J; Schueller, O; Singh, N; Willson, A, 2022
)
0.95
"The optimal dosage of new generation proton pump inhibitors (PPIs) in increasing cure rate of Helicobacter pylori (H."( Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pylori.
Dai, X; Gao, C; Wang, Y; Yang, X, 2023
)
1.15
"Based on the available evidence, R40bid and E40bid might be the optimum dosage to increase the cure rate; however, E40qd was superior for adverse events."( Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pylori.
Dai, X; Gao, C; Wang, Y; Yang, X, 2023
)
1.15
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitorAn EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that inhibits H(+)/K(+)-exchanging ATPase, EC 3.6.3.10. Such compounds are also known as proton pump inhibitors.
anti-ulcer drugOne of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
sulfoxideAn organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Rabeprazole Action Pathway1013
Rabeprazole Metabolism Pathway22

Protein Targets (15)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)IC50 (µMol)53.00007.80008.25708.7140AID1600079
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)3.21900.00001.89408.5470AID625196
Adenosine receptor A3Homo sapiens (human)Ki1.82000.00000.930610.0000AID625196
Insulin-degrading enzymeHomo sapiens (human)IC50 (µMol)11.00000.01402.35207.0000AID1600069
Urease subunit alphaHelicobacter pylori 26695IC50 (µMol)0.29000.29003.87606.7000AID1632334
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.21900.00021.874210.0000AID625196
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki1.82000.00010.949010.0000AID625196
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)1.73700.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.79300.00020.725710.0000AID625202
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)2.32600.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.79000.00000.602010.0000AID625254
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.21900.00001.819410.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki1.82000.00000.965010.0000AID625196
Fatty acid synthaseHomo sapiens (human)IC50 (µMol)52.00000.00772.46245.8000AID1195927
Fatty acid synthaseHomo sapiens (human)Ki5.90000.28003.44675.9000AID1195927
WD repeat-containing protein 5Homo sapiens (human)IC50 (µMol)0.49000.22302.45625.9000AID1688549
Urease subunit betaHelicobacter pylori 26695IC50 (µMol)0.29000.29003.87606.7000AID1632334
Histone-lysine N-methyltransferase 2AHomo sapiens (human)IC50 (µMol)0.49000.45002.30935.9000AID1688549
NAD(+) hydrolase SARM1Homo sapiens (human)IC50 (µMol)3.25003.20004.90008.7000AID1622860; AID1622861
Cytosolic endo-beta-N-acetylglucosaminidaseHomo sapiens (human)IC50 (µMol)4.47004.47004.47004.4700AID1453445
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)8.50000.00401.966610.0000AID1873205
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (164)

Processvia Protein(s)Taxonomy
citrulline metabolic processN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
regulation of systemic arterial blood pressureN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
arginine catabolic processN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
nitric oxide mediated signal transductionN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
negative regulation of cell population proliferationN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
negative regulation of vascular permeabilityN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
positive regulation of angiogenesisN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
nitric oxide metabolic processN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
negative regulation of cellular response to hypoxiaN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
arginine metabolic processN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
proteolysisInsulin-degrading enzymeHomo sapiens (human)
insulin receptor signaling pathwayInsulin-degrading enzymeHomo sapiens (human)
bradykinin catabolic processInsulin-degrading enzymeHomo sapiens (human)
ubiquitin recyclingInsulin-degrading enzymeHomo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IInsulin-degrading enzymeHomo sapiens (human)
protein catabolic processInsulin-degrading enzymeHomo sapiens (human)
positive regulation of protein bindingInsulin-degrading enzymeHomo sapiens (human)
hormone catabolic processInsulin-degrading enzymeHomo sapiens (human)
peptide catabolic processInsulin-degrading enzymeHomo sapiens (human)
positive regulation of protein catabolic processInsulin-degrading enzymeHomo sapiens (human)
symbiont entry into host cellInsulin-degrading enzymeHomo sapiens (human)
amyloid-beta metabolic processInsulin-degrading enzymeHomo sapiens (human)
proteolysis involved in protein catabolic processInsulin-degrading enzymeHomo sapiens (human)
amyloid-beta clearanceInsulin-degrading enzymeHomo sapiens (human)
amyloid-beta clearance by cellular catabolic processInsulin-degrading enzymeHomo sapiens (human)
insulin metabolic processInsulin-degrading enzymeHomo sapiens (human)
insulin catabolic processInsulin-degrading enzymeHomo sapiens (human)
regulation of aerobic respirationInsulin-degrading enzymeHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
osteoblast differentiationFatty acid synthaseHomo sapiens (human)
glandular epithelial cell developmentFatty acid synthaseHomo sapiens (human)
fatty acid metabolic processFatty acid synthaseHomo sapiens (human)
fatty acid biosynthetic processFatty acid synthaseHomo sapiens (human)
inflammatory responseFatty acid synthaseHomo sapiens (human)
ether lipid biosynthetic processFatty acid synthaseHomo sapiens (human)
neutrophil differentiationFatty acid synthaseHomo sapiens (human)
monocyte differentiationFatty acid synthaseHomo sapiens (human)
mammary gland developmentFatty acid synthaseHomo sapiens (human)
modulation by host of viral processFatty acid synthaseHomo sapiens (human)
cellular response to interleukin-4Fatty acid synthaseHomo sapiens (human)
establishment of endothelial intestinal barrierFatty acid synthaseHomo sapiens (human)
fatty-acyl-CoA biosynthetic processFatty acid synthaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIWD repeat-containing protein 5Homo sapiens (human)
skeletal system developmentWD repeat-containing protein 5Homo sapiens (human)
gluconeogenesisWD repeat-containing protein 5Homo sapiens (human)
regulation of DNA-templated transcriptionWD repeat-containing protein 5Homo sapiens (human)
regulation of transcription by RNA polymerase IIWD repeat-containing protein 5Homo sapiens (human)
positive regulation of gluconeogenesisWD repeat-containing protein 5Homo sapiens (human)
transcription initiation-coupled chromatin remodelingWD repeat-containing protein 5Homo sapiens (human)
positive regulation of DNA-templated transcriptionWD repeat-containing protein 5Homo sapiens (human)
regulation of embryonic developmentWD repeat-containing protein 5Homo sapiens (human)
regulation of cell divisionWD repeat-containing protein 5Homo sapiens (human)
regulation of cell cycleWD repeat-containing protein 5Homo sapiens (human)
regulation of tubulin deacetylationWD repeat-containing protein 5Homo sapiens (human)
apoptotic processHistone-lysine N-methyltransferase 2AHomo sapiens (human)
visual learningHistone-lysine N-methyltransferase 2AHomo sapiens (human)
post-embryonic developmentHistone-lysine N-methyltransferase 2AHomo sapiens (human)
anterior/posterior pattern specificationHistone-lysine N-methyltransferase 2AHomo sapiens (human)
methylationHistone-lysine N-methyltransferase 2AHomo sapiens (human)
circadian regulation of gene expressionHistone-lysine N-methyltransferase 2AHomo sapiens (human)
embryonic hemopoiesisHistone-lysine N-methyltransferase 2AHomo sapiens (human)
exploration behaviorHistone-lysine N-methyltransferase 2AHomo sapiens (human)
response to potassium ionHistone-lysine N-methyltransferase 2AHomo sapiens (human)
protein modification processHistone-lysine N-methyltransferase 2AHomo sapiens (human)
T-helper 2 cell differentiationHistone-lysine N-methyltransferase 2AHomo sapiens (human)
transcription initiation-coupled chromatin remodelingHistone-lysine N-methyltransferase 2AHomo sapiens (human)
positive regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase 2AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase 2AHomo sapiens (human)
fibroblast proliferationHistone-lysine N-methyltransferase 2AHomo sapiens (human)
negative regulation of fibroblast proliferationHistone-lysine N-methyltransferase 2AHomo sapiens (human)
regulation of short-term neuronal synaptic plasticityHistone-lysine N-methyltransferase 2AHomo sapiens (human)
spleen developmentHistone-lysine N-methyltransferase 2AHomo sapiens (human)
homeostasis of number of cells within a tissueHistone-lysine N-methyltransferase 2AHomo sapiens (human)
membrane depolarizationHistone-lysine N-methyltransferase 2AHomo sapiens (human)
definitive hemopoiesisHistone-lysine N-methyltransferase 2AHomo sapiens (human)
protein-containing complex assemblyHistone-lysine N-methyltransferase 2AHomo sapiens (human)
cellular response to transforming growth factor beta stimulusHistone-lysine N-methyltransferase 2AHomo sapiens (human)
negative regulation of DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase 2AHomo sapiens (human)
signal transductionNAD(+) hydrolase SARM1Homo sapiens (human)
nervous system developmentNAD(+) hydrolase SARM1Homo sapiens (human)
response to glucoseNAD(+) hydrolase SARM1Homo sapiens (human)
NAD catabolic processNAD(+) hydrolase SARM1Homo sapiens (human)
cell differentiationNAD(+) hydrolase SARM1Homo sapiens (human)
negative regulation of MyD88-independent toll-like receptor signaling pathwayNAD(+) hydrolase SARM1Homo sapiens (human)
regulation of neuron apoptotic processNAD(+) hydrolase SARM1Homo sapiens (human)
innate immune responseNAD(+) hydrolase SARM1Homo sapiens (human)
response to axon injuryNAD(+) hydrolase SARM1Homo sapiens (human)
regulation of dendrite morphogenesisNAD(+) hydrolase SARM1Homo sapiens (human)
nervous system processNAD(+) hydrolase SARM1Homo sapiens (human)
protein localization to mitochondrionNAD(+) hydrolase SARM1Homo sapiens (human)
protein foldingCytosolic endo-beta-N-acetylglucosaminidaseHomo sapiens (human)
protein deglycosylationCytosolic endo-beta-N-acetylglucosaminidaseHomo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (60)

Processvia Protein(s)Taxonomy
catalytic activityN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
dimethylargininase activityN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
metal ion bindingN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
amino acid bindingN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
virus receptor activityInsulin-degrading enzymeHomo sapiens (human)
endopeptidase activityInsulin-degrading enzymeHomo sapiens (human)
metalloendopeptidase activityInsulin-degrading enzymeHomo sapiens (human)
protein bindingInsulin-degrading enzymeHomo sapiens (human)
ATP bindingInsulin-degrading enzymeHomo sapiens (human)
zinc ion bindingInsulin-degrading enzymeHomo sapiens (human)
peptide bindingInsulin-degrading enzymeHomo sapiens (human)
protein homodimerization activityInsulin-degrading enzymeHomo sapiens (human)
insulin bindingInsulin-degrading enzymeHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
RNA bindingFatty acid synthaseHomo sapiens (human)
[acyl-carrier-protein] S-acetyltransferase activityFatty acid synthaseHomo sapiens (human)
[acyl-carrier-protein] S-malonyltransferase activityFatty acid synthaseHomo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] synthase activityFatty acid synthaseHomo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
protein bindingFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxymyristoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
fatty acyl-[ACP] hydrolase activityFatty acid synthaseHomo sapiens (human)
phosphopantetheine bindingFatty acid synthaseHomo sapiens (human)
cadherin bindingFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxybutanoyl-[acyl-carrier-protein] hydratase activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
enoyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseHomo sapiens (human)
fatty acid synthase activityFatty acid synthaseHomo sapiens (human)
protein bindingWD repeat-containing protein 5Homo sapiens (human)
methylated histone bindingWD repeat-containing protein 5Homo sapiens (human)
histone H3K4 methyltransferase activityWD repeat-containing protein 5Homo sapiens (human)
histone bindingWD repeat-containing protein 5Homo sapiens (human)
minor groove of adenine-thymine-rich DNA bindingHistone-lysine N-methyltransferase 2AHomo sapiens (human)
chromatin bindingHistone-lysine N-methyltransferase 2AHomo sapiens (human)
protein bindingHistone-lysine N-methyltransferase 2AHomo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase 2AHomo sapiens (human)
histone H3K4 methyltransferase activityHistone-lysine N-methyltransferase 2AHomo sapiens (human)
identical protein bindingHistone-lysine N-methyltransferase 2AHomo sapiens (human)
protein homodimerization activityHistone-lysine N-methyltransferase 2AHomo sapiens (human)
unmethylated CpG bindingHistone-lysine N-methyltransferase 2AHomo sapiens (human)
lysine-acetylated histone bindingHistone-lysine N-methyltransferase 2AHomo sapiens (human)
protein-cysteine methyltransferase activityHistone-lysine N-methyltransferase 2AHomo sapiens (human)
histone H3K4 monomethyltransferase activityHistone-lysine N-methyltransferase 2AHomo sapiens (human)
histone H3K4 trimethyltransferase activityHistone-lysine N-methyltransferase 2AHomo sapiens (human)
NAD+ nucleosidase activityNAD(+) hydrolase SARM1Homo sapiens (human)
protein bindingNAD(+) hydrolase SARM1Homo sapiens (human)
signaling adaptor activityNAD(+) hydrolase SARM1Homo sapiens (human)
NADP+ nucleosidase activityNAD(+) hydrolase SARM1Homo sapiens (human)
NAD+ nucleotidase, cyclic ADP-ribose generatingNAD(+) hydrolase SARM1Homo sapiens (human)
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase activityCytosolic endo-beta-N-acetylglucosaminidaseHomo sapiens (human)
hydrolase activity, hydrolyzing O-glycosyl compoundsCytosolic endo-beta-N-acetylglucosaminidaseHomo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
cytosolN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
extracellular exosomeN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
nucleusInsulin-degrading enzymeHomo sapiens (human)
extracellular spaceInsulin-degrading enzymeHomo sapiens (human)
nucleusInsulin-degrading enzymeHomo sapiens (human)
cytoplasmInsulin-degrading enzymeHomo sapiens (human)
mitochondrionInsulin-degrading enzymeHomo sapiens (human)
peroxisomeInsulin-degrading enzymeHomo sapiens (human)
peroxisomal matrixInsulin-degrading enzymeHomo sapiens (human)
cytosolInsulin-degrading enzymeHomo sapiens (human)
external side of plasma membraneInsulin-degrading enzymeHomo sapiens (human)
cell surfaceInsulin-degrading enzymeHomo sapiens (human)
basolateral plasma membraneInsulin-degrading enzymeHomo sapiens (human)
extracellular exosomeInsulin-degrading enzymeHomo sapiens (human)
peroxisomal matrixInsulin-degrading enzymeHomo sapiens (human)
mitochondrionInsulin-degrading enzymeHomo sapiens (human)
cytosolInsulin-degrading enzymeHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
Golgi apparatusFatty acid synthaseHomo sapiens (human)
cytosolFatty acid synthaseHomo sapiens (human)
plasma membraneFatty acid synthaseHomo sapiens (human)
membraneFatty acid synthaseHomo sapiens (human)
melanosomeFatty acid synthaseHomo sapiens (human)
glycogen granuleFatty acid synthaseHomo sapiens (human)
extracellular exosomeFatty acid synthaseHomo sapiens (human)
cytoplasmFatty acid synthaseHomo sapiens (human)
nucleusWD repeat-containing protein 5Homo sapiens (human)
nucleoplasmWD repeat-containing protein 5Homo sapiens (human)
NSL complexWD repeat-containing protein 5Homo sapiens (human)
MLL1/2 complexWD repeat-containing protein 5Homo sapiens (human)
MLL3/4 complexWD repeat-containing protein 5Homo sapiens (human)
Set1C/COMPASS complexWD repeat-containing protein 5Homo sapiens (human)
MLL1 complexWD repeat-containing protein 5Homo sapiens (human)
mitotic spindleWD repeat-containing protein 5Homo sapiens (human)
ATAC complexWD repeat-containing protein 5Homo sapiens (human)
histone acetyltransferase complexWD repeat-containing protein 5Homo sapiens (human)
histone methyltransferase complexWD repeat-containing protein 5Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase 2AHomo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase 2AHomo sapiens (human)
cytosolHistone-lysine N-methyltransferase 2AHomo sapiens (human)
MLL1 complexHistone-lysine N-methyltransferase 2AHomo sapiens (human)
histone methyltransferase complexHistone-lysine N-methyltransferase 2AHomo sapiens (human)
cytoplasmNAD(+) hydrolase SARM1Homo sapiens (human)
mitochondrionNAD(+) hydrolase SARM1Homo sapiens (human)
mitochondrial outer membraneNAD(+) hydrolase SARM1Homo sapiens (human)
cytosolNAD(+) hydrolase SARM1Homo sapiens (human)
microtubuleNAD(+) hydrolase SARM1Homo sapiens (human)
cell surfaceNAD(+) hydrolase SARM1Homo sapiens (human)
axonNAD(+) hydrolase SARM1Homo sapiens (human)
dendriteNAD(+) hydrolase SARM1Homo sapiens (human)
synapseNAD(+) hydrolase SARM1Homo sapiens (human)
protein-containing complexNAD(+) hydrolase SARM1Homo sapiens (human)
dendriteNAD(+) hydrolase SARM1Homo sapiens (human)
cytosolCytosolic endo-beta-N-acetylglucosaminidaseHomo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (106)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1195927Inhibition of purified recombinant FASN TE activity (unknown origin) using 4-MUH as substrate preincubated for 30 mins before substrate addition measured after 1 hr by fluorescence assay2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1688541Inhibition of MLL1-WDR5 interaction in human MV4-11 cells assessed as downregulation of Hoxa9 gene expression incubated for 6 days by qRT-PCR analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1873205Inhibition of human ABCG2 expressed in human HEK293 cells membrane vesicles mediated transport of 3[H]-MTX for 2 mins using [3H]-methotrexate as substrate by rapid filtration technique2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID556016Antibacterial activity against GAT-susceptible Helicobacter pylori infected in human assessed as bacterial eradication rate for 7 days2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
AID1688534Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as late apoptotic cells at 10 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 1.85 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID556014Antibacterial activity against Helicobacter pylori infected in human assessed as bacterial eradication rate at 1 g, po BID for 7 days2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
AID1688529Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as early apoptotic cells at 5 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 4.35 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1600069Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectrophotometri2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1688530Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as late apoptotic cells at 5 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 1.85 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1688539Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as necrotic cells at 25 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 0.05 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID54913Inhibition of cytochrome P450 3A42002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
A neural network based virtual screening of cytochrome P450 3A4 inhibitors.
AID631830Antiprotozoan activity against Entamoeba histolytica HM1-IMSS trophozoites compound treated for 48 hrs measured after 48 hrs washout period2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
Antiprotozoal activity of proton-pump inhibitors.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1453445Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
AID1688532Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as viable cells at 10 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 93.75 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1688551Inhibition of MLL1-WDR5 interaction in human MV4-11 cells assessed as downregulation of Meis1 gene expression at 10 uM incubated for 6 days by qRT-PCR analysis relative to control2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1688527Cytotoxicity against HUVEC cells2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1688523Antiproliferative activity against human MV4-11 cells harboring MLL1-AF42020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1184074Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1688545Inhibition of MLL1-WDR5 interaction in human MV4-11 cells assessed as reduction in H3K4me1 expression incubated for 6 days by Western blot analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1688531Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as necrotic cells at 5 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 0.05 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1688535Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as necrotic cells at 10 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 0.05 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1688550Inhibition of MLL1-WDR5 interaction in human MV4-11 cells assessed as downregulation of Hoxa9 gene expression at 10 uM incubated for 6 days by qRT-PCR analysis relative to control2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1632334Inhibition of Helicobacter pylori ATCC 43504 urease assessed as amount of ammonia after 15 mins by indophenol method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1070214Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate after 40 mins by NMR spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
AID1688526Cytotoxicity against human L02 cells2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1688533Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as early apoptotic cells at 10 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 4.35 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1688540Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID556015Antibacterial activity against Helicobacter pylori infected in human assessed as bacterial eradication rate at 20 mg, po BID for 7 days2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1688524Antiproliferative activity against human MOLM-13 cells harboring MLL1-AF92020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1688546Inhibition of MLL1-WDR5 interaction in human MV4-11 cells assessed as reduction in H3K4me2 expression incubated for 6 days by Western blot analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184075Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1600080Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 100 uM preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectro2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1688549Inhibition of MLL1-WDR5 interaction in human MV4-11 cells assessed as reduction in MLL1 binding to WDR5 WIN site by 5-FAM probe based fluorescence polarization assay2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1688542Inhibition of MLL1-WDR5 interaction in human MV4-11 cells assessed as downregulation of Meis1 gene expression incubated for 6 days by qRT-PCR analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1688528Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as viable cells at 5 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 93.75 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1070215Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
AID631764Antiprotozoan activity against Giardia intestinalis IMSS:0989:1 trophozoites compound treated for 48 hrs measured after 48 hrs washout period2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
Antiprotozoal activity of proton-pump inhibitors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1348173Anti-Trichomonas activity against Trichomonas vaginalis JT assessed as reduction in parasite growth after 24 hrs by haemocytometry2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent developments in anti-Trichomonas research: An update review.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1688536Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as viable cells at 25 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 93.75 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1600079Inhibition of human recombinant DDAH1 reduction in L-citrulline formation using ADMA as substrate2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID556013Antibacterial activity against Helicobacter pylori infected in human assessed as bacterial eradication rate at 400 mg, po QD for 7 days2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
AID631763Antiprotozoan activity against Trichomonas vaginalis GT3 trophozoites compound treated for 48 hrs measured after 48 hrs washout period2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
Antiprotozoal activity of proton-pump inhibitors.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1688537Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as early apoptotic cells at 25 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 4.35 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1688525Antiproliferative activity against human K562 cells harboring MLL12020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1195928Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1184068Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1688538Induction of apoptosis in human MV4-11 cells harboring MLL1-AF4 assessed as late apoptotic cells at 25 uM incubated for 72 hrs by annexin V-FITC and propidium iodide staining based assay (Rvb = 1.85 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID310878Dissociation constant, pKa of the compound2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,024)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's62 (6.05)18.2507
2000's515 (50.29)29.6817
2010's352 (34.38)24.3611
2020's95 (9.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 109.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index109.13 (24.57)
Research Supply Index7.33 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index201.87 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (109.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials446 (41.57%)5.53%
Reviews117 (10.90%)6.00%
Case Studies57 (5.31%)4.05%
Observational10 (0.93%)0.25%
Other443 (41.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (202)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1, Fixed Sequence, Open-label Study in Healthy Adult Subjects to Evaluate the Effect of Multiple Doses of Rabeprazole on the Pharmacokinetics of a Single Dose of Vadadustat [NCT03789032]Phase 120 participants (Actual)Interventional2018-10-03Completed
14-day PCAB-based and Reverse Hybrid Therapy Fro Helicobacter Pylori [NCT05191888]Phase 4906 participants (Anticipated)Interventional2021-08-06Recruiting
Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study [NCT00844675]Phase 4120 participants (Actual)Interventional2007-10-31Completed
A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection [NCT01219764]Phase 4200 participants (Actual)Interventional2010-10-31Completed
A Double-blind Randomized Placebo Controlled Trial of Rabeprazole for Prevention of NSAID-associated Dyspepsia and Gastroduodenal Injury [NCT01140828]Phase 3112 participants (Anticipated)Interventional2009-05-31Completed
Single-Dose Food In Vivo Bioequivalence Study of Rabeprazole Sodium Delayed-Release Tablets (20 mg; Mylan) to Aciphex® Tablets (20 mg; Eisai) in Healthy Volunteers [NCT00649194]Phase 172 participants (Actual)Interventional2003-08-31Completed
A Randomized Controlled Trial of Triple Therapy With Conventional Proton Pump Inhibitor vs Triple Therapy With Vonoprazan as First Line Therapy for Helicobacter Pylori Gastritis [NCT03908619]Phase 4252 participants (Anticipated)Interventional2019-04-16Recruiting
A Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Effect on 24-hour, Intragastric pH Following Daily Oral Dose Administration of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40-mg Capsules and Rabeprazole (Aciphex) 20-mg Tab [NCT01153659]Phase 190 participants (Actual)Interventional2010-07-31Completed
Relative Bioavailability of Rabeprazole Sodium Sprinkle Capsule Formulation Using Different Dosing Vehicles Following Single-dose Administration in Healthy Adult Subjects [NCT01186497]Phase 135 participants (Actual)Interventional2010-08-31Completed
An Open-label, Randomized, Crossover Study in Healthy Subjects to Evaluate the Effect of Food and Acid Reducing Agent(s) on the Pharmacokinetics of Capivasertib [NCT04944771]Phase 148 participants (Actual)Interventional2021-07-26Completed
A New System for Diagnosis and Treatment of Gastroesophageal Refulx Diseases : Based on Endoscopy, pH Parameter, Impedence Parameter, High Resolution Manometry and Psychology [NCT03600974]200 participants (Anticipated)Observational2019-02-01Not yet recruiting
Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding [NCT05624229]Phase 4672 participants (Anticipated)Interventional2023-10-01Not yet recruiting
An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors [NCT03094416]Phase 466 participants (Actual)Interventional2018-07-30Completed
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori [NCT01264822]108 participants (Actual)Observational2011-01-13Completed
A Clinical Pharmacology Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease [NCT00165672]Phase 326 participants (Actual)Interventional2005-05-31Completed
A Multi-Center, Open-Label, All-Comers, Single Group Observational Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC )Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms [NCT01286194]1,500 participants (Anticipated)Observational2006-04-30Completed
Effect of Inhibitors of the Proton Pump on Intestinal Transporters and Their Impact on the Pharmacokinetics of Dabigatran - Mechanistic and Clinical Approach -BIPP Study [NCT02524210]Phase 112 participants (Actual)Interventional2014-05-31Completed
A Post-marketing Surveillance of Pariet Tab. 5 mg to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin, 100 mg or Less Daily, Administration in Korean Patients With a History of Gastric and Duodenal Ulcer [NCT05208268]676 participants (Actual)Observational2020-07-23Completed
A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition) [NCT01085708]Phase 116 participants (Actual)Interventional2010-04-30Completed
Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) [NCT02477306]Phase 160 participants (Actual)Interventional2014-03-31Completed
A Phase Ⅰb/Ⅱa, Single-center, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Helicobacter Pylori Eradication Efficacy in Asymptomatic Subjects With Helicobacter Pylori Infection After Multiple Doses of [NCT06076681]Phase 1/Phase 240 participants (Actual)Interventional2021-09-27Completed
Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: an Open Randomized Pilot Study [NCT03658733]Phase 4120 participants (Anticipated)Interventional2018-12-15Not yet recruiting
Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: a Pilot Study [NCT03616405]Phase 460 participants (Anticipated)Interventional2019-04-01Not yet recruiting
A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endosc [NCT00787891]Phase 3127 participants (Actual)Interventional2009-01-31Completed
A Single-center, Randomized, Double-blinded, Placebo and Active Controlled Phase 1 Study to Evaluate the Safety and Pharmacology of Multiple Ascending Dose Administration of Anaprazole in Healthy Chinese Subjects [NCT04471922]Phase 145 participants (Actual)Interventional2019-03-21Completed
Double-blind, Phase III Study to Evaluate Gastroprotection Obtained by the Use of Rebamipide 300 mg (2x Daily) and Rabeprazole 20 mg/Day (1x Daily) Associated or Not to Prevent Naproxen (1100 mg/Day)-Induced Gastric Lesions for 7 Days. [NCT03658473]Phase 332 participants (Actual)Interventional2014-11-12Completed
Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan [NCT03521726]Phase 420 participants (Actual)Interventional2018-05-11Completed
Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial [NCT03134378]Phase 473 participants (Anticipated)Interventional2016-10-03Recruiting
A Phase 1, Open-Label Fixed-Sequence 2-Period Crossover Study Of Palbociclib (pd-0332991) In Healthy Volunteers To Estimate The Effect Of Antacid Treatment On The Bioavailability Of A 125 Mg Single Dose Of Six Experimental Formulations Of Palbociclib Rela [NCT02311946]Phase 160 participants (Actual)Interventional2015-01-31Completed
The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients [NCT02149914]120 participants (Anticipated)Interventional2014-05-31Enrolling by invitation
A Phase 1, Randomized, Open-label Study Of Glasdegib (Pf-04449913) In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The Glasdegib Ich Formulation And To Estimate The Potential Effect Of Food And A Proton Pump Inhibitor O [NCT03130556]Phase 124 participants (Actual)Interventional2017-05-01Completed
Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets on Intragastric and Intraesophageal Acidity [NCT03037606]Phase 448 participants (Actual)Interventional2017-08-01Completed
An Open-Label, Pharmacokinetic Study to Evaluate the Pharmacokinetics and Relative Bioavailability of BIIB091 Formulations and to Assess the Impact of Food, a Proton Pump Inhibitor and CYP3A4 Inhibitor on BIIB091 Exposure Using the Selected Formulation in [NCT04564612]Phase 159 participants (Actual)Interventional2020-09-28Completed
[NCT01136317]Phase 20 participants Interventional2010-04-30Completed
Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections [NCT01566643]Phase 4231 participants (Anticipated)Interventional2011-01-31Recruiting
The Effect of Proton Pump Inhibitors on Calcium and Bone Metabolism: A Prospective Single-Blind Matched Controlled Study [NCT01139645]58 participants (Actual)Interventional2009-10-31Completed
Study on The Efficacy and Safety of Berberine,Amoxicillin and Vonoprazan Containing Triple Therapy in Helicobacter Pylori First-Line Eradication [NCT05014334]Phase 4300 participants (Actual)Interventional2021-12-01Completed
Efficacy and Safety of Berberine Hydrochloride, Amoxicillin and Rabeprazole Triple Therapy in the First Eradication of Helicobacter Pylori [NCT04697186]Phase 4524 participants (Actual)Interventional2021-01-07Completed
A Phase 1, Open-label, 4-period, Randomized 6-sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers [NCT05571787]Phase 126 participants (Actual)Interventional2022-07-13Completed
Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial [NCT02635191]Phase 4200 participants (Anticipated)Interventional2014-03-31Recruiting
An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen [NCT01860482]Phase 439 participants (Actual)Interventional2013-04-30Completed
A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD) [NCT00911534]Phase 3305 participants (Actual)Interventional2009-01-31Completed
A Randomized Placebo Controlled Trial on the Effect of Proton Pump Inhibitors on Palpitations With no Apparent Cause to Explain Such a Symptom [NCT02826408]30 participants (Actual)Interventional2016-10-31Completed
A Pharmacokinetic, Pharmacodynamic and Short-term Safety Study of Single and Multiple Day Doses of Rabeprazole Sodium in Neonates and Pre-term Infants With a Corrected Age of Less Than 44 Weeks With a Presumptive Diagnosis of GERD [NCT00855361]Phase 169 participants (Actual)Interventional2009-07-31Completed
Single-center, Randomized, Open-label Phase Ic/IIb Clinical Study to Evaluate the Efficacy and Safety of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules Combined With Multiple Doses of Rabeprazole Sodium Enteric-coate [NCT06076694]Phase 280 participants (Actual)Interventional2022-06-26Completed
The Relative Bioavailability of an ESK-001 Tablet Versus Liquid Formulation, and the Effect of Food or Gastric Acid Reduction on the Pharmacokinetics of ESK-001 in Healthy Participants [NCT05330858]Phase 114 participants (Actual)Interventional2022-03-17Completed
A Randomized, Open-label, Crossover, Pharmacokinetic and Pharmacodynamic Study of Z-215 Compared With Rabeprazole Sodium in Healthy Male Subjects [NCT02509923]Phase 154 participants (Actual)Interventional2015-07-31Completed
A Randomized, Open-label, Multiple-dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of AD-214 10/600mg to Rabeprazole 10mg in Healthy Volunteers [NCT04494243]Phase 140 participants (Actual)Interventional2020-08-28Completed
Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study [NCT02483715]Phase 4589 participants (Actual)Interventional2015-07-31Completed
A Phase I, Open-label, Randomized, Single-dose Study of Acalabrutinib in Healthy Subjects to Evaluate the Effect of Proton-pump Inhibitor (Rabeprazole) on Acalabrutinib Capsule When Administered Orally With COCA-COLA [NCT04489797]Phase 135 participants (Actual)Interventional2020-07-20Completed
A Phase I, Single Center, Randomized, Open-Label Study Investigating the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics of GDC-0853 in Healthy Subjects [NCT03290703]Phase 163 participants (Actual)Interventional2017-04-18Completed
A Phase I Open-Label Study to Determine the Relative Bioavailability of GDC-0134 and to Investigate the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Subjects of Non-childbearing Potential [NCT03237741]Phase 124 participants (Anticipated)Interventional2017-08-07Completed
A Phase 1, Open-label, 2-period, Fixed Sequence Study Of The Effect Of A Proton Pump Inhibitor On The Relative Bioavailability Of The Proposed Commercial Tablet Formulation Of Palbociclib In Healthy Volunteers [NCT03220191]Phase 112 participants (Actual)Interventional2017-07-21Completed
Distribution of Helicobacter Pylori According to the Use of Proton Pump Inhibitor [NCT02449941]30 participants (Actual)Observational2014-03-31Completed
A Phase 1, Open-Label, 3-Period Crossover Study Of The Effect Of An Antacid, A Proton Pump Inhibitor And An H2-Receptor Antagonist On Palbociclib (PD-0332991) Bioavailability Under Fed Conditions In Healthy Volunteers [NCT02097329]Phase 127 participants (Actual)Interventional2014-04-30Completed
The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT) [NCT00464308]Phase 41,392 participants (Actual)Interventional2006-11-30Completed
A Double-Blind, Placebo-Controlled Study of Rabeprazole 20 mg Maintenance Intermittent Therapy Following Acute Treatment in Patients Wth Symptomatic Gastroesophageal Reflux Disease [NCT00165841]Phase 2200 participants (Actual)Interventional2004-10-31Completed
A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With GERD 1 to 11 Years Old, Inclusive [NCT00747695]Phase 131 participants (Actual)Interventional2008-03-31Completed
A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Fasting Condition) [NCT01085695]Phase 116 participants (Actual)Interventional2010-04-30Completed
Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel. A Prospective, placebo-and Active Treatment-controlled, Open Label, Randomized 3-way Cross Over Study in Healthy Subjects [NCT00989300]Phase 139 participants (Actual)Interventional2009-11-30Completed
Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI [NCT00539240]Phase 2/Phase 3236 participants (Actual)Interventional2006-04-30Completed
An Open-Label, Two-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers [NCT00999128]Phase 150 participants (Actual)Interventional2009-10-26Completed
A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) [NCT00658775]Phase 31,069 participants (Actual)Interventional2008-02-29Completed
Treatment Response of High-dose and Standard-dose Rabeprazole for Gastroesophageal Reflux Disease With Extra-esophageal Manifestations: a Single-center, Randomized, Open-label Trial. [NCT04001400]Phase 373 participants (Actual)Interventional2012-10-10Completed
A Phase 1, Open-Label, Randomized, Crossover Study to Assess the Relative Bioavailability of Rabeprazole Phase 3 Pediatric Bead Formulation Versus the Phase 1 Pediatric Bead Formulation and Effect of Food on the Pharmacokinetics of Rabeprazole Phase 3 Ped [NCT01101646]Phase 136 participants (Actual)Interventional2008-08-31Completed
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis [NCT00770913]Phase 2/Phase 3337 participants (Actual)Interventional2008-10-31Completed
The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori [NCT06004401]400 participants (Anticipated)Interventional2023-08-20Not yet recruiting
Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Rabeprazole-Controlled,Multicenterand Phase3 Trial in China in China [NCT02847455]Phase 2/Phase 3408 participants (Actual)Interventional2008-08-31Completed
Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. [NCT02638584]Phase 4176 participants (Actual)Interventional2015-12-31Completed
Sequential Helicobacter Pylori Eradication Therapy in Myanmar; a Randomized Clinical Trial of Efficacy and Tolerability [NCT04132479]Phase 4313 participants (Actual)Interventional2018-01-01Completed
A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis [NCT02655614]Phase 154 participants (Actual)Interventional2016-05-31Completed
A Randomized Controlled Trial of Transoral Incisionless Fundoplication (TIF) Versus Proton Pump Inhibitors (PPIs) for Treatment of GERD: The TIF vs. PPIs Study [NCT00857597]Phase 360 participants (Actual)Interventional2009-03-31Terminated(stopped due to Study was terminated after unplanned interim analysis of single centre data and results were reported)
Clinical Study of Jinsang Liyan Capsules Combined With Proton Pump Inhibitors in the Treatment of Laryngeal Reflux Disease (LPRD): a Randomized, Double-blind, Placebo-controlled Trial [NCT05879029]Phase 472 participants (Anticipated)Interventional2023-06-30Not yet recruiting
A Phase 1, Open-Label, Non-Randomized, Two-Part, Fixed-Sequence, Study to Evaluate the Effects of Acid Reducing Agents on the Pharmacokinetics of PC14586 in Healthy Volunteers [NCT06054464]Phase 150 participants (Anticipated)Interventional2023-09-19Recruiting
Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping™ Assay [NCT01023360]Phase 430 participants (Anticipated)Interventional2008-05-31Recruiting
Practice and Patient Compliance on the PPI(Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea: A Prospective Observational Study [NCT01018160]1,197 participants (Actual)Observational2008-06-30Completed
A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects With GERD 1 to 11 Months Old, Inclusive [NCT00747526]Phase 151 participants (Actual)Interventional2007-12-31Completed
Single-Dose Food In Vivo Bioequivalence Study of Rabeprazole Sodium Tablets (20 mg; Mylan) and Aciphex® Tablets (20 mg; Eisai) in Healthy Volunteers [NCT00649493]Phase 172 participants (Actual)Interventional2003-05-31Completed
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis [NCT01321567]2,157 participants (Actual)Observational2011-01-01Completed
A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes [NCT00681005]178 participants (Actual)Interventional2006-04-30Completed
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) [NCT00658528]Phase 31,061 participants (Actual)Interventional2008-02-29Completed
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) [NCT00839306]Phase 3240 participants (Actual)Interventional2008-08-31Completed
Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers [NCT00838682]Phase 4106 participants (Actual)Interventional2006-04-30Terminated(stopped due to Terminated before the complete enrollment due to slow enrollment)
Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) [NCT00838526]Phase 3240 participants (Actual)Interventional2008-08-31Completed
A Phase 1, Open-label Study to Assess the Single Dose Pharmacokinetics and Relative Bioavailability of a Test Capsule Formulation of CC-92480 Compared to a Reference CC 92480 Capsule Formulation and the Effect of a Proton Pump Inhibitor on the Pharmacokin [NCT04211545]Phase 124 participants (Actual)Interventional2019-10-21Completed
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed Release Rabeprazole in 1- to 11-Month-Old Pediatric Subjects With Symptomatic/Gastroesophageal Erosive Reflux Dis [NCT00992589]Phase 3344 participants (Actual)Interventional2009-11-30Completed
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective Randomized, Comparative Study [NCT05332444]Phase 4450 participants (Anticipated)Interventional2022-04-11Recruiting
Single-Dose Fasting In Vivo Bioequivalence Study of Rabeprazole Sodium Delayed-Release Tablets (20 mg; Mylan) to Aciphex® Delayed-Release Tablets (20 mg; Eisia) in Healthy Volunteers [NCT00648349]Phase 172 participants (Actual)Interventional2003-05-31Completed
Comparison of Ulcer Healing in Patients Taking Rabeprazole Plus Aspirin Versus Rabeprazole Plus Clopidogrel for Acute Peptic Ulcer [NCT01037491]200 participants (Anticipated)Interventional2009-10-31Recruiting
A PHASE 1, OPEN-LABEL, TWO-PERIOD, FIXED SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF A PROTON PUMP INHIBITOR ON THE PHARMACOKINETICS OF SISUNATOVIR IN HEALTHY ADULT PARTICIPANTS [NCT06105983]Phase 116 participants (Anticipated)Interventional2023-11-03Recruiting
Observational Study: Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period [NCT00614536]1,142 participants (Actual)Observational2007-09-30Completed
Multicenter, Phase II/III Study of Carboplatin Plus Etoposide With AL3810 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) [NCT04254471]Phase 2/Phase 3313 participants (Anticipated)Interventional2019-11-14Recruiting
Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study [NCT01008696]Phase 4217 participants (Actual)Interventional2007-05-31Completed
A Randomized, Open-label, Multiple-dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of AD-214-02 to Rabeprazole in Healthy Volunteers [NCT04622358]Phase 143 participants (Actual)Interventional2020-12-05Completed
Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD: a Randomized Controlled Trial [NCT01391715]Phase 30 participants (Actual)Interventional2011-08-31Withdrawn(stopped due to patients could not be recuited within study duration)
Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA) [NCT01408186]Phase 3264 participants (Actual)Interventional2011-01-31Completed
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD) [NCT00658632]Phase 31,397 participants (Actual)Interventional2008-02-29Completed
Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori [NCT01573975]Phase 4345 participants (Actual)Interventional2009-01-31Completed
Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori (CREATION Study) [NCT02767479]Phase 3200 participants (Actual)Interventional2012-07-31Completed
The Cross-Over Study to Investigate the Effect of Proton Pump Inhibitor on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Korean Men. [NCT01857609]Phase 124 participants (Actual)Interventional2012-08-31Completed
Efficacies of High-dose Dual Therapy With or Without Bismuth Versus Amoxicillin-metronidazole Bismuth Quadruple Therapy for First-line Helicobacter Pylori Eradication - A Prospective, Randomized, Comparative Study [NCT03897244]Phase 4702 participants (Anticipated)Interventional2019-05-30Recruiting
Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis [NCT02555852]4,238,504 participants (Actual)Observational2011-09-30Completed
Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients [NCT00517114]200 participants (Anticipated)Interventional2005-01-31Completed
High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study. [NCT00517270]200 participants (Anticipated)Interventional2003-03-31Recruiting
Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol [NCT00511966]1,049 participants (Actual)ObservationalTerminated(stopped due to Due to the achievement of minimum required sample size and new changes in local regulations.)
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers [NCT00236197]Phase 3619 participants (Actual)Interventional2005-10-31Completed
A Double-Blind, Placebo-Controlled, Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease [NCT00165646]Phase 3288 participants (Actual)Interventional2004-09-30Completed
Safety and Efficacy of Rabeprazole in the Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients [NCT00132496]Phase 2111 participants (Actual)Interventional2005-08-31Completed
Prophylactic Efficacy of Proton Pump Inhibitor on Recurrence of Peptic Ulcer in Patients Continuously Treated With Low-dose Aspirin-Randomized, Multi-center, Single-blinded, Parallel-group, Comparative Study [NCT01051388]Phase 3280 participants (Actual)Interventional2008-08-31Completed
An Open-Label, Single-Sequence Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole on the Pharmacokinetics of BMS-986165 in Healthy Participants [NCT03979248]Phase 121 participants (Actual)Interventional2019-05-16Completed
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers [NCT00236184]Phase 3629 participants (Actual)Interventional2005-10-31Completed
A Phase 1, Open-Label Fixed-Sequence 2-Period Crossover Study Of Palbociclib In Healthy Subjects To Investigate The Potential Effect Of Antacid Treatment On The Pharmacokinetics Of A Single Oral Dose Administered Under Fasted Conditions [NCT01918176]Phase 126 participants (Actual)Interventional2013-09-30Completed
A PHASE 1, RANDOMIZED, OPEN-LABEL STUDY IN HEALTHY PARTICIPANTS TO ESTIMATE THE BIOAVAILABILITY OF TWO NEW ENCORAFENIB FORMULATIONS RELATIVE TO THE CURRENT FORMULATION AND TO EVALUATE THE EFFECT OF A PROTON-PUMP INHIBITOR ON ENCORAFENIB PLASMA PHARMACOKIN [NCT05446142]Phase 118 participants (Actual)Interventional2022-07-01Completed
Identification of Molecular Markers of Inflammatory Mediators in Posterior Laryngitis Due to Laryngopharyngeal Reflux and Evolution With PPI Treatment [NCT00204698]Phase 2/Phase 324 participants (Actual)Interventional2003-08-31Completed
Overall Assessment of Improvement in Bronchial Asthma Patients With Extraesophageal Reflux After Effective Acid Suppression [NCT00234117]40 participants (Anticipated)Interventional2005-07-31Completed
Bismuth-Metronidazole Triple Versus Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Randomized Controlled Trial [NCT04667299]Phase 4270 participants (Anticipated)Interventional2020-12-20Recruiting
An Open-label Study to Evaluate the Effects of a Potent CYP3A4 Inducer and the Effects of a pH Elevating Agent on the Repeat Dose Pharmacokinetics of Dabrafenib (GSK2118436) in Subjects With BRAF V600 Mutation Positive Tumors [NCT01954043]Phase 123 participants (Actual)Interventional2013-12-20Completed
An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Rabeprazole Sodium Delayed Release Tablets 20 mg (Test, Torrent Pharmaceuticals Limited., India) Versus Aciphex® (Rabeprazole Sodium) Delayed Rele [NCT01990378]Phase 10 participants InterventionalCompleted
An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Rabeprazole Sodium Delayed Release Tablets 20 mg (Test, Torrent Pharmaceuticals Limited., India) Versus Aciphex® (Rabeprazole Sodium) Delayed Rele [NCT01990586]Phase 10 participants InterventionalCompleted
A Multi-Center, Randomized, Double-Blind Study of E3810 for Japanese Subjects With Functional Dyspepsia [NCT01089543]Phase 2338 participants (Actual)Interventional2010-04-30Completed
Esophagoprotection by Rabeprazole Mediated by Restoration of an Impairment in Esophageal Mucin Production: Its Potential Therapeutic Benefit in Patients With Gastroesophageal Reflux Disease (GERD) [NCT00222170]Phase 224 participants (Actual)Interventional2005-05-31Completed
A Phase 1, Open-Label, Randomized, Two-Part Study in Healthy Adult Participants to Evaluate the Relative Bioavailability of Maribavir Pediatric Formulation Compared to the Commercial Formulation, as Well as, Food Effect, and Rabeprazole Gastric Acid-Reduc [NCT05918822]Phase 132 participants (Actual)Interventional2023-08-10Completed
The Comparison of Oral Rabeprazole vs. Intravenous Omeprazole in the Treatment of Patients With Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding [NCT00861640]Phase 4200 participants (Anticipated)Interventional2009-03-31Recruiting
A Phase 1, Randomized, Crossover, Open-Label, 4 Period Study In Healthy Volunteers To Demonstrate The Lack Of Effect Of Rabeprazole And Food On The Pharmacokinetics Of PF-06463922 And To Assess The Relative Bioavailability Of Oral Solution To The Tablet F [NCT02569554]Phase 127 participants (Actual)Interventional2015-12-31Completed
Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection [NCT02541786]Phase 4177 participants (Actual)Interventional2015-01-31Completed
A Phase 1, Open-Label, 3 Period, Randomized 2-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of Fruquintinib in Healthy Subjects [NCT04645940]Phase 114 participants (Actual)Interventional2020-09-24Completed
A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers. [NCT04215653]Phase 3448 participants (Anticipated)Interventional2020-01-20Not yet recruiting
Double-blind, Placebo-controlled, Randomized Study for Assesment of the Efficiency and Safety Quadruple Therapy for Helicobacter Pylori Infection With or Without the Addition of Saccharomyces Boulardi Probiotic [NCT03997279]Phase 4200 participants (Anticipated)Interventional2019-06-30Not yet recruiting
A Phase I, Single Center, Randomized, Open-Label, Study Investigating the Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics of GDC-0853 and the Effect of GDC-0853 on the Pharmacokinetics of Methotrexate in Healthy Subjects [NCT02699710]Phase 150 participants (Actual)Interventional2015-09-03Completed
The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity [NCT02689999]Phase 412 participants (Actual)Interventional2016-02-29Completed
Clinical Usefulness of Proton Pump Inhibitor Test for Identifying Gastroesophageal Reflux Disease in Patients With Extraesophageal Symptoms [NCT00539786]100 participants (Anticipated)Interventional2006-03-31Recruiting
Effects of Gastric pH on the Pharmacokinetics of Dasatinib in Healthy Volunteers [NCT01398046]Phase 110 participants (Actual)Interventional2011-08-31Completed
A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects [NCT04703868]Phase 188 participants (Anticipated)Interventional2021-01-13Recruiting
Post-nasal Drainage as an Extraesophageal Manifestation of Reflux [NCT00199953]Phase 250 participants Interventional2002-06-30Completed
An Open Observational Study For The Rabeprazole Administration In Adult Subjects With Helicobacter Pylori (H. Pylori) Infection [NCT00216450]Phase 480 participants (Actual)Interventional2004-10-31Completed
A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD) [NCT00216489]Phase 4191 participants (Actual)Interventional2003-03-31Completed
Rapid Protection of the Gastroduodenal Mucosa Against Aspirin-Induced Damage by Rabeprazole [NCT00220857]Phase 430 participants (Anticipated)Interventional2005-09-30Completed
Pivotal Study to Assess the Bioequivalence of the To-be-Marketed Sprinkle Capsule Formulation and the Phase 3 Sprinkle Capsule Formulation of Rabeprazole Sodium in Fasted Condition and to Assess the Effect of Food on the To-be-Marketed Formulation in Heal [NCT01241409]Phase 178 participants (Actual)Interventional2010-10-31Completed
A Phase 1, Open-label, 4-period, Randomized 6-sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers [NCT05930119]Phase 124 participants (Actual)Interventional2023-03-17Completed
Effects of YF476, a Gastrin Antagonist, and Rabeprazole, a Proton Pump Inhibitor, Alone and in Combination, on Gastric Function in Healthy Subjects [NCT01699113]Phase 132 participants (Actual)Interventional2006-08-31Completed
Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication [NCT02934152]Phase 4400 participants (Anticipated)Interventional2016-10-31Not yet recruiting
Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment - a Randomized Trial [NCT05152004]240 participants (Actual)Interventional2018-09-01Completed
A Randomised, Controlled, Parallel-group, Open-label Study to Evaluate Different Dosing Regimens of Rabeprazole in Controlling Nocturnal Heartburn Symptoms in Patients With Gastroesophageal Reflux Disease. [NCT00553449]Phase 348 participants (Actual)Interventional2004-07-31Completed
A Phase 1, Open-Label, 4-Part, Fixed-Sequence Study to Assess the Effect of Itraconazole, a Strong CYP3A Inhibitor, the Effect of Fluconazole, a Moderate CYP3A/2C9 Inhibitor, the Effect of Rifampin, a Strong CYP3A Inducer, and the Effect of Rabeprazole, a [NCT05602597]Phase 159 participants (Actual)Interventional2022-06-01Completed
Helicobacter Pylori Eradication and Follow-up in Zhongshan Hospital [NCT05061732]Phase 44,447 participants (Anticipated)Interventional2021-09-30Recruiting
A Phase 1, Open-Label, 3-Period, Randomized, Crossover Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of GDC-0973 in Healthy Subjects [NCT01277718]Phase 120 participants (Actual)Interventional2011-01-31Completed
"Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of On-Demand Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week [NCT00236392]Phase 3422 participants (Actual)Interventional2001-10-31Completed
A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn [NCT00237367]Phase 452 participants (Actual)InterventionalCompleted
The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease [NCT00354757]Phase 4200 participants (Actual)Interventional2005-06-30Completed
A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium [NCT00125736]Phase 4520 participants (Actual)Interventional2005-08-01Completed
Pilot Study Evaluating Gastric Re-acidification Using Betaine Hydrochloride in Healthy Volunteers With Pharmacologically Induced Hypochlorhydria [NCT01237353]6 participants (Actual)Interventional2011-03-31Completed
Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection [NCT00197418]Phase 2/Phase 30 participants Interventional2003-08-31Recruiting
A PHASE 1, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, SINGLE-DOSE STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE RELATIVE BIOAVAILABILITY OF TWO TABLET FORMULATIONS OF PF-07220060, AND TO INVESTIGATE THE EFFECT OF FOOD AND A PROTON PUMP INHIBITOR ON THE RE [NCT05923411]Phase 184 participants (Anticipated)Interventional2023-07-11Recruiting
Ph. 1, Open-label, 2 Part, 2 Period Fixed-Sequence Crossover Study to Assess the Effect of Rabeprazole, a Proton Pump Inhibitor, and the Effect of Rifampin, a Strong CYP3A Inducer, on the Pharmacokinetics of Surufatinib in Healthy Subjects [NCT04510649]Phase 128 participants (Actual)Interventional2020-07-09Completed
New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection:a Pilot Study [NCT01513785]Phase 240 participants (Actual)Interventional2011-04-30Completed
A Double-blind Placebo Controlled Clinical Trial to Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma. [NCT00214552]Phase 380 participants (Anticipated)Interventional2002-09-30Completed
The Role of CYP2C19 Poor Metabolizers and Extensive Metabolizers of PPI in Short-Term Triple Therapy on the Eradication of H. Pylori Infection: Implication of PK/PD Relationships [NCT00162877]80 participants Interventional2004-06-30Active, not recruiting
A Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Z-215 Compared With Rabeprazole Sodium in the Treatment of Erosive Esophagitis [NCT02463643]Phase 2503 participants (Actual)Interventional2015-05-31Completed
Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Open-label Trial- [NCT01398410]Phase 2/Phase 3405 participants (Actual)Interventional2011-12-31Completed
Efficacy of Quadruple Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests as First-line Treatment for Helicobacter Pylori Infection [NCT05718609]Phase 4855 participants (Anticipated)Interventional2023-03-01Recruiting
Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis [NCT04923113]281 participants (Actual)Interventional2021-06-28Completed
Ten-day Amoxicillin-containing Dual Therapy as First-line Helicobacter Pylori Treatment in Elderly Patients: a Randomized Trial [NCT05419674]Phase 4393 participants (Anticipated)Interventional2022-08-01Recruiting
Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI. [NCT00251732]Phase 4150 participants (Actual)Interventional2005-03-31Completed
The Impact of Gastroesophageal Reflux Disease in Sleep Disorders: A Pilot Investigation of Rabeprazole, 20 mg Twice Daily for the Relief of GERD-Related Insomnia. [NCT00287391]Phase 420 participants Interventional2004-09-30Completed
A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers [NCT01202071]Phase 224 participants (Actual)Interventional2010-09-30Completed
Comparison of the Nighttime Effects of Rabeprazole 20 mg to Pantoprazole 40 mg on Standard Meal Stimulated Gastric Acid Secretion and Intragastric pH in H. Pylori Negative Volunteer Subjects With GERD [NCT00304421]Phase 423 participants (Anticipated)Interventional2004-01-31Completed
Impact of Rabeprazole-induced Elevated Gastric pH on APO-Dabigatran Exposure in Healthy Volunteers [NCT04157881]Phase 446 participants (Actual)Interventional2020-01-03Completed
Effects of Gastric pH on the Pharmacokinetics of Atazanavir in Healthy Volunteers [NCT01759875]Phase 18 participants (Actual)Interventional2013-01-31Completed
A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib [NCT01772290]Phase 192 participants (Actual)Interventional2013-02-28Completed
Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole From Raperazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) After a Single Oral Dose Administration of Each to H [NCT02605395]Phase 470 participants (Actual)Interventional2014-03-22Completed
The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole [NCT02986685]Phase 40 participants (Actual)Interventional2016-11-30Withdrawn(stopped due to Lack of funds)
Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial- [NCT01397448]Phase 2/Phase 3472 participants (Actual)Interventional2011-07-31Completed
A Study to Investigate the Effect of Increased Gastric pH From the Administration of the Proton Pump Inhibitor (PPI) Rabeprazole on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Subjects [NCT02475161]Phase 116 participants (Actual)Interventional2015-06-30Completed
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients [NCT02135107]Phase 3517 participants (Actual)Interventional2013-09-30Completed
Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori [NCT01922765]Phase 4540 participants (Anticipated)Interventional2013-08-31Recruiting
Personalized Treatment for Refractory H Pylori Infection [NCT02547025]126 participants (Actual)Interventional2012-08-01Completed
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection [NCT05857163]Phase 3700 participants (Anticipated)Interventional2023-05-18Recruiting
Effect of Histamine 2 Receptor Antagonist (H2RA) and Proton Pump Inhibitor (PPI) on the Positivity Rates and Clinical Outcomes of Coronavirus Disease-19 (COVID-19). [NCT04834752]400,000 participants (Anticipated)Observational2021-05-01Not yet recruiting
Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy. [NCT01572597]Phase 4120 participants (Anticipated)Interventional2011-06-30Recruiting
A Phase 1 Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, PPI Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects [NCT03464058]Phase 128 participants (Actual)Interventional2018-03-21Completed
A Multicenter, Randomized, Double-blind, Double-dummy, Positive Drug Parallel Controlled Phase II Clinical Trial to Evaluate Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis [NCT05604261]Phase 2156 participants (Anticipated)Interventional2022-12-31Not yet recruiting
A Randomized, Controlled, Double-blind, Cross-over Study of the Effect of Oral Rabeprazole 20mg and Intravenous Pantoprazole 40mg on Intragastric pH in Patients [NCT00378287]Phase 137 participants (Actual)Interventional2005-10-31Completed
An Open-Label, Five-Period Study in Healthy Subjects to Investigate the Relative Bioavailability of AZD5055 Film-Coated Tablet Versus AZD5055 Oral Suspension Formulation, the Absolute Oral Bioavailability of AZD5055 and to Evaluate the Effect of Food and [NCT05630677]Phase 118 participants (Actual)Interventional2022-11-04Completed
Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt)and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) After a Single Oral Dose Administration of Each to Heal [NCT02446483]Phase 460 participants (Actual)Interventional2014-03-19Completed
Efficacies of Hybrid, High-dose Dual and Bismuth Quadruple Therapies for the First-line Anti-H Pylori Treatment and Tetracycline-levofloxacin Quadruple Therapy for the Second-line Anti-H Pylori Treatment - a Multicentre Randomized Trial [NCT03779074]Phase 3918 participants (Actual)Interventional2018-09-03Completed
Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study [NCT02490839]Phase 4450 participants (Actual)Interventional2015-07-31Completed
Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori [NCT03108287]Phase 4162 participants (Actual)Interventional2013-04-01Completed
A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating the Effect of Rifampin (Part 1) and Rabeprazole (Part 2) on the Pharmacokinetics of a Single Dose of Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions [NCT05899829]Phase 132 participants (Anticipated)Interventional2023-06-30Not yet recruiting
Clarithromycin-, Metronidazole-, or Levofloxacin-containing Therapy for Helicobacter Pylori-infected Penicillin-allergic Patients: A Randomized Controlled Trial [NCT05023577]Phase 4504 participants (Anticipated)Interventional2021-08-26Recruiting
Proton Pump Inhibitor and Amoxicillin Combined Bismuth or Metronidazole for Helicobacter Pylori First-line Treatment: A Randomized Controlled Trial [NCT05014685]Phase 4732 participants (Anticipated)Interventional2021-08-20Recruiting
Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori. [NCT01575899]Phase 4208 participants (Actual)Interventional2007-12-31Terminated(stopped due to Early termination due to efficacy)
Diagnostic Value of Narrow-band Imaging, Autofluorescence Imaging & White-light Imaging on Gastroesophageal Reflux Disease [NCT01504971]95 participants (Actual)Observational2011-01-31Active, not recruiting
A Comparison Study of Helicobacter Pylori Eradication Rates Between Daily Four Times and Daily Two Times Usage of Proton Pump Inhibitor and Amoxicillin for the First Line and the Second Line Eradication Therapy [NCT03802318]530 participants (Anticipated)Interventional2019-01-02Enrolling by invitation
Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Metachronous Cancer in Patients Undergoing Endoscopic Mucosal Resection for Gastric Cancer [NCT02407119]Phase 3470 participants (Actual)Interventional2003-06-30Active, not recruiting
Relative Bioavailability of BI 1810631 as Two Different Oral Formulations Given as Single Doses and Investigation of the Effects of Food and Multiple-dose Rabeprazole on the Pharmacokinetics of Single-dose BI 1810631 Following Oral Administration in Healt [NCT05380947]Phase 113 participants (Actual)Interventional2022-06-23Completed
Bismuth Quadruple Therapy With Tetracycline Versus Doxycycline as Rescue Therapy for Helicobacter Pylori Infection: a Randomized Controlled Trial [NCT05018923]Phase 4242 participants (Anticipated)Interventional2021-08-24Recruiting
Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases: A Multicenter, Randomized, Double-blinded, Controlled Trial [NCT03320538]360 participants (Anticipated)Interventional2017-07-10Recruiting
A 2-Part, Non-randomized, Open-label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of Belumosudil (KD025) [NCT03530995]Phase 173 participants (Actual)Interventional2018-04-09Completed
An Open-Label, Single-Dose Study to Assess the Effect of Food Intake and Drug-Drug Interactions of E7090 When Co-administered With Rabeprazole (Gastric Acid-Reducing Agent), or Rifampin (Strong CYP3A Inducer) in Healthy Subjects [NCT04565574]Phase 142 participants (Actual)Interventional2020-10-16Completed
A Phase 2,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers. [NCT04503629]Phase 2150 participants (Actual)Interventional2018-10-09Completed
Phase 3 Open-Label Crossover Pharmacodynamic Study to Evaluate the Acid-inhibitory Effect of TAK-438 20 mg With Esomeprazole 20 mg or Rabeprazole Sodium 10 mg in Healthy Adult Male Subjects [NCT02037477]Phase 320 participants (Actual)Interventional2014-01-31Completed
An Open-Label, 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet [NCT01287091]Phase 146 participants (Actual)Interventional2010-10-14Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00132496 (1) [back to overview]Treatment-emergent Adverse Events Experienced by >=5% of Patients in Any Treatment Group
NCT00165646 (1) [back to overview]Percentage of Participants With Complete Relief of Heartburn at Final Evaluation
NCT00165672 (1) [back to overview]The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring).
NCT00165841 (1) [back to overview]The Percentage of Heartburn-free Days (24-hour Periods) During the 6-month Maintenance Treatment Phase (ITT Population).
NCT00236184 (1) [back to overview]Complete Heartburn Relief During the First Full 24-Hour Period in the ITT Population.
NCT00236197 (1) [back to overview]Complete Heartburn Relief During the First Full 24-Hour Period in Intent-to-Treat (ITT) Population
NCT00464308 (7) [back to overview]The Median Time to Complete Relief of Regurgitation Symptoms
NCT00464308 (7) [back to overview]The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4
NCT00464308 (7) [back to overview]The Number of Patients With Complete Resolution of Heartburn by Week 4
NCT00464308 (7) [back to overview]The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods
NCT00464308 (7) [back to overview]The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4
NCT00464308 (7) [back to overview]The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4
NCT00464308 (7) [back to overview]The Median Time to Complete Resolution of Heartburn Symptoms.
NCT00539240 (4) [back to overview]Health Related Quality of Life
NCT00539240 (4) [back to overview]Nighttime Heartburn, Number of Days in Week Symptom Activity Score <3 (Better) in Week 6 Compared to Baseline
NCT00539240 (4) [back to overview]Acid Regurgitation, Number of Days in Week Symptoms Intensity Score < 3 (Better)
NCT00539240 (4) [back to overview]Daytime Heartburn, Number of Days in Week Symptoms Intensity Score < 3 (Better)
NCT00658528 (3) [back to overview]Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks
NCT00658528 (3) [back to overview]Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4
NCT00658528 (3) [back to overview]Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks
NCT00658632 (3) [back to overview]Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks
NCT00658632 (3) [back to overview]Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks
NCT00658632 (3) [back to overview]Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4
NCT00658775 (3) [back to overview]Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4
NCT00658775 (3) [back to overview]Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks
NCT00658775 (3) [back to overview]Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks
NCT00770913 (1) [back to overview]Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N)
NCT00787891 (6) [back to overview]The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)
NCT00787891 (6) [back to overview]The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)
NCT00787891 (6) [back to overview]The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)
NCT00787891 (6) [back to overview]The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)
NCT00787891 (6) [back to overview]The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)
NCT00787891 (6) [back to overview]The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)
NCT00838526 (3) [back to overview]Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26
NCT00838526 (3) [back to overview]Percentage of Participants With Adverse Events by Category
NCT00838526 (3) [back to overview]Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26
NCT00838682 (6) [back to overview]Surgery
NCT00838682 (6) [back to overview]Rebleeding Within 3 Days
NCT00838682 (6) [back to overview]Rebleeding After 3 Days
NCT00838682 (6) [back to overview]Mean Units of Blood Transfusion
NCT00838682 (6) [back to overview]Death
NCT00838682 (6) [back to overview]Duration of Hospital Stay
NCT00839306 (2) [back to overview]Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26
NCT00839306 (2) [back to overview]Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26
NCT00911534 (4) [back to overview]Percentage of Participants With Complete Heartburn Relief
NCT00911534 (4) [back to overview]Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4
NCT00911534 (4) [back to overview]Time to Achieve First 24-Hour Period Without Heartburn
NCT00911534 (4) [back to overview]Change From Baseline in Average Daily Severity Score of Gastroesophageal Reflux Disease (GERD)-Related Symptoms at Week 4
NCT00992589 (8) [back to overview]Change From Baseline in I-GERQ-R Total Score (Double-blind Phase/ Baseline Observation Carried Forward)
NCT00992589 (8) [back to overview]Change From Baseline in Weekly Average I-GERQ-DD Discomfort Subscale Score (Double-blind Phase/ Last Observation Carried Forward)
NCT00992589 (8) [back to overview]Change From Baseline in Weight-for-Age Z-Score (Double-blind Phase/ Baseline Observation Carried Forward)
NCT00992589 (8) [back to overview]The Daily Average Number of Episodes Related to Each Volume of Regurgitation During the Double-blind Treatment Period
NCT00992589 (8) [back to overview]Change From Baseline in Weekly Average I-GERQ-DD Eating Behavior Subscale Score (Double-blind Phase/ Last Observation Carried Forward)
NCT00992589 (8) [back to overview]Change From Baseline in Weekly Average I-GERQ-DD Regurgitation Subscale Score (Double-blind Phase/ Last Observation Carried Forward)
NCT00992589 (8) [back to overview]Change From Baseline in Average Daily Frequency of Regurgitation (Double-blind Phase/ Baseline Observation Carried Forward)
NCT00992589 (8) [back to overview]Change From Baseline in in Weekly Average I-GERQ-DD Total Score (Double-blind Phase/ Baseline Observation Carried Forward)
NCT01008696 (3) [back to overview]Change From Baseline in Symptoms of Reflux Esophagitis Evaluated by the Symptom Assessment Questionnaire
NCT01008696 (3) [back to overview]Overall Assessment of Study Medication by Investigator
NCT01008696 (3) [back to overview]Percentage of Participants Completely Cured of Reflux Esophagitis Evaluated by Endoscopy Based on CYP2C19
NCT01089543 (2) [back to overview]Rate of Complete Dyspepsia Symptom Relief
NCT01089543 (2) [back to overview]Rate of Satisfactory Symptom Relief
NCT01202071 (3) [back to overview]Pharmacokinetic Parameter: Maximal Drug Concentration (Cmax)
NCT01202071 (3) [back to overview]Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours Of Day 5 Administration
NCT01202071 (3) [back to overview]Pharmacokinetic Parameter: Area Under the Plasma Concentration-Time Curve From Time 0 to Time t (AUC[0-t])
NCT01237353 (2) [back to overview]Change in Gastric pH After Administration of Betaine Hydrochloride (HCl)
NCT01237353 (2) [back to overview]Duration of Gastric pH Status
NCT01277718 (2) [back to overview]Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Cobimetinib
NCT01277718 (2) [back to overview]Maximum Observed Concentration of Cobimetinib
NCT01397448 (2) [back to overview]Cumulative Incidence of Bleeding Ulcers
NCT01397448 (2) [back to overview]Cumulative Recurrent Rates of Gastric or Duodenal Ulcers
NCT01398410 (2) [back to overview]Percentage of Participants With Treatment Emergent Adverse Events (AEs)
NCT01398410 (2) [back to overview]Cumulative Recurrent Rate of Gastric or Duodenal Ulcers
NCT01504971 (1) [back to overview]Diagnostic Ability of Each Endoscopic Finding for GERD Symptom.
NCT01575899 (3) [back to overview]Re-eradication Rate
NCT01575899 (3) [back to overview]Eradication Rate (Participants Naive to Anti-H. Pylori Treatment)
NCT01575899 (3) [back to overview]Eradication Rate of Participants Living in Rural Area.
NCT02037477 (5) [back to overview]Intragastric pH Time Course Over 24 Hours
NCT02037477 (5) [back to overview]Frequency of Adverse Events
NCT02037477 (5) [back to overview]Number of Participants With Abnormal 12-lead Electrocardiogram (at Rest) Findings
NCT02037477 (5) [back to overview]Number of Participants With Abnormal Changes From Baseline in Vital Signs
NCT02037477 (5) [back to overview]Number of Participants With Markedly Abnormal Laboratory Values
NCT02135107 (9) [back to overview]Cumulative Non-recurrence Rate at Week 52
NCT02135107 (9) [back to overview]Frequency of Heartburn (Daytime / Nighttime) During the Maintenance Therapy Period
NCT02135107 (9) [back to overview]Frequency of Sleep Disorders During the Maintenance Therapy Period
NCT02135107 (9) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02135107 (9) [back to overview]Percentage of Participants With Heartburn (Daytime / Nighttime) During the Maintenance Therapy Period
NCT02135107 (9) [back to overview]Rate of Non-recurrence at Weeks 12 and 24
NCT02135107 (9) [back to overview]Severity of Heartburn (Daytime / Nighttime) During the Maintenance Therapy Period
NCT02135107 (9) [back to overview]Rate of Non-recurrence at Week 52
NCT02135107 (9) [back to overview]Percentage of Participants With Sleep Disorders During the Maintenance Therapy Period
NCT02446483 (4) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)
NCT02446483 (4) [back to overview]Apparent First-order Elimination or Terminal Rate Constant
NCT02446483 (4) [back to overview]Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose
NCT02446483 (4) [back to overview]Time of the Maximum Plasma Concentration (T-max) and Terminal Half-life (T-half)
NCT02605395 (6) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC [0-t]) of Rabeprazole
NCT02605395 (6) [back to overview]Maximal Measured Plasma Concentration (Cmax) of Rabeprazole
NCT02605395 (6) [back to overview]Mean Apparent First-order Elimination or Terminal Rate Constant (Ke) of Rabeprazole
NCT02605395 (6) [back to overview]Mean Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC [0 to Infinity]) of Rabeprazole
NCT02605395 (6) [back to overview]Mean Time to the Maximum Plasma Concentration (Tmax) of Rabeprazole
NCT02605395 (6) [back to overview]Mean Terminal Half Life (t1/2) of Rabeprazole
NCT03094416 (14) [back to overview]Creatine Phosphokinase (CPK)
NCT03094416 (14) [back to overview]Cholesterol, Total
NCT03094416 (14) [back to overview]Very Low Density Lipoprotein (VLDL)-Cholesterol
NCT03094416 (14) [back to overview]Triglycerides
NCT03094416 (14) [back to overview]Total Triiodothyronine (TT3)
NCT03094416 (14) [back to overview]Total Thyroxine (TT4)
NCT03094416 (14) [back to overview]Thyroid Stimulating Hormone (TSH)
NCT03094416 (14) [back to overview]Sex Hormone Binding Globulin (SHBG)
NCT03094416 (14) [back to overview]Low Density Lipoprotein (LDL)-Cholesterol
NCT03094416 (14) [back to overview]Angiotensin Converting Enzyme (ACE)
NCT03094416 (14) [back to overview]High Density Lipoprotein (HDL)-Cholesterol
NCT03094416 (14) [back to overview]Free Triiodothyronine (FT3)
NCT03094416 (14) [back to overview]Free Thyroxine (FT4)
NCT03094416 (14) [back to overview]Ferritin
NCT03530995 (5) [back to overview]Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2
NCT03530995 (5) [back to overview]Pharmacokinetics: Cmax of KD025m1 in Part 1
NCT03530995 (5) [back to overview]Pharmacokinetics: AUC(0-inf) and AUC(0-24) of KD025 and KD025 m2 for Subject in Part 1 and Part 2
NCT03530995 (5) [back to overview]Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1
NCT03530995 (5) [back to overview]Pharmacokinetics: Cmax of KD025, KD025m1, and KD025m2 in Part 2
NCT06076681 (1) [back to overview]The Eradication Rate of Helicobacter Pylori Infection
NCT06076694 (1) [back to overview]The Eradication Rate of Helicobacter Pylori Infection

Treatment-emergent Adverse Events Experienced by >=5% of Patients in Any Treatment Group

Primary safety outcomes include adverse events, physical examinations and clinical laboratory results. AE results are presented in the table. (NCT00132496)
Timeframe: 8 weeks from randomization and end of treatment

,
InterventionParticipants (Number)
DiarrheaNauseaUpper abdominal painChest painUpper respiratory tract infectionBronchitisPharyngitisSinusitisNasopharyngitisOtitis mediaHeadachePharyngolaryngeal painCoughNasal congestionTotal # subjects reporting AEs
Rabeprazole 10 mg3310433211565441
Rabeprazole 20 mg2233322343653445

[back to top]

Percentage of Participants With Complete Relief of Heartburn at Final Evaluation

"Heartburn diary will be given to each subject and ask him/her to keep the diary every day throughout the study period. The subject will be requested to record the occurrence of heartburn during the daytime and the nighttime in the diary. Primary End Point is the rate of complete disappearance of heartburn. The rate of heartburn do not occur in the past week will be calculated based on the diary. Participants were evaluated at week 4 about episodes of heartburn in the last 7 days" (NCT00165646)
Timeframe: 4 weeks

InterventionPercentage of participants (Number)
Placebo20.9
E3810 5 mg34.4
E3810 10 mg43.6

[back to top]

The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring).

Mean and standard deviation of percent time pH<4.0 on 24 hour esophageal pH monitoring. (NCT00165672)
Timeframe: Baseline and 4 weeks

,
InterventionPercent Time (Mean)
Baseline4 weeks
E3810 Pariet (Rabeprazole Sodium) 10 mg7.030.87
E3810 Pariet (Rabeprazole Sodium) 5 mg6.721.38

[back to top]

The Percentage of Heartburn-free Days (24-hour Periods) During the 6-month Maintenance Treatment Phase (ITT Population).

The percentage of heartburn-free days during the 6-month Maintenance Treatment Phase in patients treated with rabeprazole 20 mg compared to patients who received placebo in the ITT Population. Heartburn-free day was defined as no heartburn in both the daytime and nighttime period on a given day. Note a total 388 subjects were enrolled at the beginning of Acute Phase and 200 subjects were enrolled into the double-blind 6-month maintenance treatment phase. (NCT00165841)
Timeframe: 6 months double-blind maintenance phase

InterventionPercentage of Days (Mean)
Rabeprazole 20 mg82.58
Placebo62.17

[back to top]

Complete Heartburn Relief During the First Full 24-Hour Period in the ITT Population.

"Subject was considered complete relief if he/she did not heartburn during the nighttime of the first dose date and no heartburn during the daytime of 1 day after the first dose date. The difference in complete relief within the first 24 hours between treatment groups was tested using a continuity corrected chi-square test without adjustment baseline heartburn severity." (NCT00236184)
Timeframe: first 24 hours

Interventionparticipants (Number)
Placebo114
Rabeprazole 10 mg163

[back to top]

Complete Heartburn Relief During the First Full 24-Hour Period in Intent-to-Treat (ITT) Population

The difference in complete relief within the first 24 hours between treatment and placebo in ITT was tested using a continuity corrected chi-square test withput adjustment for baseline severity. (NCT00236197)
Timeframe: First 24 hours

InterventionParticipants (Number)
Placebo100
Rabeprazole 10 mg121

[back to top]

The Median Time to Complete Relief of Regurgitation Symptoms

(NCT00464308)
Timeframe: 4 weeks

Interventiondays (Median)
Rabeprazole 20 mg/Day9
Esomeprazole 40 mg/Day11
Esomeprazole 20 mg/Day13

[back to top]

The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4

Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe. (NCT00464308)
Timeframe: 4 weeks

Interventionparticipants (Number)
Rabeprazole 20 mg/Day281
Esomeprazole 40 mg/Day283
Esomeprazole 20 mg/Day276

[back to top]

The Number of Patients With Complete Resolution of Heartburn by Week 4

Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe. (NCT00464308)
Timeframe: week 4 of treatment

Interventionparticipants (Number)
Rabeprazole 20 mg/Day272
Esomeprazole 40 mg/Day302
Esomeprazole 20 mg/Day278

[back to top]

The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods

(NCT00464308)
Timeframe: 4 weeks

Interventionpercent of participants (Mean)
Rabeprazole 20 mg/Day56.3
Esomeprazole 40 mg/Day63.4
Esomeprazole 20 mg/Day56.1

[back to top]

The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4

Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe. (NCT00464308)
Timeframe: 4 weeks

Interventionparticipants (Number)
Rabeprazole 20 mg/Day397
Esomeprazole 40 mg/Day413
Esomeprazole 20 mg/Day402

[back to top]

The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4

Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe. (NCT00464308)
Timeframe: 4 weeks

Interventionparticipants (Number)
Rabeprazole 20 mg/Day405
Esomeprazole 40 mg/Day418
Esomeprazole 20 mg/Day414

[back to top]

The Median Time to Complete Resolution of Heartburn Symptoms.

(NCT00464308)
Timeframe: week 4 of treatment

Interventiondays (Median)
Rabeprazole 20 mg/Day11
Esomeprazole 40 mg/Day9
Esomeprazole 20 mg/Day12

[back to top] [back to top]

Nighttime Heartburn, Number of Days in Week Symptom Activity Score <3 (Better) in Week 6 Compared to Baseline

the number of days with Symptom Intensity Score < 3 (better) for nighttime heartburn during week 6 as compared to baseline (NCT00539240)
Timeframe: Symptom control after 6 weeks of treatment

Interventiondays (Mean)
Arm 16.6
Arm 25.8
Arm 36.0

[back to top]

Acid Regurgitation, Number of Days in Week Symptoms Intensity Score < 3 (Better)

the number of days with Symptom Intensity Score < 3 (better) for acid regurgitation during week 6 as compared to baseline (NCT00539240)
Timeframe: Symptom control after 6 weeks of treatment

Interventiondays (Mean)
Arm 16.7
Arm 25.9
Arm 36.3

[back to top]

Daytime Heartburn, Number of Days in Week Symptoms Intensity Score < 3 (Better)

the number of days with Symptom Intensity Score < 3 (better) for daytime heartburn during week 6 as compared to baseline (NCT00539240)
Timeframe: Symptom control after 6 weeks of treatment

Interventiondays (Mean)
Arm 16.6
Arm 25.9
Arm 36.1

[back to top]

Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

"Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5 mm in maximum length. Grade B: One or more mucosal breaks more than 5 mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Gread D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658528)
Timeframe: Baseline and Week 8

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40 mg7520.34.7
RAB ER 50 mg8014.95.2

[back to top]

Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of hearburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days. (NCT00658528)
Timeframe: Week 4

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40 mg48.246.35.5
RAB ER 50 mg48.344.37.4

[back to top]

Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

"Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5 mm in maximum length. Grade B: One or more mucosal breaks more than 5 mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658528)
Timeframe: Baseline and Week 4

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40 mg50.347.81.9
RAB ER 50 mg54.842.62.7

[back to top]

Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

"Healing at Week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade A or B from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Gread D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658632)
Timeframe: Baseline and Week 8

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40 mg87.86.35.9
RAB ER 50 mg88.25.95.9

[back to top]

Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

"Healing at Week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade A or B from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Gread D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658632)
Timeframe: Baseline and Week 4

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40 mg75.3213.7
RAB ER 50 mg75.919.15

[back to top]

Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days. (NCT00658632)
Timeframe: Week 4

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40 mg38.550.810.7
RAB ER 50 mg41.947.111

[back to top]

Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days. (NCT00658775)
Timeframe: Week 4

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40mg52.5407.4
RAB ER 50mg53.239.67.2

[back to top]

Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

"Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658775)
Timeframe: Baseline and Week 4

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40mg50.746.43
RAB ER 50mg50.9472.1

[back to top]

Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

"Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658775)
Timeframe: Baseline and Week 8

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40mg78.416.65
RAB ER 50mg77.518.44.2

[back to top]

Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N)

Grade N indicates a normal appearance of lower esophageal mucosa (NCT00770913)
Timeframe: 8 weeks

InterventionPercentage of Participants (Number)
E3810 20 mg Once Daily58.8
E3810 10 mg Twice Daily78.4
E3810 20 mg77.0

[back to top]

The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)

Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 36 weeks

InterventionPercentage of patients (Number)
Rabeprazole Sodium 0.5 mg/kg92
Rabeprazole Sodium 1.0 mg/kg88

[back to top]

The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)

Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 12 weeks

InterventionPercentage of participants (Number)
Rabeprazole Sodium 0.5 mg/kg78
Rabeprazole Sodium 1.0 mg/kg83

[back to top]

The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)

The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 12

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg-11.5
Rabeprazole Sodium 1.0 mg/kg-8.5

[back to top]

The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)

The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 36

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg-2.9
Rabeprazole Sodium 1.0 mg/kg-1.4

[back to top]

The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)

The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 36

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg0.2
Rabeprazole Sodium 1.0 mg/kg0.2

[back to top]

The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)

The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 12

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg-1.3
Rabeprazole Sodium 1.0 mg/kg-1.0

[back to top]

Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26

eGERD (erosive gastroesophageal reflux disease) healing measured by the Time-to-Relapse of Oesophageal Erosions using an Esophagogastroduodenoscopy (EGD). Lesions were identified and graded using the following Los Angeles (LA) classification of Oesophagitis: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference. (NCT00838526)
Timeframe: Baseline to Week 26

InterventionPercentage of Participants (Number)
RAN 150mg BID32.9
RAB ER 50mg QD84.9

[back to top]

Percentage of Participants With Adverse Events by Category

An adverse event (AE) was any untoward medical occurrence in a participant administered an investigational product. A treatment emergent AE (TEAE) was any AE beginning on or after the confirmed date of first dose of study medication, up to and including 7 days after the last dose of study medication. A TEAE was considered related to study treatment if a causal relationship between the study treatment and the AE was a reasonable possibility. AEs were graded as severe if they were incapacitating, with inability to work or to perform normal daily activity. Serious AEs (SAEs) were events that resulted in death, were life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or were a congenital anomaly/birth defect. (NCT00838526)
Timeframe: From the time of administration of the first dose of study drug up to a maximum of approximately 30 weeks.

,
InterventionPercentage of participants (Number)
Any TEAETreatment-related TEAESevere TEAESevere, treatment-related TEAEDeathOther SAETreatment-related SAETEAEs leading to discontinuation of treatment
RAB ER 50mg QD64.214.58.10.606.406.9
RAN 150mg BID47.58.53.41.701.706.8

[back to top]

Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26

Heartburn or other GERD-associated symptoms (regurgitation, epigastric or chest pain, dysphagia, belching, bloating, early satiety, other) was based on a 4-point Likert scale that included the following: None (No symptoms); Mild (Awareness of symptoms but easily tolerated); Moderate (Discomforting symptom sufficient to cause interference with normal activities including sleep); Severe (Incapacitating symptom, inability to perform normal activities). (NCT00838526)
Timeframe: Baseline to Week 26

,
InterventionPercentage of Participants (Number)
YesNoMissing
RAB ER 50mg QD57.418.823.9
RAN 150mg BID8.525.466.1

[back to top]

Surgery

"This sencodary endpoint surgery is the operation for bleeding control of peptic ulcer bleeding such as gastric or duodenal primary closure, and subtotal gastrectomy with/without vagotomy." (NCT00838682)
Timeframe: 6wk

Interventionparticipants (Number)
Rabeprazole Sodium2
Omeprazole0

[back to top]

Rebleeding Within 3 Days

(NCT00838682)
Timeframe: day 3

Interventionparticipants (Number)
Rabeprazole Sodium2
Omeprazole1

[back to top]

Rebleeding After 3 Days

Rebleeding after 3 days was assessed by checking the patients from day 3 to discharge and bleeding event or regular follow-up after discharge to week 6. (NCT00838682)
Timeframe: 6wk

Interventionparticipants (Number)
Rabeprazole Sodium1
Omeprazole0

[back to top]

Mean Units of Blood Transfusion

In order to compare the total amount of blood transfusion, mean units of blood transfusion was used. (NCT00838682)
Timeframe: day 3

InterventionMean units of blood transfusion (Mean)
Rabeprazole Sodium1.3
Omeprazole1.4

[back to top]

Death

(NCT00838682)
Timeframe: 6wk

Interventionparticipants (Number)
Rabeprazole Sodium1
Omeprazole0

[back to top]

Duration of Hospital Stay

(NCT00838682)
Timeframe: 6wk

Interventiondays (Mean)
Rabeprazole Sodium8.0
Omeprazole6.7

[back to top]

Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26

Heartburn or other GERD-associated symptoms (regurgitation, epigastric or chest pain, dysphagia, belching, bloating, early satiety, other) was based on a 4-point Likert scale that included the following: None (No symptoms); Mild (Awareness of symptoms but easily tolerated); Moderate (Discomforting symptom sufficient to cause interference with normal activities including sleep); Severe (Incapacitating symptom, inability to perform normal activities). (NCT00839306)
Timeframe: Baseline to Week 26

,
InterventionPercentage of Participants (Number)
YesNoMissing
RAB ER 50mg QD53.717.528.8
RAN 150mg BID8.316.775

[back to top]

Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26

"eGERD (erosive gastroesophageal reflux disease) healing measured by the Time-to-Relapse of Oesophageal Erosions using an Esophagogastroduodenoscopy (EGD). Lesions were identified and graded using the following Los Angeles (LA) classification of Oesophagitis: Not Present: No breaks (erosions) in the oesophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00839306)
Timeframe: Baseline to Week 26

InterventionPercentage of Participants (Number)
RAN 150mg BID31.7
RAB ER 50mg QD88.4

[back to top]

Percentage of Participants With Complete Heartburn Relief

Participants completed a daily symptom diary. (NCT00911534)
Timeframe: Week 2 and Week 4

,
InterventionPercentage of Participants (Number)
Week 2 (n=147, 148)Week 4 (n=147, 148)
Placebo3.47.5
RAB ER 50mg1522.2

[back to top]

Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4

Participants completed a daily symptom diary. A heartburn-free day was defined as participant report of 'No Heartburn' from nighttime and daytime of the diary for the same day. (NCT00911534)
Timeframe: Week 4

InterventionPercentage of Days (Mean)
Placebo21.23
RAB ER 50mg41.14

[back to top]

Time to Achieve First 24-Hour Period Without Heartburn

Participants completed a daily symptom diary. (NCT00911534)
Timeframe: Baseline to Week 4

InterventionDays (Mean)
Placebo14.4
RAB ER 50mg10.6

[back to top] [back to top]

Change From Baseline in I-GERQ-R Total Score (Double-blind Phase/ Baseline Observation Carried Forward)

The Infant Gastroesophageal Reflux Questionnaire-Revised (I-GERQ-R) is a 12-item questionnaire that is completed by the primary caregiver at every office or telephonic visit. It has a weekly recall and the items cover the frequency, amount and discomfort attributed to spit-up, refusal or stopping feeding, crying and fussing, hiccups, arching back and stopping breathing or changing color. The total score is calculated as the sum of all 12 scores for the individual questions, and ranges from 0 to 42. A higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8

Interventionscores on a scale (Mean)
Double-Blind Placebo-3.6
Double-Blind Rabeprazole Sodium 5 mg-3.8
Double-Blind Rabeprazole Sodium 10 mg-4.1
Double-Blind Rabeprazole Sodium Total-3.9

[back to top]

Change From Baseline in Weekly Average I-GERQ-DD Discomfort Subscale Score (Double-blind Phase/ Last Observation Carried Forward)

The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the subject has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Discomfort subscale score will be calculated as the sum of the 3 questions regarding discomfort (Questions, 7, 8, 9) and will range from 0 to 12. For each subscale score, a higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8

Interventionscores on a scale (Mean)
Double-Blind Placebo0.0
Double-Blind Rabeprazole Sodium 5 mg-0.1
Double-Blind Rabeprazole Sodium 10 mg-0.4
Double-Blind Rabeprazole Sodium Total-0.2

[back to top]

Change From Baseline in Weight-for-Age Z-Score (Double-blind Phase/ Baseline Observation Carried Forward)

Body weight was measured with the participant unclothed and before a feeding during each office visit. In the analysis of weight data, weight will be transformed to the weight-for-age Z-score using World Health Organization Child Growth Standards, taking into account the infant's age and gender (Borghi E, 2006). (NCT00992589)
Timeframe: Baseline, Week 8

InterventionZ-score (Mean)
Double-Blind Placebo0.11
Double-Blind Rabeprazole Sodium 5 mg0.16
Double-Blind Rabeprazole Sodium 10 mg0.11
Double-Blind Rabeprazole Sodium Total0.14

[back to top] [back to top]

Change From Baseline in Weekly Average I-GERQ-DD Eating Behavior Subscale Score (Double-blind Phase/ Last Observation Carried Forward)

The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the subject has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Eating Behavior subscale score will be calculated as the sum of the 3 questions regarding eating behavior (Questions 4, 5, 6) and will range from 0 to 12. For each subscale score, a higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8

Interventionscores on a scale (Mean)
Double-Blind Placebo-0.1
Double-Blind Rabeprazole Sodium 5 mg-0.1
Double-Blind Rabeprazole Sodium 10 mg-0.4
Double-Blind Rabeprazole Sodium Total-0.3

[back to top]

Change From Baseline in Weekly Average I-GERQ-DD Regurgitation Subscale Score (Double-blind Phase/ Last Observation Carried Forward)

The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the participant has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Regurgitation subscale will be calculated as the sum of the 3 questions regarding regurgitation (Questions 1, 2, 3) and will range from 0 to 13. For each subscale score, a higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8

Interventionscores on a scale (Mean)
Double-Blind Placebo-0.8
Double-Blind Rabeprazole Sodium 5 mg-0.8
Double-Blind Rabeprazole Sodium 10 mg-1.0
Double-Blind Rabeprazole Sodium Total-0.9

[back to top]

Change From Baseline in Average Daily Frequency of Regurgitation (Double-blind Phase/ Baseline Observation Carried Forward)

(NCT00992589)
Timeframe: Baseline, Week 8

Interventionfrequency of Regurgitation (Mean)
Double-Blind Placebo-0.8
Double-Blind Rabeprazole Sodium 5 mg-0.8
Double-Blind Rabeprazole Sodium 10 mg-1.6
Double-Blind Rabeprazole Sodium Total-1.2

[back to top]

Change From Baseline in in Weekly Average I-GERQ-DD Total Score (Double-blind Phase/ Baseline Observation Carried Forward)

The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the participant has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. Each of the 9 items will be assigned a numeric score. The total score will be calculated as the sum of all 9 items, and ranges from 0 to 37. A higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8

Interventionscores on a scale (Mean)
Double-Blind Placebo-1.9
Double-Blind Rabeprazole Sodium 5 mg-1.6
Double-Blind Rabeprazole Sodium 10 mg-2.1
Double-Blind Rabeprazole Sodium Total-1.9

[back to top]

Change From Baseline in Symptoms of Reflux Esophagitis Evaluated by the Symptom Assessment Questionnaire

Gastroesophageal reflux disease and abdominal GI-related symptoms (heartburn, regurgitation, globus sensation, chronic cough, epigastric pain, non cardiac chest pain, hoarseness, dysphagia, abdominal distension, bloating, post-prandial discomfort, early satiety, nausea, vomiting, belching) experienced by participants were assessed and graded into 4 categories: 0 (Nothing)=No symptom, 1 (Mild)=A little but not uncomfortable, 2 (Moderate)=Present but interfering daily life activities a little, 3 (Severe)=Very uncomfortable, interfering daily life activities or sleeping. (NCT01008696)
Timeframe: Baseline and Day 57

,
InterventionUnits on a scale (Mean)
Baseline: Heartburn (n=87, 91)Baseline:Regurgitation (n=87, 91)Baseline: Globus sensation (n=87, 91)Baseline: Chronic cough (n=87, 91)Baseline: Epigastric pain (n=87, 90)Baseline: Non cardiac chest pain (n=85, 90)Baseline: Hoarseness (n=87, 90)Baseline: Dysphagia (n=87, 91)Baseline: Abdominal distension (n=87, 91)Baseline: Bloating (n=87, 90)Baseline: Post-prandial discomfort (n=87, 91)Baseline: Early satiety (n=86, 91)Baseline: Nausea (n=87, 91)Baseline: Vomiting (n=87, 91)Baseline: Belching (n=87, 91)Change at Day 57: Heartburn (n=87, 91)Change at Day 57: Regurgitation (n=87, 91)Change at Day 57: Globus sensation (n=87, 91)Change at Day 57: Chronic cough (n=87, 91)Change at Day 57: Epigastric pain (n=87, 90)Change at Day 57:Non cardiac chest pain (n=85, 90)Change at Day 57: Hoarseness (n=87, 90)Change at Day 57: Dysphagia (n=87, 91)Change at Day 57: Abdominal distension (n=87, 91)Change at Day 57: Bloating (n=87, 90)Change at Day57:Post-prandial discomfort (n=87,91)Change at Day 57: Early satiety (n=86, 91)Change at Day 57: Nausea (n=87, 91)Change at Day 57: Vomiting (n=87, 91)Change at Day 57: Belching (n=87, 91)
Lansoprazole0.590.930.820.300.940.260.220.220.590.440.550.250.130.020.36-0.54-0.84-0.32-0.21-0.77-0.20-0.17-0.14-0.40-0.37-0.35-0.16-0.11-0.02-0.29
Rabeprazole0.610.980.550.340.910.330.230.160.610.550.530.270.160.080.38-0.55-0.89-0.31-0.22-0.77-0.28-0.14-0.11-0.38-0.41-0.45-0.21-0.16-0.08-0.25

[back to top]

Overall Assessment of Study Medication by Investigator

Investigator's overall assessment of study medication based on the global symptom assessment was measured. The assessment was categorized as: 2=very good, 1=good, 0=as usual, -1=bad and -2=very bad. (NCT01008696)
Timeframe: Day 57

InterventionUnits on a scale (Mean)
Rabeprazole1.37
Lansoprazole1.43

[back to top]

Percentage of Participants Completely Cured of Reflux Esophagitis Evaluated by Endoscopy Based on CYP2C19

Reflux esophagitis evaluated by endoscopy as per LA Classification graded as: A=1 or more mucosal breaks no longer than 5 millimeter (mm) that did not extend between tops of 2 mucosal folds, B=1 or more mucosal breaks more than 5 mm long that did not extend between tops of 2 mucosal folds, C=1 or more mucosal break continuous between the tops of 2 or more mucosal folds but involves less than 75 percent of circumference, D=1 or more mucosal break involving at least 75 percent of circumference. Participants that were not categorized in any of the above mentioned grades (A to D) were considered as cured of reflux esophagitis. Participants were classified as CYP2C19 homozygous extensive, heterozygous extensive and poor metabolizers. (NCT01008696)
Timeframe: Day 57

,
InterventionPercentage of participants (Number)
Homozygous Extensive Metabolizer (n=42, 35)Heterozygous Extensive Metabolizer (n=30, 38)Poor Metabolizer (n=15, 18)
Lansoprazole93.94100.00100.00
Rabeprazole97.37100.0093.33

[back to top]

Rate of Complete Dyspepsia Symptom Relief

The rate of complete dyspepsia symptom relief according to the Dyspepsia Symptom Questionnaire (DSQ) was defined as a score of 1 for all four major dyspeptic symptoms at week 8 and according to the diary defined as all four dyspepsia symptoms recorded absent during the 7 days prior to week 8. Values presented as percentage of participants. (NCT01089543)
Timeframe: Up to 8 Weeks (including 7 days prior)

,,,
InterventionPercentage of Participants (Number)
DSQ (n= 76, n= 75, n= 74, n= 78)Diary Recordings (n= 77, n= 76, n=74, n=80)
Placebo17.917.5
Rabeprazole 10 mg22.422.1
Rabeprazole 20 mg29.328.9
Rabeprazole 40 mg27.027.0

[back to top]

Rate of Satisfactory Symptom Relief

"The rate of satisfactory symptom relief according to the DSQ defined as scores of <= 2 for all four major dyspepsia symptoms at week 8 and the diary recordings defined as a frequency of <= 1 day for all four major dyspepsia symptoms during the 7 days before week 8. Lastly, treatment success according to the participants' impression questionnaire where participants answered yes or no when asked if given the choice, whether they would want to continue to take the study drug after clinical trial completion. Values presented as percentage of participants." (NCT01089543)
Timeframe: Up to 8 Weeks (including 7 days prior)

,,,
InterventionPercentage of participants (Number)
DSQ (n=76, n=75, n=74, n=78)Diary Recordings (n=77, n=76, n=74, n=80)Treatment Success (n=76, n=75, n=74, n=78)
Placebo28.230.059.0
Rabeprazole 10 mg42.137.772.4
Rabeprazole 20 mg45.348.785.3
Rabeprazole 40 mg39.239.264.9

[back to top]

Pharmacokinetic Parameter: Maximal Drug Concentration (Cmax)

"Pharmacokinetic parameter: maximal drug concentration (Cmax) measured in nanograms per milliliter (ng/mL) was calculated on Day 1 and Day 5 of administration during each Period (I-IV).~Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity." (NCT01202071)
Timeframe: Day 1 and Day 5 of administration during Period I-IV

,,,
Interventionng/mL (Mean)
Day 1: CYP2C19 Extensive Metabolizers 'EM' (n=16)Day 5: CYP2C19 Extensive Metabolizers 'EM' (n=16)Day 1: CYP2C19 Poor Metabolizers 'PM' (n=8)Day 5: CYP2C19 Poor Metabolizers 'PM' (n=8)
Rabeprazole Sodium 10 mg Tablet253.6382.8434.7508.5
Rabeprazole Sodium 20 mg Tablet520.0654.1891.9821.9
Rabeprazole Sodium 40 mg Tablet1007.61018.51574.21986.5
Rabeprazole Sodium 5 mg Tablet137.7146.0185.1251.9

[back to top]

Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours Of Day 5 Administration

The 24-hour intragastric pH monitoring was performed on Day 5 of administration in each study period (Period I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity. (NCT01202071)
Timeframe: Day 5 of administration during Period I-IV

,,,
InterventionPercentage of Time in a 24 Hour Period (Mean)
CYP2C19 Extensive Metabolizers 'EM' (n=16)CYP2C19 Poor Metabolizers 'PM' (n=8)
Rabeprazole Sodium 10 mg Tablet57.8171.83
Rabeprazole Sodium 20 mg Tablet61.3675.74
Rabeprazole Sodium 40 mg Tablet71.5283.08
Rabeprazole Sodium 5 mg Tablet45.6362.51

[back to top]

Pharmacokinetic Parameter: Area Under the Plasma Concentration-Time Curve From Time 0 to Time t (AUC[0-t])

"Pharmacokinetic parameter: Area under the plasma concentration-time curve from time 0 (administration of the drug) to time t (the last quantifiable concentration time point). AUC measured in nanogram hours per milliliter (ng*h/mL) was calculated on Day 1 and Day 5 of administration during each Period (I-IV).~Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity." (NCT01202071)
Timeframe: Day 1 and Day 5 of administration during Period I-IV (0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24 hours post-dose)

,,,
Interventionng*h/mL (Mean)
Day 1: CYP2C19 Extensive Metabolizers 'EM' (n=16)Day 5: CYP2C19 Extensive Metabolizers 'EM' (n=16)Day 1: CYP2C19 Poor Metabolizers 'PM' (n=8)Day 5: CYP2C19 Poor Metabolizers 'PM' (n=8)
Rabeprazole Sodium 10 mg Tablet429.7539.11029.61230.4
Rabeprazole Sodium 20 mg Tablet866.9993.72112.92330.6
Rabeprazole Sodium 40 mg Tablet1807.21929.64002.34627.9
Rabeprazole Sodium 5 mg Tablet215.5235.7455.0584.6

[back to top]

Change in Gastric pH After Administration of Betaine Hydrochloride (HCl)

Gastric pH levels monitored with a Heidelberg pH capsule (HC) which sends real-time signals to a computer system that visually plots intestinal pH on a minute-by-minute basis. When subject's pH remained above 4.0 for at least 15 minutes, a 1500 mg dose of betaine HCl was given orally with 90 mL of water, and gastric pH was continuously monitored for 2 hours. (NCT01237353)
Timeframe: 30 minutes

Interventionunits on a scale (Mean)
Betaine Hydrochloride and Rabeprazole4.54

[back to top]

Duration of Gastric pH Status

When subject's pH remained above 4.0 for at least 15 minutes, a 1500 mg dose of betaine HCl was given orally with 90 mL of water, and gastric pH was continuously monitored for 2 hours (NCT01237353)
Timeframe: 2 hours after dose of betaine HCl

Interventionminutes (Mean)
Mean time to pH <3.0Mean minutes of pH < 3.0Mean minutes of pH < 4.0
Betaine Hydrochloride and Rabeprazole6.372.576.8

[back to top]

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Cobimetinib

AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf). (NCT01277718)
Timeframe: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose

Interventionnanograms*hours/milliliter (ng*hr/mL) (Geometric Mean)
Cobimetinib [Fasted]778
Cobimetinib [Fasted] + Rabeprazole864
Cobimetinib [Fed] + Rabeprazole846

[back to top]

Maximum Observed Concentration of Cobimetinib

(NCT01277718)
Timeframe: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose

Interventionnanograms per milliliter (ng/mL) (Geometric Mean)
Cobimetinib [Fasted]17.0
Cobimetinib [Fasted] + Rabeprazole17.2
Cobimetinib [Fed] + Rabeprazole14.8

[back to top]

Cumulative Incidence of Bleeding Ulcers

(NCT01397448)
Timeframe: 24 weeks

InterventionEvents/100 participants/24 weeks (Number)
Rabeprazole 5 mg0
Rabeprazole 10 mg0
Teprenone 150 mg4.6

[back to top]

Cumulative Recurrent Rates of Gastric or Duodenal Ulcers

Mucosal injuries with a white coat measuring 3 mm in diameter will be diagnosed as ulcers. When ulcer is confirmed by endoscopic examination during the trial, it will be regarded as recurrence of ulcer and the trial will be discontinued for the patient involved. (NCT01397448)
Timeframe: 24 weeks

InterventionEvents/100 participants/24 weeks (Number)
Rabeprazole 5 mg2.8
Rabeprazole 10 mg1.4
Teprenone 150 mg21.7

[back to top]

Percentage of Participants With Treatment Emergent Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered with the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening (ie, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was as a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). In this study, treatment emergent AEs (defined as an AE (serious/non-serious) that started/increased in severity on/after the first dose of study drug up to 30 days after the final dose of study drug) were assessed. The data is presented as percentage of participants with treatment emergent AEs. (NCT01398410)
Timeframe: For each participant, from administration of first dose of study drug (rabeprazole) up to 30 days from administration of last dose of study drug (rabeprazole) or up to 76 weeks (including data from the Double-Blind Phase)

InterventionPercentage of participants (Number)
Rabeprazole 5 mg77.1
Rabeprazole 10 mg83.8

[back to top]

Cumulative Recurrent Rate of Gastric or Duodenal Ulcers

Mucosal injuries with a white coat measuring greater than or equal to 3 mm in diameter was diagnosed as ulcers. When ulcer was confirmed by endoscopic examination during the trial, it was regarded as recurrence of ulcer and the trial was discontinued for the participant involved. The presence or absence of ulcer recurrence was determined by the endoscopy central review panel that were blinded to the investigators' assessments. Cumulative recurrent rate was estimated by the Kaplan-Meier method. The data is presented as percentage of participants with cumulative recurrent rate of gastric or duodenal ulcers. (NCT01398410)
Timeframe: Baseline, Week 12, Week 24, Week 52, and Week 76 (including data from the Double-Blind Phase)

,
InterventionPercentage of participants (Number)
Baseline (N=150, 151)Week 12 (N=150, 151)Week 24 (N=139, 142)Week 52 (N=107, 121)Week 76 (N=93, 96)
Rabeprazole 10 mg001.42.22.2
Rabeprazole 5 mg01.32.83.73.7

[back to top]

Diagnostic Ability of Each Endoscopic Finding for GERD Symptom.

Patients with GERD symptom receive endoscopic tri-modal imaging within 1 month (NCT01504971)
Timeframe: 1 month

Interventionpercentage of participants (Number)
Participants21
Participants Same to arm177
Participants Same to Previous Arm60

[back to top]

Re-eradication Rate

Re-eradication successful rate (percentage of participants with a negative result of C13 or CLO test at least four weeks after the 2nd treatment) with 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole for patients still with Hp infection previously treated with regimen without levofloxacin and Augmentin. (NCT01575899)
Timeframe: 4 weeks after complete use of drug for treatment

Interventionpercentage of successful re-eradication (Number)
Levofloxacin-Amox/Clav. (Re-eradication)72.6

[back to top]

Eradication Rate (Participants Naive to Anti-H. Pylori Treatment)

A negative post-treatment 13C-urea breath test or CLO test result at more than 4 weeks after complete use of drug for treatment. (NCT01575899)
Timeframe: 4 weeks after complete use of drug for treatment

Interventionpercentage of eradicated participants (Number)
Levofloxacin-Amox/Clav.78.1
Clarithromycin-Amoxicillin57.5

[back to top]

Eradication Rate of Participants Living in Rural Area.

Subgroup analysis on eradication rate (percentage of participants with a negative result of C13 or CLO test at least four weeks after treatment) according to resident area of participants, especially who are living in rural area. (NCT01575899)
Timeframe: 4 weeks after complete use of drug for treatment

Interventionpercentage of eradicated participants (Number)
Levofloxacin-Amox/Clav.81.4
Clarithromycin-Amoxicillin51.3

[back to top]

Intragastric pH Time Course Over 24 Hours

Intragastric pH was measured continuously for 24 hours (hr) by pH monitor. pH holding time ratio (HTR) is the percentage of time a pH is maintained at a particular level. For example, pH 4 HTR is the percentage of time the pH = 4. (NCT02037477)
Timeframe: At baseline (Day -2 to Day -1), administration period (Days 1 to Day 2 and Days 7 to Day 8)

,,,
Interventionpercentage of time (Mean)
0-24 hr pH 4 HTR (%)-Baseline0-24 hr pH 4 HTR (%)-Day 10-24 hr pH 4 HTR (%)-Day 70-12 hr pH 4 HTR (%)-Baseline0-12 hr pH 4 HTR (%)-Day 10-12 hr pH 4 HTR (%)-Day 712-24 hr pH 4 HTR (%)-Baseline12-24 hr pH 4 HTR (%)-Day 112-24 hr pH 4 HTR (%)-Day 7
Cohort 1 - Esomeprazole 20 mg10.6323.9261.2112.9834.8977.628.1812.9444.81
Cohort 1 - Vonoprazan 20 mg10.6371.3785.8212.9874.8396.458.1867.8675.21
Cohort 2 - Rabeprazole Sodium 10 mg8.9026.2965.098.0137.2676.069.7715.3454.13
Cohort 2 - Vonoprazan 20 mg8.9084.1693.798.0184.0398.839.7784.3488.77

[back to top]

Frequency of Adverse Events

The frequency of adverse events by type, seriousness, time to onset. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug. (NCT02037477)
Timeframe: 31 days

,,,
Interventionparticipants (Number)
Treatment Emergent Adverse EventsRelatedNot RelatedMildModerateSevereLeading to Study Drug Discontinuation
Cohort 1 - Esomeprazole 20 mg0000000
Cohort 1 - Vonoprazan 20 mg0000000
Cohort 2 - Rabeprazole Sodium 10 mg1011000
Cohort 2 - Vonoprazan 20 mg3122101

[back to top]

Number of Participants With Abnormal 12-lead Electrocardiogram (at Rest) Findings

(NCT02037477)
Timeframe: At Screening, baseline (Day -3), administration period (Day 8), and post-test (Day 28)

Interventionparticipants (Number)
Cohort 1 - Vonoprazan 20 mg0
Cohort 1 - Esomeprazole 20 mg0
Cohort 2 - Vonoprazan 20 mg0
Cohort 2 - Rabeprazole Sodium 10 mg0

[back to top]

Number of Participants With Abnormal Changes From Baseline in Vital Signs

Vital signs included body temperature (oral or tympanic measurement), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm). (NCT02037477)
Timeframe: At screening, baseline (Day -3, Day -2, Day -1), administration period (Days 1, Day 2, Day 7, Day 8), and post-test (Day 28)

Interventionparticipants (Number)
Cohort 1 - Vonoprazan 20 mg0
Cohort 1 - Esomeprazole 20 mg0
Cohort 2 - Vonoprazan 20 mg0
Cohort 2 - Rabeprazole Sodium 10 mg0

[back to top]

Number of Participants With Markedly Abnormal Laboratory Values

The number of participants with markedly abnormal laboratory values for Chemistry, Hematology and Urinalysis during the study is reported. (NCT02037477)
Timeframe: At Screening, baseline (Day -3), administration period (Day 1, Day 8), and post-test (Day 28)

Interventionparticipants (Number)
Cohort 1 - Vonoprazan 20 mg0
Cohort 1 - Esomeprazole 20 mg0
Cohort 2 - Vonoprazan 20 mg0
Cohort 2 - Rabeprazole Sodium 10 mg0

[back to top]

Cumulative Non-recurrence Rate at Week 52

Non-recurrence rate at Week 52 was estimated using the Kaplan-Meier method. (NCT02135107)
Timeframe: Week 52

InterventionPercentage of non-recurrence (Number)
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily41.5
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily71.4

[back to top]

Frequency of Heartburn (Daytime / Nighttime) During the Maintenance Therapy Period

A comparison of rabeprazole 10 mg once daily group and the rabeprazole 10 mg twice daily group shall be performed for participants who did not exhibit daytime or nighttime heartburn at 0 weeks of the maintenance therapy period. Daytime and nighttime heartburn, and nighttime sleep disorders shall likewise be compared. For the participants who had recurrence, values at the final evaluation were imputed using a last observation carried forward (LOCF) method. (NCT02135107)
Timeframe: From Week 4 up to Week 52

,
InterventionPercentage of participants (Number)
0 Days (no symptoms)1 to 2 Days (occasional symptoms)3 to 4 Days (sometimes had symptoms)5 to 6 Days (often had symptoms)7 Days (always had symptoms)
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily85.212.31.90.00.6
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily85.111.20.61.91.2

[back to top]

Frequency of Sleep Disorders During the Maintenance Therapy Period

Sleep disorders were defined as the condition of lack of dead sleep and arousal during sleep arising from heartburn or acid reflux. Evaluation of sleep disorders arising from heartburn or acid reflux included recording if sleep-inducing drugs were being taken before enrollment; their type, method of use, and dosage. It was requested that no changes in sleep-inducing drug be made after enrollment. Sleep disorders were rated from 0-day (no) to 7-day (always). Heartburn was evaluated prior to 7 days of each visit. (NCT02135107)
Timeframe: From Week 4 up to Week 52

,
InterventionPercentage of participants (Number)
0 Day (none)1 to 2 Days (occasional symptoms)3 to 4 Days (sometimes had symptoms)5 to 6 Days (often had symptoms)7 Days (always had symptoms)
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily96.92.50.60.00.0
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily98.10.60.00.60.6

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Safety was assessed by monitoring and recording all adverse events (AEs) and SAEs, regular monitoring of hematology, clinical chemistry, urine values, and regular measurement of vital signs. All AEs were graded on a 3-point scale; 1) mild was defined as discomfort that did not interfere with normal daily activities, 2) moderate was defined as discomfort that interfered with normal activities, and 3) severe was defined as discomfort that interfered with the ability to work or normal daily activities were impossible. SAEs were medical events that led to death, were life-threatening, required hospitalization or prolongation of hospitalization, caused persistent disability, or resulted in a congenital abnormality. TEAEs were AEs with an onset date on or after the first dose of study drug and up to 30 days after receiving the last dose of study drug. Treatment-related AEs were medical events that were considered by the investigator to be possibly or probably related to rabeprazole. (NCT02135107)
Timeframe: From date of first dose up to 30 days after the last dose of study drug, up to approximately 1 year 3 months (Treatment Period; 8 weeks, Maintenance Therapy Period; 52 weeks, and Follow-up Period; 30 days)

,,,
InterventionParticipants (Count of Participants)
TEAEsTreatment-related TEAEsSevere TEAEsSerious TEAEs
Rabeprazole: 10 mg Twice Daily1112026
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once daiArm C1117411
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily12511317
Rabeprazole: 20 mg Twice Daily21114

[back to top]

Percentage of Participants With Heartburn (Daytime / Nighttime) During the Maintenance Therapy Period

A comparison of the rabeprazole 10 mg once daily group and the rabeprazole 10 mg twice daily group was performed for participants who did not exhibit daytime or nighttime heartburn at Week 0 of the Maintenance Therapy Period. Heartburn is a burning sensation in the stomach or lower chest; it is worsened by bending or pressure on the abdomen. Heartburn frequency was rated from 0-day (no) to 7-day (always) and severity was graded on a 3-point scale (mild, moderate, severe). Heartburn was evaluated in the daytime (from wake-up time to time for bed) and nighttime (from time for bed to wake-up time). (NCT02135107)
Timeframe: From Week 4 up to Week 52

,
InterventionPercentage of participants (Number)
Heartburn (yes)Heartburn (no)
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily23.276.8
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily8.092.0

[back to top]

Rate of Non-recurrence at Weeks 12 and 24

The non-recurrence rate (up to 52 weeks) was determined by the endoscopy central review panel who were blinded to the investigator's assessment, based on the modified Los Angeles Classification using endoscopy photos were submitted by each of the institutions. Participants showing Grade A or above based on the modified Los Angeles Classification were included as a recurrence. The 95% CI was calculated by normal approximation. (NCT02135107)
Timeframe: Weeks 12 and 24

,
InterventionPercentage of participants (Number)
Week 12, Non-recurrenceWeek 12, RecurrenceWeek 24, Non-recurrenceWeek 24, Recurrence
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily62.537.555.844.2
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily92.47.685.114.9

[back to top]

Severity of Heartburn (Daytime / Nighttime) During the Maintenance Therapy Period

"A comparison of the rabeprazole (10 mg once daily group) and the rabeprazole (10 mg twice daily group) was performed for participants who did not exhibit daytime or nighttime heartburn at Week 0 of the Maintenance Therapy Period. The presence or absence of heartburn was assessed by the investigators during medical interviews. The heartburn incidence during each of the 7-day periods immediately before visiting the hospital was assessed on a scale of five stages based on the number of days with symptoms: 0 (no symptoms), 1 to 2 (occasional symptoms), 3 to 4 (sometimes had symptoms), 5 to 6 (often had symptoms), and 7 (always had symptoms). The incidence was tabulated by an analysis classifying the states into two groups: no symptom group (0 days with symptoms) and with symptoms group (1 day or more with symptoms). The severity of heartburn was as below: Mild (feel heartburn but tolerable), Moderate (feel heartburn and hard), and Severe (feel heartburn and terrible)." (NCT02135107)
Timeframe: From Week 4 up to Week 52

,
InterventionPercentage of participants (Number)
NoneMildModerateSevere
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily85.214.80.00.0
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily85.114.30.60.0

[back to top]

Rate of Non-recurrence at Week 52

The non-recurrence rate (at 52 weeks) was determined by the endoscopy central review panel who were blinded to the investigator's assessment, based on the modified Los Angeles Classification using endoscopy photos were submitted by each of the institutions. Participants showing Grade A or above based on the modified Los Angeles Classification were included as a recurrence. (NCT02135107)
Timeframe: Week 52

,
InterventionPercentage of participants (Number)
Non-recurrenceRecurrence
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily44.855.2
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily73.926.1

[back to top]

Percentage of Participants With Sleep Disorders During the Maintenance Therapy Period

"Sleep disorders were defined as the condition of lack of dead sleep and arousal during sleep arising from heartburn or acid reflux. Sleep disorders during each of the 7-day periods immediately before visiting the hospital were assessed. Evaluation of sleep disorders arising from heartburn or acid reflux included recording if sleep-inducing drugs were being taken before enrollment; their type, method of use, and dosage. It was requested that no changes in sleep-inducing drug be made after enrollment. Sleep disorders were rated from 0-day (no) to 7-day (always). The incidence of sleep disorder was tabulated by an analysis classifying the stages into two groups: No (0 days with sleep disorder) and Yes (1 or more days with sleep disorder). Heartburn was evaluated prior to 7 days of each visit." (NCT02135107)
Timeframe: From Week 4 up to Week 52

,
InterventionPercentage of participants (Number)
Sleep disorders from heartburn/acid reflux (yes)Sleep disorders from heartburn/acid reflux (no)
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily2.597.5
Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily2.597.5

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. AUC0-t was calculated by the linear trapezoidal method. AUC0-infinity was calculated as the sum of the AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, where first-order elimination or terminal rate constant was calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. Values were reported as Least Squares Geometric Means with respective % CV. (NCT02446483)
Timeframe: Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period.

,
Interventionng.h/mL (Geometric Mean)
AUC0-tAUC0-infinity
Treatment A- Rabeprazole 20 mg916.07971.38
Treatment B- Rabeprazole 20 mg922.52959.78

[back to top]

Apparent First-order Elimination or Terminal Rate Constant

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. Apparent first-order elimination or terminal rate constant calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. (NCT02446483)
Timeframe: Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period

InterventionPer hour (Geometric Mean)
Treatment A- Rabeprazole 20 mg0.35
Treatment B- Rabeprazole 20 mg0.28

[back to top]

Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose

Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. Cmax was defined as maximal measured plasma concentration over the time span specified. Values were reported as Least Squares Geometric Means with respective Geometric Coefficient of Variation (% CV). (NCT02446483)
Timeframe: Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period.

InterventionNanogram per mL (ng/mL) (Geometric Mean)
Treatment A- Rabeprazole 20 mg543.78
Treatment B- Rabeprazole 20 mg530.34

[back to top]

Time of the Maximum Plasma Concentration (T-max) and Terminal Half-life (T-half)

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. If the maximum value occurs at more than one point T-max was defined as the first time point with this value. The elimination or terminal half-life was calculated by dividing 0.693 (natural logarithm of 2) with b obtained as the slope of the linear regression of the logarithmically transformed plasma concentrations versus time in the terminal period of the plasma curve. (NCT02446483)
Timeframe: Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period.

,
Interventionh (Median)
TmaxT-half
Treatment A- Rabeprazole 20 mg2.662.79
Treatment B- Rabeprazole 20 mg3.002.50

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC [0-t]) of Rabeprazole

Blood samples were collected for pharmacokinetic analyses in each period at specified time points. Pharmacokinetic parameters of rabeprazole were estimated using standard non-compartmental methods. AUC (0-t) was calculated from measured data points from time of administration to time of last quantifiable concentration (Clast) by the linear trapezoidal rule. (NCT02605395)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

InterventionHour*nanograms per milliliter (Mean)
Idiazole 20 mg812.30
Pariet 20 mg843.68

[back to top]

Maximal Measured Plasma Concentration (Cmax) of Rabeprazole

Blood samples were collected for pharmacokinetic analyses in each period at specified time points. Pharmacokinetic parameters of rabeprazole were estimated using standard non-compartmental methods. The Cmax was computed directly from measured data. (NCT02605395)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

InterventionNanograms per milliliter (Mean)
Idiazole 20 mg393.50
Pariet 20 mg415.83

[back to top]

Mean Apparent First-order Elimination or Terminal Rate Constant (Ke) of Rabeprazole

Blood samples were collected for pharmacokinetic analysis in each period at specified time points. Pharmacokinetic parameters of Rabeprazole were estimated using standard non-compartmental methods. Ke was derived from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. (NCT02605395)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

InterventionPer hour (Mean)
Idiazole 20 mg0.21
Pariet 20 mg0.16

[back to top]

Mean Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC [0 to Infinity]) of Rabeprazole

Blood samples were collected for pharmacokinetic analyses in each period at specified time points. Pharmacokinetic parameters of rabeprazole were estimated using standard non-compartmental methods. (NCT02605395)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

InterventionHour*nanograms per milliliter (Mean)
Idiazole 20 mg798.59
Pariet 20 mg931.81

[back to top]

Mean Time to the Maximum Plasma Concentration (Tmax) of Rabeprazole

Blood samples were collected for pharmacokinetic analysis in each period at specified time points. Pharmacokinetic parameters of Rabeprazole were estimated using standard non-compartmental methods. Tmax was computed directly from the measured data. (NCT02605395)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

InterventionHour (Mean)
Idiazole 20 mg3.93
Pariet 20 mg3.86

[back to top]

Mean Terminal Half Life (t1/2) of Rabeprazole

Half life is the period of time required for the concentration or amount of drug in the body to be reduced by one-half. Blood samples were collected for pharmacokinetic analysis in each period at specified time points. Pharmacokinetic parameters of Rabeprazole were estimated using standard non-compartmental methods. t1/2 was calculated as: t1/2 = Ln(2) / (-b), where b was obtained as the slope of the linear regression of the Ln-transformed plasma concentrations versus time in the terminal period of the plasma curve. (NCT02605395)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 14 and 24 hours post-dose in period 1 and 2

InterventionHour (Mean)
Idiazole 20 mg4.49
Pariet 20 mg5.81

[back to top]

Creatine Phosphokinase (CPK)

Change in Serum Levels of creatine phosphokinase (CPK) from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

InterventionU/L (Mean)
Tirosint Capsules-35.073

[back to top]

Cholesterol, Total

Change in total cholesterol levels from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionmmol/L (Mean)
Tirosint Capsules-0.198

[back to top]

Very Low Density Lipoprotein (VLDL)-Cholesterol

Change in Very Low Density Lipoprotein (VLDL)-cholesterol levels from baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionmmol/L (Mean)
Tirosint Capsules0.049

[back to top]

Triglycerides

Change in triglycerides levels from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionmmol/L (Mean)
Tirosint Capsules0.075

[back to top]

Total Triiodothyronine (TT3)

Change in Serum Levels of TT3 (total triiodothyronine) from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionnmol/L (Mean)
Tirosint Capsules0.098

[back to top]

Total Thyroxine (TT4)

Change in Serum Levels of TT4 (total thyroxine) from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionnmol/L (Mean)
Tirosint Capsules2.558

[back to top]

Thyroid Stimulating Hormone (TSH)

Change in Serum Levels of TSH (Thyroid Stimulating Hormone) from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

InterventionmIU/L (Mean)
Tirosint Capsules-0.676

[back to top]

Sex Hormone Binding Globulin (SHBG)

Change in Serum Levels of SHBG (sex hormone binding globuline) from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionnmol/L (Mean)
Tirosint Capsules0.884

[back to top]

Low Density Lipoprotein (LDL)-Cholesterol

Change in low density lipoprotein (LDL)-cholesterol levels from baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionmmol/L (Mean)
Tirosint Capsules-0.210

[back to top]

Angiotensin Converting Enzyme (ACE)

Change in Serum Levels of ACE (angiotensin converting enzyme) from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

InterventionU/L (Mean)
Tirosint Capsules-0.395

[back to top]

High Density Lipoprotein (HDL)-Cholesterol

Change in High Density Lipoprotein (HDL)-cholesterol levels from baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionmmol/L (Mean)
Tirosint Capsules-0.029

[back to top]

Free Triiodothyronine (FT3)

Change in Serum Levels of FT3 (free triiodothyronine) from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionpmol/L (Mean)
Tirosint Capsules0.263

[back to top]

Free Thyroxine (FT4)

Change in Serum Levels of FT4 (free thyroxine) from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionpmol/L (Mean)
Tirosint Capsules0.593

[back to top]

Ferritin

Change in Serum Levels of ferritin from Baseline (NCT03094416)
Timeframe: baseline and 12 weeks

Interventionmcg/L (Mean)
Tirosint Capsules-6.442

[back to top]

Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2

Area under concentration-time curve from zero hours to 24 hours post-dose (AUC[0-24]) for Metabolite 1, KD025m1, for subjects in Part 1 and for subjects in Part 2 (NCT03530995)
Timeframe: Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12, and 24 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22, and 24 hours post-dose

Intervention(ng*h)/mL (Geometric Mean)
Part 1, Period 1: Belumosudil Alone75.6
Part 1, Period 4: Belumosudil + Rifampicin148
Part 2, Period 1: Belumosudil Alone138
Part 2, Period 2: Belumosudil + Omeprazole91.5

[back to top]

Pharmacokinetics: Cmax of KD025m1 in Part 1

Maximum concentration (Cmax) of Metabolite 1 (KD025m1) for belumosudil alone and for belumosudil + rifampicin up to 48 hours post-dose (NCT03530995)
Timeframe: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose

Interventionng/mL (Geometric Mean)
Part 1, Period 1: Belumosudil Alone23.2
Part 1, Period 4: Belumosudil + Rifampicin52.5

[back to top]

Pharmacokinetics: AUC(0-inf) and AUC(0-24) of KD025 and KD025 m2 for Subject in Part 1 and Part 2

Area under concentration-time curve from zero hours to infinity (AUC[0-inf]) and from zero hours to 24 hours post-dose (AUC[0-24)) for the parent drug KD025, and Metabolite 2, KD025m2, for subjects up to 48 hours each for Part 1 and for Part 2 (NCT03530995)
Timeframe: Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose

,,,,,
Intervention(ng*h)/mL (Geometric Mean)
AUC(0-inf): KD025AUC(0-inf): KD025m2AUC(0-24): KD025AUC(0-24): KD025m2
Part 1, Period 1: Belumosudil Alone9080123084301100
Part 1, Period 2: Belumosudil + Itraconazole1120084310400745
Part 1, Period 3: Belumosudil + Rabeprazole16801741510110
Part 1, Period 4: Belumosudil + Rifampicin25003962490376
Part 2, Period 1: Belumosudil Only188001900168001950
Part 2, Period 2: Belumosudil + Omeprazole988011107970767

[back to top]

Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1

Maximum concentration (Cmax) of the parent drug, KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) for belumosudil alone, belumosudil + itraconazole, belumosudil + rabeprazole, and belumosudil + rifampicin at 0 to 48 hours post-dose (NCT03530995)
Timeframe: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose

,,,
Interventionng/mL (Geometric Mean)
Parent Drug KD025KD025m2
Part 1, Period 1: Belumosudil Alone1770337
Part 1, Period 2: Belumosudil + Itraconazole2130221
Part 1, Period 3: Belumosudil + Rabeprazole22723.5
Part 1, Period 4: Belumosudil + Rifampicin712148

[back to top]

Pharmacokinetics: Cmax of KD025, KD025m1, and KD025m2 in Part 2

Maximum concentration (Cmax) of the parent drug (KD025), for Metabolite 1 (KD025m1), and for Metabolite 2 (KD025m2), for belumosudil alone and for belumosudil + omeprazole up to 48 hours post-dose (NCT03530995)
Timeframe: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose

,
Interventionng/mL (Geometric Mean)
Cmax--1st dose: KD025Cmax--2nd dose: KD025Cmax--1st Dose: KD025m1Cmax--2nd Dose: KD025m1Cmax--1st Dose: KD025m2Cmax--2nd Dose: KD025m2
Part 2, Period 1: Belumosudil Alone1790176023.823.6282257
Part 2, Period 2: Belumosudil + Omeprazole57590318.018.972.3115

[back to top]

The Eradication Rate of Helicobacter Pylori Infection

Eradication rate of H. pylori is defined as negative urea breath test result. (NCT06076681)
Timeframe: Urea breath test is assessed 4-6 weeks after the treatment (Day 44~ Day 50)

InterventionParticipants (Count of Participants)
Group A0
Group B3
Group C4
Group D8

[back to top]

The Eradication Rate of Helicobacter Pylori Infection

Eradication rate of H. pylori is defined as negative urea breath test result. (NCT06076694)
Timeframe: Group A, B,C,control group: Urea breath test is assessed Day 44~Day 50 after the first dose; Group D: Urea breath test is assessed Day 37~ Day 43 after the first dose

InterventionParticipants (Count of Participants)
Group A18
Group B17
Group C5
Group D10
Control Group16

[back to top]